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Scaffold based delivery of RNA interference (RNAi) molecules such as free small 
interfering RNA (siRNA) and microRNA has recently begun to be employed towards 
treatment of diseases such as cancer, bone regeneration, muscular dystrophy and 
cardiovascular disease. Effective translation from bench side to clinical use of RNAi has 
been limited in part because upon systemic delivery the RNAi molecules are degraded 
by RNases and flushed by excretory organs causing an inefficient duration of gene 
silencing effect at target tissues. These challenges can potentially be minimised by 
delivering RNAi molecules via non-viral nanoparticle carriers encapsulated in 
biocompatible, biodegradable and injectable scaffolds such as hydrogels. Various 
scaffolds have been shown to aid in sustained localised delivery of RNAi molecules and 
improve gene silencing. This research focused on optimising and establishing such an 
RNAi hydrogel-siRNA-nanoparticle (hydrogel-nanocomplex) system for targeted and 
sustained gene knockdown both in vitro and in vivo using dendrimer and lipid based 
nanoparticles in combination with synthetic polyethylene glycol (PEG) and natural fibrin 
hydrogel scaffolds. 
Four siRNA nanocarriers were investigated for siRNA delivery, that is, fourth generation 
dendrimer nanoparticles poly(amidoamine) (D) and its modified version (MD) with PEG 
and a lipid 1, 2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) molecule, 
commercial lipid based Lipofectamine® RNAiMax and Invivofectamine® 3.0 
nanoparticles. D and MD achieved better RNase protection compared to lipid 
nanocomplexes though Invivofectamine® 3.0 nanocomplexes protected a small 
percentage of siRNA over 10 days. The MD nanoparticle displayed improved siRNA 
release and transfection efficacy compared to D but efficacy of the dendrimers was lower 
than the lipid particles.  
Four hydrogels that have not been investigated for RNAi were assessed for 
sustainability. Namely, hydrolytically and proteolytically degradable PEG-acrylate (PEG-
AC), proteolytically degradable PEG - vinyl sulfone (PEG-VS) hydrogels, unmodified 
fibrin and PEGylated fibrin hydrogel. The nanocomplex release rate in vitro from the 
various hydrogels showed minimal release from PEGylated hydrogels, burst release 
from unmodified fibrin and sustained release from PEGylated fibrin. Invivofectamine® 
3.0 nanocomplexes retained efficacy optimally after release from PEGylated fibrin hence 




For in vivo sustained delivery to be effective, determination of hydrogel persistence in 
vivo was required. After injection in the mouse tibialis anterior (TA) muscle PEG-AC and 
PEGylated fibrin gels degraded within 2 days.  
The efficacy of the various nanocomplexes was assayed in a 3D assay that more closely 
resembled delivery in soft tissue. PEGylated fibrin containing nanocomplexes with cell 
death siRNA sequences was polymerised around a preformed PEGylated fibrin cell 
containing droplet. Invivofectamine® 3.0 nanocomplex consistently achieved the highest 
gene knockdown effect with no evidence of cytotoxicity whilst Lipofectamine® RNAiMax 
was ineffective. MD showed signs of cytotoxicity when delivered in a sustained fashion. 
Thus Invivofectamine® 3.0 nanocomplexes in PEGylated fibrin hydrogel were found to 
be the optimal gel-nanocomplex system to proceed to in vivo assessment. 
BALB/c GFP transgenic injected in their TA muscle with Invivofectamine® 3.0 
nanocomplexes made with siRNA targeting GFP or myostatin (siGFP/siMSTN) in the 
presence or absence of PEGylated fibrin gel were analysed 7 days post treatment for 
siRNA retention and GFP and Mstn gene knockdown. Increased retention of siRNA after 
encapsulation in PEGylated fibrin was observed at 7 days. A non-significant reduction in 
GFP protein was seen for limbs injected with siGFP- fibrin after 7 days. A substantial and 
significant reduction in Mstn mRNA levels was elicited by delivery of siMstn–fibrin. 
Furthermore, only siMstn-fibrin resulted in significant increase in muscle mass. 
In this study, dendrimer based nanoparticles were found to effectively protect siRNA 
against RNases however lipid based nanocomplexes were the most efficacious at gene 
knockdown. The combination of Invivofectamine® 3.0 and PEGylated fibrin was shown 
to be the most effective in 3D assays and as an injectable controlled release scaffold 










    
1.1   RNA interference 
 
Ribonucleic acid interference (RNAi) has great potential in providing therapeutic 
solutions to a wide range of pathologies [4]. RNAi is a conserved post transcriptional 
gene regulation process carried out by double stranded non-coding small RNA 
molecules to regulate the expression of proteins [5]. The discovery of RNAi in C. elegans 
by Andrew Fire and Craig Mello in 1998 [5] allowed for a revolution of research into the 
elucidation of gene function. Studying gain or loss in function of genes by RNAi has 
enabled mapping of cellular pathways and deciphering the stages of human 
development [5-8]. These double stranded small RNA molecules include endogenously 
expressed micro RNA (miRNA), exogenously applied small interfering (siRNA) and short 
hairpin RNA (shRNA) [9, 10], which at their mature stage are ≈21-25 nucleotides long 
with their site of action being in the cytoplasm [7]. siRNA, miRNA mimics and shRNA 
mirror the endogenous miRNA processing and RNAi pathway in the cytoplasm, that is, 
they all follow a similar processing and post transcriptional gene silencing path in the 
cytoplasm but they are differentiated by their origin and number of mRNA targets. 
 
1.1.1 miRNA biogenesis, exogenous RNA processing and RNAi in cells 
 
As illustrated in Fig.1 miRNA is transcribed from DNA by RNA polymerase II [11] into 
long transcripts that form pri-miRNA stem loops in the nucleus with matching and 
mismatching base pairs. siRNA on the other hand is introduced exogenously into the cell 
cytoplasm as synthetic long complementary double stranded RNA (dsRNA) which is then 
processed into mature short siRNA in the cytoplasm or introduced as short 
complementary double stranded siRNA [10]. shRNA sequences are introduced 
exogenously into cells by plasmid transfection or very commonly via lentiviral vector 
infection, the latter is particularly used in cells that are not easily transfected [10, 12, 13]. 
The constructs introduced by lentiviral infection are nuclear imported, with the shRNA 
sequence stably integrated into the cells’ genome. They are transcribed into hairpins 




 miRNA depending on the sequence design, resulting in long term gene knockdown. 
When plasmids are used in cell transfection, they also need to be transported into the 
nucleus but do not usually integrate into the genome and the resulting gene knockdown 
effect is transient [10].  Pre-shRNA is transcribed from DNA by RNA polymerase II or III 
into two complementary sequences of ≈19-22 base pairs (bp) linked by a short loop of 
≈4-11 nucleotides, similar to the endogenous pre-miRNA, and join the miRNA biogenesis 
and processing pathway [9, 10]. Although shRNA are potent gene silencing molecules, 
they are limited by the need for nuclear transportation and introduction into the host DNA 
and this process carries a risk of insertional gene mutations. Therefore miRNA mimics 
















In the nucleus, the long pri-miRNA loop transcripts are cleaved by the nuclear enzyme, 
ribonuclease III Drosha, to shorter 65-75 nucleotide pre-miRNAs. These pre-miRNAs 
and shRNA are exported to the cytoplasm by nuclear exportin 5 where ribonuclease III 
Figure 1: Schematic representation of miRNA biogenesis and exogenous RNA processing in 




Dicer processes the precursors, pre-miRNA and exogenously introduced long dsRNA 
into mature miRNA and siRNA duplexes with 2-nucleotide overhangs at the 3’ end [10, 
15].  The small RNAs (exogenous short siRNA and miRNA mimics, dicer processed 
mature miRNA and siRNA) are coupled into the RNA-induced silencing complex (RISC) 
where the duplex is dissociated and the sense strand is cleaved leaving the antisense 
strand. The RISC complex then binds to complementary mRNA and induces mRNA 
cleavage in the case of siRNA where the siRNA base pairs perfectly match the target 
mRNA. For miRNA, the RISC complex inhibits mRNA translation as miRNA has been 
shown in most eukaryotes to have mismatches with their target mRNA sequences 
typically at their three prime untranslated regions [16]. The mismatch creates a physical 
barrier for mRNA transcription and cleavage and allows the molecules to have multiple 
similar sets of mRNA targets whilst siRNA only has one specific mRNA target [17-20]. 
 
1.1.2 RNAi as a therapeutic tool 
 
The aberrant expression and/or mutation of genes is related to the disease state or 
pathophysiology of many diseases and genetic disorders. These were observations 
realized partly by the application of the post transcriptional RNAi based tool in in vitro 
and in vivo screening studies to characterise gene knockdown phenotypes [21, 22]. The 
RNAi approach has led to the provision of novel therapeutic targets for many diseases 
including those previously considered undruggable [21, 23, 24]. Therefore, by knocking 
down disease causing and promoting genes, RNAi has great potential in bringing a new 
generation of biodrugs forward to treat diseases such as lung and liver diseases, 
inflammatory disorders,  cancer, viral infections, cardiovascular diseases (CVD), 
Huntington disease and many other genetic disorders [9, 25-29]. There is however at 
present, only a relatively small range of RNAi therapeutics that target macular 
degeneration, cancer, liver, gastrointestinal tract, skin and infectious diseases that are 
in stage I-III clinical trials [9]. Furthermore, we are aware of just two United States Food 
and Drug administration (FDA) approved RNAi drugs that are currently on the market 
that is mipomersen and patisiran [9, 30, 31]. Mipomersen is used for the treatment of 
inherited familial homozygous hypercholesterolemia disorder [30], and patisiran is being 
used in the treatment of TTR-mediated amyloid polyneuropathy in adults heart [31]. This 
relative paucity of RNAi clinical application is in part due to the various systemic barriers 




Since exogenously introduced miRNA mimics and siRNA have similar functions, 
properties, and encounter similar systemic fates, siRNA is focussed on below. 
 
1.2 Barriers to siRNA transfection and delivery in vivo 
	
The progression of RNAi application in the clinic is impeded by systemic and cellular 
barriers encountered by naked nucleic acids when administered systemically. These 
barriers include immune response, clearance from the circulatory system by phagocytes 
and uptake by non-target tissue. They also include a short plasma half-life of less than 
10 minutes due to degradation by nucleases, clearance and accumulation in excretory 
organs such as the kidneys, liver and spleen [32-38]. The cellular challenges faced by 
exogenous siRNA is a result of their unfavourable physicochemical properties, which 
inhibit siRNA from passively crossing the cell membrane due to their hydrophilic nature 
as well as their relatively large molecular weight and size [34, 39]. The phosphate 
backbone of siRNA results in a highly negatively charged molecule that is naturally 
repelled by the cellular membrane with a negative surface charge [39]. Furthermore, 
upon cellular uptake, RNAi molecules need to be able to escape degradation in the endo-
lysosomes. These limitations have led to a growing need to find ways to deliver siRNA 
to the targeted tissue and aid its passage through the cell membrane to their site of action 
in the cytoplasm. These delivery methods should aid RNAi molecules in stealth 
systematic movement, transport across the cell membrane and endo-lysosomal escape 
in order for their implementation as a therapeutic measure in a clinical setting to be more 
efficacious. 
 
1.3 siRNA delivery methods 
 
There are a variety of emerging measures being explored to increase the efficacy of 
siRNA that partially evade the above mentioned barriers. Modifying the nucleic acid 
backbone to improve siRNA stability in systemic circulation and increase cellular 
transfection is one approach, another is to use nanocarrier transport vehicles such as 
viruses and non-viral nanoparticles. These nanoparticles, also termed nanomedicines, 
are defined as nanoscale drugs with various medical purposes including diagnosis, 
biosensing, imagery and drug delivery [40, 41]. siRNA modifications and the use of 




but have both been shown to improve delivery in various diseases such as 
neurodegenerative disorders [42] and hepatitis B [43] for example and also target tissues 
such as the heart [44], tumors [27] and particularly excretory organs [26, 35, 45] where 
systemically injected biodrugs are highly likely to accumulate . However, each of these 
delivery methods comes with their limitations which will be discussed separately in the 
following sections [34, 46].  
 
1.3.1 Modified siRNA 
 
siRNA modifications include changes to the siRNA structure and addition of conjugates 
to the siRNA. The most commonly used modifications that have been shown to enhance 
serum stability by elevating RNase resistance, avoiding immune response and 
increasing circulation time in vivo include: cholesterol conjugation, addition of a partial 
phosphorothioate backbone and 2’- modifications on the sugar ring structures of several 
bases on the siRNA sense and antisense strands with methyl, methoxyethyl and fluoro 
groups [38, 45]. For example, cholesterol was conjugated to siRNA targeting 
apolipoprotein B (ApoB) and delivered intravenously in mice. After intravenous (i.v) 
injection of the cholesterol-ApoB-siRNA, ApoB mRNA was found to be reduced in the 
mice liver. ApoB protein levels in the serum as well as total cholesterol were also reduced 
when compared to cholesterol-siNegative control. In addition, cholesterol-siRNA was 
found to have improved pharmacokinetics, circulatory retention, accumulation in the liver 
and jejunum relative to the same negative control [45]. Some of these siRNA 
modifications are a central aspect to the FDA approved RNAi drug currently on the 
market, mipomersen [47]. The drug is a modified siRNA (modRNA) sequence that again 
targets apolipoprotein B-100 (ApoB) mRNA, to reduce ApoB protein production and thus 
result in low density lipoprotein (LDL) and total cholesterol levels [48]. The antisense 
oligonucleotide is modified on its 5’ and 3’ ends with 2’ methoxyethyl groups, as well as 
a modified phosphorothioate backbone to increase nuclease resistance and reduce 
protein binding and the inflammatory response [30, 48, 49].  
Although modifications to the siRNA can be introduced to improve serum stability and 
allow them to be systemically injected or directly injected at the site of action such as 
tumors, muscle and myocardial infarction (MI) site, their efficacy is still limited due to off 
target effects; clearance by the circulatory system; macrophages and excretory organs 




is a reduced gene silencing effect because the RNAi system can only tolerate moderate 
changes to the RNA structure [51, 52].  
1.3.2 Viral nanoparticles 
 
Viral vectors that are being explored in gene therapy as potential therapeutics are 
recombinant viruses that are devoid of viral integrase and replication proteins. They 
include retroviruses, lentiviruses (LV), adenoviruses and adeno-associated viruses 
(AAV) [53-55]. Retroviruses can only infect mitotic cells and they were amongst the first 
to be developed and used in vitro and in vivo [56-59], but in recent years research in vitro 
and in clinics has shifted more towards exploring the use of LV and AAV because of their 
ability to infect both non-dividing and dividing cells hence offering a wider range of target 
tissues [54, 60, 61].  Viral nanoparticles have the natural ability to infect cells and deliver 
genetic material with high efficiency and the potential to cause long term gene 
knockdown effect, a trait desirable in some applications but not others [62, 63]. However 
they are associated with: immunogenicity, inflammation, pose a risk of insertional gene 
mutagenicity and the possibility of recombination events during the viral vector 
manufacturing process that may result in replication-competent viruses [64-69]. There 
are studies in clinical trials using viral vectors in gene therapy for several genetic 
disorders and cancer in phases I/II [70]. However regulatory agencies require rigorous 
testing for replication-competent particles in the viral products before use in trials and 
patients have longer follow up post treatment to fully establish the safety of the vectors 
[70].  Despite the advances that have been made in the field to improve viral vector 
biosafety and application in the clinic, the risk factors mentioned above hinder their 
clinical translation progress and approval [70]. Therefore non-viral nanoparticles with 
their more desirable safety profile are considered more immediate candidates for clinical 
translation [71].  
 
1.3.3 Non-viral nanoparticles 
 
Non-viral nanoparticles come with a range of physicochemical properties which 
encompass size, charge and material composition and these properties strongly 
influence a nanoparticles’ biocompatibility and clinical application [40, 41]. Particles in 
the 10-100 nm size range are most widely used and have been shown to have optimal 




have also been shown to have a range of other clinical application such as diagnostics, 
imaging and drug delivery in many diseases including cancer, CVD and MI [40, 72-74]. 
All nanoparticles are susceptible to clearance by macrophages as well as biodistribution 
and clearance by the liver and spleen [75-80], however smaller nanoparticles (<10nm) 
are especially prone to clearance from the bloodstream by kidneys and larger 
nanoparticles (>100nm) are more susceptible to opsonisation and phagocytosis [73, 81, 
82].  
The surface charge of nanoparticles can affect cell membrane interaction differently 
which results in differing cellular uptake process and toxicity depending on the cell type 
with which it comes into contact with. Therefore this ultimately affects the nanoparticle’s 
systemic biodistribution, intracellular localisation as well as efficacy [83]. A study of 
nanoparticles with a range of charges showed that zwitterionic nanoparticles entered 
human epithelial cells (HeLa) cells by passive membrane fusion whilst anionic and 
cationic particles crossed their membranes through multiple endocytotic pathways [84]. 
Charge difference not only affects nanoparticles’ intracellular entry pathway and 
localisation, it also affects their escape ability from the endolysosomal system, thus 
determining their delivery efficiency [85, 86]. Cationic particles were shown to have a 
high rate of cellular entry and endosomal escape compared to neutral or anionic particles 
[86]. Nanoparticles with either a high positive or negative surface charge are more likely 
to be phagocytosed by endocytotic cells, whilst non-phagocytic cells prefer internalising 
particles that are positively charged in comparison to highly negative or neutral 
nanoparticles [87-89]. For example, a study with ovarian cancer cells showed an 
increase in nanoparticle uptake with a decrease in negative zeta potential ranging from 
-40mV to  -14mV [90]. Inversely another study showed that cationic nanoparticles with 
an increasing number of amino groups (positive charge) were increasingly taken up by 
HeLa and human bone marrow derived mesenchymal stem cells (MSC) cells compared 
to their neutral counterparts [91]. However, although increasing positive charge improves 
cellular entry, an increase in cytotoxicity of such particles has been reported [92, 93]. 
Since the cell membrane surface charge is negatively charged, nanoparticles with a high 
positive charge become more cytotoxic because they can alter the membrane zeta 
potential and disrupt the plasma membrane [83, 94]. The different uptake preferences of 
phagocytic and non-phagocytic cells for nanoparticles with varying degrees of charge 
may influence the selectivity of nanoparticles for drug delivery, their efficacy as well as 
their fate in distribution. Thus, the effects of these fundamental nanoparticle 
physiochemical properties of size and charge can serve as a guide towards the design 




A wide range of materials have been used in the production of nanoparticles as a 
nanocarrier for RNA molecules for RNAi via complexation, also referred to as 
nanocomplexes. These materials include organic polymeric, lipid, protein and crystalline 
based nanoparticles as well as inorganic metallic based nanoparticles [95-98]. Examples 
of some of the different types of nanoparticles being studied for siRNA delivery in vivo 
are shown in Table 1 [41, 97-100]. Polymeric and lipid nanoparticles will be discussed 
further in sections to follow. 
 




Condition Target Observations  Ref 
Organic      
Lipid Nanoemulsions Lung cancer HDM2,  
c-myc,  
VEGF 
Cell proliferation, angiogenesis and 









α-synuden Reduced α-synuden mRNA and 
protein expression in mice striatum 





Cancer tumors PLK1 Reduced target mRNA in tumour 
biopsies and reduced tumor growth 
of cancer xenografts in the nude 
mice. 
[103] 
 Cyclodextrin Melanoma RRM2 Accumulation of nanocomplexes, 
reduced target mRNA and protein in 
melanoma human patient biopsies 
and reduced tumor growth. 
[104] 
 Chitosan Kidney disease COX-2 COX-2 immunoreactivity in 
macrophages reduced in mouse 
kidneys.  
[105] 
 Polymeric micelle Cancer tumors  VEGF, 
VEGFR2 
Inhibited subcutaneous HeLa cell-








 siRNA-Cy5 improved 
pharmacokinetic profile, reduced 
kidney, liver accumulation of siRNA 




Cancer tumors VEGF Tumor growth inhibition in mice. [108] 
Inorganic 
& Metallic 
     













Superparamagnetic iron oxide 
(SPIONS) nanocomplexes knocked 
down Polo-like kinase-1 in tumour 
bearing mice.   
[110]  
 Graphene oxide 
 
MI VEGF-165 Graphene oxide nanocomplexes in 
hydrogel injected in peri-infarct zone 
reduced VEGF-165 gene in rat MI. 
[111] 
 Quantum dots (Q-
dots) 
Cancer tumors EGFR EGFR knockdown and reduced mice 
tumor xenografts.  
[112] 
 Nanodiamond Cancer tumors survivin Knockdown of survivin in mice with 
tumor xenografts and tumor 
reduction  
[113] 
      
Nanocomplex=nucleic acidmolecules complexed to nanoparticle, HDM2= Human doubleminute 2 protein, 
VEGF=Vascular endothelial growth factor, VEGFR2=VEGF receptor 2, PLK1=Serine/threonine-protein 
kinase, RRM2=Ribonucleotide reductase family member 2, COX2=Cyclooxygenase-II enzyme, 
EGFR=estimated glomerular filtration rate, Cy5=Near-infrared.  
 
The reasoning for focusing on lipid and polymeric based nanoparticles is derived from a 
comprehensive review by Bobo et al. 2016 that found that from 1995-2015, 51 
nanomedicines (not restricted to RNAi) have been FDA approved and 77 products with 
the same definition were in various phases of clinical trials [41]. The list of non-viral 
nanomaterials being applied in the clinic is dominated by lipid and polymeric 
nanoparticles, which in combination make up over 60% of approved nanomaterials as 
well as 40% nanomaterials in various stages of clinical trials, over the protein, metallic, 
nanocrystals and other materials [41]. The most frequently used non-viral 
nanomedicines for clinical use are lipid and polymeric based nanoparticles with the main 
target disease being cancer therapy [72, 98, 100]. 
Focusing on materials being used for RNAi, the FDA clinical trial database 
(www.clinicaltrials.gov) was queried using key search terms siRNA and RNAi. The 
search results yielded an output of 41 RNAi based studies in various stages of clinical 
trials. Interventions using naked siRNA with or without conjugations or modifications 
made up 65% of the studies whilst siRNA complexed to or in lipid, polymer, viral and 
exosome based nanoparticles made up 20%, 10%, 2.5% and 2.5% respectively. 
Polymeric and lipid based nanoparticles are the most widely used for siRNA delivery 
because of their relatively simple design and ready interaction with siRNA, feasibility for 
mass production, ability to interact favourably with cell membranes and high efficiency, 






 Polymeric nanoparticles  
 
Polymeric nanoparticles (PNPs) have been made from a number of different synthetic 
and natural polymers. Some of the synthetic polymeric based PNPs being extensively 
investigated for the delivery of different therapeutic drugs including plasmid DNA (pDNA) 
and siRNA are poly (D,L-lactide-co-glycolide) (PLGA) [114] , polylactic acid (PLA) [115], 
cyclodextrin [116], PEI and dendrimeric polyamidoamine (PAMAM) [95]. Some of the 
natural polymers being used for siRNA include gelatin [117] and chitosan [95, 118, 119]. 
PNPs can be further grouped as anionic, neutral or cationic dependent on their net 
polymeric surface charge [120]. Those used for siRNA delivery, however, are necessarily 
cationic nanoparticles because they allow for electrostatic interaction with 
oligonucleotide molecules [121]. Additionally, biodegradable nanoparticles are mostly 
used because they can be hydrolysed in the body into metabolisable biocompatible 
nontoxic monomers which can be excreted without affecting normal cellular function 
[122]. Hence biodegradable cationic polymeric nanoparticles have shown the most 
success in RNAi therapeutic development and biomaterial application [122-125].  
Cationic PNPs are a class of nanoparticles which function by condensing the negatively 
charged nucleic acids to the positively charged functional groups on the polymers, which 
are usually primary amines, via non-covalent electrostatic forces [124]. This 
condensation provides siRNA with protection from RNases, promotes cellular uptake via 
endocytosis, and improves the delivery of siRNA to the cytoplasm through endosomal 
and lysosomal escape via the proton sponge effect. This effect is attributed to the 
polymers strong buffering capacity in the pH range from 5 to 7 due to the presence of 
the amine groups, which prevents lysosome acidification, promotes H+ proton influx, 
enhanced chorine ion accumulation followed by osmotic swelling and rupture of the 
endosome/lysosome releasing the imported siRNA [126-128].  
Biodegradable polymers tend to be more soluble and stable in circulation and have 
reduced immunogenicity, inflammatory and thrombogenic effects [122, 123, 129]. 
However, when delivered systemically without modifications, these nanoparticles 
encounter barriers and fate similar to that of naked siRNA. When in vivo, nanoparticles 
may absorb proteins onto their surfaces making them targets for immune response and 
phagocytosis [130, 131]. Intermolecular interactions between the chemical groups on the 
surface of PNPs may result in agglomeration with an increase in particle size and surface 
charge resulting in reduced transfection efficiency and an increased systemic clearance 




capillaries and the extracellular matrix (ECM), a network of fibrous proteins and 
polysaccharides that presents a physical barrier creating further resistance to the 
movement of nanoparticles into cells [39, 134]. Further to this, the majority of the 
nanoparticles or siRNA with weaker buffering capacity that makes it into the cell via 
endocytosis inadequately escape endosomal entrapment and are either secreted back 
into the ECM or targeted for lysosomal degradation [135, 136]. These mechanisms, of 
course, can reduce the efficiency of siRNA. 
To avoid these challenges, one approach that is extensively researched is to modify the 
cationic PNP nanoparticles’ surfaces coating through covalently attaching targeting 
ligands, oligopeptides, lipids and non-ionic surfactant copolymers such as polyethylene 
glycol (PEG) to the polymeric components of the nanoparticles [95, 137-142]. Modifying 
PNP surfaces reduces the potential for agglomeration and protein absorption to their 
surfaces and improves stealth circulation in the system (avoiding eliciting an innate 
immune response), cell penetration as well as endosomal escape and siRNA release 
into the cytoplasm [33, 137-139, 143]. Some of the commonly used cationic PNPs being 
applied in vivo for siRNA delivery are shown in Table 1. Dendrimer examples are not 
included in the table as they will be discussed later.  
A wide variety of PEI, chitosan, PLGA, cylodextrin and dendrimers PNPs with various 
formulations, structures, and surface modifications to improve biocompatibility and 
efficacy in gene silencing have been extensively investigated in vitro, but their 
biocompatibility and efficacy in vivo has not been adequately demonstrated [144, 145]. 
PEI, chitosan and PLGA have proven gene delivery efficiency both in vitro and in animal 
models, however, undesirable cytotoxicity associated with PEI (though it is highly 
efficacious), low solubility under physiological conditions and poor efficacy associated 
with chitosan and PLGA nanoparticles remain the most challenging aspects for their use 
as therapeutics in the clinic [103, 146-148]. According to the clinical trials database, 
unlike PEI and cyclodextrin, chitosan and PLGA have not been investigated for 
oligonucleotide delivery in humans though they are FDA approved polymers.  
PEI is a commercially available cationic PNP, commonly used as a gold standard 
polymeric RNAi molecule delivery system and has been used in multiple in vitro and in 
vivo studies [126, 149]. PEI is made of repeating units of an amine and two aliphatic 
carbons and is available in various sizes and charge [150]. Although highly efficacious, 
high levels of cytotoxicity have been reported limiting its clinical progression as a delivery 
vehicle. Various efforts have been made to render the nanoparticle less cytotoxic and 




trials in phase I and II involving in vivo-jetPEI® and pDNA gene therapy of pancreatic 
cancer have been reported however none have been reported for siRNA delivery [152, 
153]. Cyclodextrin, a cyclic (α-1,4)-linked oligosaccharide consisting of a hydrophobic 
core and a hydrophilic outer surface [121], has been investigated in vivo [154-156]. They 
have also made it to clinical trials for cancer therapy applications but their efficacy is yet 
to be proven for clinical application [104, 157]. Dendrimers are emerging as PNPs of 
interest for siRNA delivery. At the right size and charge (to be discussed further below) 
they are less cytotoxic and can be easily synthesised to exact specifications and 
geometry making their mass production feasible. The presence of multiple reactive 
surface groups permits for multiple surface modifications allowing for substantial space 
for improving efficacy, and because they have been successfully formulated for other 
FDA approved therapeutic treatments, which will also be addressed further below, they 
are a good potential candidate for clinical application in RNAi [158].   
 


















Dendrimers (illustrated in Fig.2) are well-defined, multivalent, symmetrically spherical 
molecules of uniform size with a distinct molecular architecture made up of three layers: 
(i) a central core monomer, consisting of an atom with at least two identical functional 
groups (ii) dendrons, which are monomers added to the core molecule forming branched 
layers (generations, G) and (iii) a charged surface composed of reactive surface groups, 
usually primary amines. One of the characteristics that make dendrimers a potential 
candidates for gene therapy application is that it follows a branched dendritic structure, 
a common architectural structure seen in many biological systems including the naturally 
occurring nanometric compounds such as glycogen and proteoglycans found in the body 
[95, 159]. This pattern or architecture offers distinct functional and performance benefits, 
that is, the hyperbranched nature of the nanoparticle provides flexibility of the particle 
and creates a high surface area to volume ratio which allows for compact siRNA 
condensation [144, 159]. There are various types of dendrimers used for siRNA delivery 
such as  poly(prolene imine) [160], triazine [161], carbosilane [162], poly(L-lysine) [163], 
polyglycerol-based [164] and nanocarbon-containing dendrimers [165], however, 
emphasis will be placed on PAMAM dendrimers as they are the species of dendrimers 
most widely studied for RNAi delivery and they are the least complex to manufacture 
[158].  
The biocompatibility, size and charge of dendrimers are determined by their surface 
groups and generation levels which range from 1-10 [95, 166]. High generation PAMAMs 
G5-G8 which are large in size and have high cationic charges become more cytotoxic 
with or without siRNA complexation, therefore lower generations are mostly investigated 
for siRNA delivery [158, 167, 168]. The known number of multiple reactive groups on the 
surface of PAMAM dendrimers allows for the precise attachment of various therapeutic 
compounds, cell targeting ligands and surface modifications such as PEGylation, lipid 
molecules, amino acids and oligopeptides [169-172]. These modifications can improve 
dendrimers’ biological activities which include efficient siRNA binding and delivery, 
improved gene silencing effect, reducing cytotoxicity and improving RNase protection 
[140, 170, 173].   
A 4th generation PAMAM dendrimer [G(4)-D, also referred to as D], with an 
ethylenediamine core was conjugated with PEG2K and lipid molecule 1, 2-dioleoyl-sn-
glycero-3-phosphoethanolamine (DOPE), to form a non-cytotoxic lipid triblock 
amphiphilic copolymer molecule [G(4)-D-PEG2k-DOPE, also referred to as MD] [140]. 
The PEG molecule was added to D to improve dendrimer flexibility and siRNA 
condensation [174, 175], whilst the DOPE modification was added to improve 




were noncytotoxic. MD displayed improved siRNA delivery into cells and green 
fluorescent protein (GFP) knockdown compared to the unmodified D. In another study 
various amphiphilic PAMAM dendrons of generation 1, 2 and 3 with a long hydrophobic 
alkyl chain (varying in length) and generation 3 [G(3)] only dendron without the alkyl 
chain were formulated [177]. In vitro gene knockdown tests with these nanoparticles 
showed maximal effect was achieved with the alkylated G3 dendron with the longest 
alkyl chain optimal compared to the other alkylated and unmodified dendrons. They went 
on to use the effective nanoparticle only in in vivo RNAi experiments. Gene silencing 
experiments were carried out over a week period on nude mice bearing prostate Cancer-
3 xenograft tumors. The mice received intratumoral injections twice a week (3mg/kg 
siRNA) and the alkyl chain modified dendrimer induced ≈50% knockdown of both the 
oncogene Hsp27 mRNA and protein levels compared to scrambled siRNA nanocomplex 
control. Additionally, they showed inhibition of tumor proliferation following Hsp27-
nanocomplex treatment compared to scrambled siRNA-nanocomplex treatments. 
Another interesting in vivo study involved modifying a cystamine core G4-PAMAM 
dendrimer by adding PEG as a crosslinker between the dendrimer and an oligo-arginine 
cell penetrating peptide. In an MI model, the dendrimer nanoparticle was complexed to 
siRNA against Angiotensin II type 1 receptor (siAT1R) and showed that both in vitro 
(neonatal cardiomyocytes) and in vivo ATR1 mRNA was knocked down. Adult rats had 
their left descending coronary artery occluded for 30mins and immediately after 
reperfusion, the peptide modified dendriplex carrying angiotensin II type 1 receptor 
(AT1R) siRNA was injected in 3 regions of the infarct border zone. 3 days post treatment 
they observed improved cardiac function, reduced infarct size, and reduced AT1R 
expression in the rats treated with the dendriplex compared to saline and dendrimer only 
treated controls [178].  
Though few, there are dendrimer based nanomedicines in clinical trials for various non-
RNAi based therapies including the clinically approved vaginal microbicide Vivagel® 
(SPL7013, or astodrimer sodium). It is a lysine-based dendrimer with naphthalene 
disulfonic acid surface groups in a sodium solution with antiviral and antibacterial 
properties [72, 97]. This shows that dendrimer PNPs are increasingly gaining momentum 
as a potential therapeutic nanoparticle. The ability to generate many formulations and 
modifications to improve their RNAi efficacy further places dendrimers as good 





 Lipid based nanoparticles 
 
The two forms of lipid based nanoparticles with the highest frequency of clinical 
investigation and FDA approval are micelles and liposomes. Estrasorb™ is an example 
of a currently clinically approved micelle nanomedicine being applied in hormone 
replacement therapy [41]. Some of the 10  FDA approved liposomal nanomedicines 
reported in clinics that have been shown to increase drug delivery to the tumor site with 
reduced systemic toxicity side effect include Doxil® (liposomal doxorubicin) which is 
used in therapy of various cancers such as: metastatic breast cancer, multiple myeloma, 
ovarian cancer and Karposi’s sarcoma and the recent Onivyde® (liposomal irinotecan) 
for pancreatic cancer therapy [41, 179].  
Micelles and liposomes come in various forms depending on the phospholipids, helper 
lipid types, conjugates attached to the lipid molecules as well as the overall surface 
charge of the nanoparticle when it is completely assembled [180-182]. It is clear from 
their frequency of use and success rate in the clinic that lipid nanoparticles are effective 
at drug delivery in vivo. They have great potential for use in siRNA delivery due to their 
high cell transfection efficiency resulting from their direct interaction with the cell 




Micelles are made from long hydrocarbon fatty acid molecules with a polar head that 
self-assemble to form monolayer spherical structures with a hydrophobic core or 
hydrophilic core in the case of an inverted micelle (Fig.3) [184]. Micelles can be 
synthetically made to form polymeric micelle structures composed of complex 
amphiphilic block polymers consisting of a hydrophilic polymeric block and a hydrophobic 
polymeric block that self-aggregate to form polymeric micelles [106, 140, 182, 184, 185]. 
Micelle systems made by these complex structures allow for easy incorporation or 
attachment of oligonucleotides to the molecules. Micelles are mainly used in 
encapsulation and delivery of hydrophobic and poorly soluble drugs and the block 
polymers are designed to allow for more efficient anionic nucleic acid interaction and 
encapsulation [41, 98, 140].  
In cancer therapy, micellar drug nanoparticle systems are being explored for 




resistance in tumors [140, 182, 184, 186-189]. In an elegant study, a polymeric 
degradable poly(ethylene oxide)-block-poly(caprolactone) (PEO-b-PCL) micellar 
nanoparticle functionalised on both the PCL and PEO was developed [189]. The PCL 
block was functionalised to bind to either siRNA against multidrug resistant gene 1 
(mdr1-siRNA) which inhibits the expression of drug transporter protein P-glycoprotein 
(P-gp), or conjugate doxorubicin (Dox). The PEO surface side was also functionalised to 
bind either cancer targeting ligand RGD4C peptide (ACDCRGDCFCG) or cell 
penetrating TAT peptide (GRKKRRQRRRPQ). When injected intravenously into murine 
models with drug resistant MDR-MDA-MD-435 human tumor xenografts that express 
high levels of P-gp, the multifunctional polymeric micellar system was capable of co-
delivering mdr1-siRNA and Dox to target cells. They also showed improved Dox efficacy 
in animals that received the micelle-mdr1-siRNA system compared to non-micelle, 
micelle-Dox or micelle-scrambled siRNA controls, indicating inhibition of P-gp-mediated 
Dox resistance.  
In other studies, polymeric micelle nanoparticles have been used for the delivery of 
various oligonucleotides for cancer therapy [106, 186]. A self-assembling block 
copolymer containing poly(ethylene glycol)-hydrophilic block-poly(l-lysine) (PEG-b-PLL), 
with lysine amines modified with 2-iminothiolane that allowed for siRNA binding on the 
PLL end. The PEG terminus was modified with a cell-surface binding peptide cyclo-Arg-
Gly-Asp (cRGD) peptide which specifically binds integrin receptors displayed on the cell 
surface of tumors as well as endothelial cells associated with growing tumors [106]. 
When injected intravenously in mice these modified micelles resulted in improved blood 
circulation time and accumulation in tumors 24hrs compared to naked siRNA or micelles 
without the targeting cRGD peptide. In the study, siVEGF was in-cooperated into the 
polymeric micelles and used to knockdown VEGF in mice with subcutaneous HeLa-luc 
tumors. The modified micelle nanocomplexes showed the highest gene knockdown and 
tumor size reduction 12 days post treatment compared to micelles complexed with 
scramble siRNA negative control. Due to the hydrophobic interior of micelles, there is no 
convenient method for sequestering the hydrophilic oligonucleotides making these 




A liposome in its simplest form (Fig.3) is composed of amphiphilic phospholipid 




phosphatidylethanolamine (PE) and phosphatidylglycerol that self-aggregate to form a 
lipid bilayer with a hydrophilic core and a surface charge [98]. Lipid nanoparticles have 
high transfection potential because they fuse easily with the cell membrane, which 
consists mainly of cholesterol, PC, PS and PE phospholipids; rendering them inherently 
efficient at cell penetration and escaping endosomes to release their drug payload into 
the cytoplasm [190, 191]. They are the most easily synthesised nanoparticle that has the 
ability to incorporate both hydrophilic drugs (in its aqueous core) and hydrophobic drugs 
(in the lipid bilayer) and hence are increasingly the most commonly investigated in the 
clinic and were the first nanoparticle approved in FDA clinical trials [41, 98, 192]. The 
further modification of approved liposome based drugs by changing their chemical 
groups, stabilising helper lipid molecules and adding surface modifications to enable the 
delivery of various drugs, improve their therapeutic efficacy in various disease targets, 
reduce their toxicity and introduce stimuli responsiveness (e.g pH and temperature) [41, 
98] is under intensive investigation. In addition to liposomes being the most commonly 
used nanocarriers in clinics they are the basis of the commercially available transfection 
reagents such as Lipofectamine® RNAiMAX and Invivofectamine® 3.0, which were 
developed for the transport of siRNA. A wide range of liposomes can be constructed by 
using different combinations and proportions of phospholipids, aliphatic chain, 
conjugates (PEG, cell targeting ligands, antibodies ) and helper lipids (such as neutral 
fusogenic lipids DOPE, DOPC, DSPC , PEG-lipids and cholesterol) in their assembly 
[47, 98, 180, 193]. Described below are the liposome groups under investigation for 
siRNA based on charge [2]. 
 
1.3.3.2.2.1 Cationic Liposomes 
 
Cationic liposomes are widely used for siRNA delivery and are advantageous over 
anionic liposomes because they can interact with the negatively charged cell surface 
allowing for cell penetration and cargo delivery whereas anionic liposomes are repelled 
by the membrane [180, 193]. Cationic liposomes are made from cationic lipids such as 
1,2-dioleoyl-3-trimethylammoniumpropane (DOTAP) and 2-dioleyloxy-N,N-dimethyl-3-
aminopropane (DODMA) in combination with neutral helper lipids [2]. The right balance 
in ratio of these different types of lipids that make up the liposome however needs to be 
achieved in order to produce nanocomplexes with the right charge tolerable to cells in 




of reactive oxygen species and induction of high calcium levels in cells, a common 
feature associated with liposomes with a high cationic charge [194-196].  
 
 
For example, a study with four liposomal formulations, composed of DOTAP and 
Cholesterol (Chol)-derivative cationic lipids in combination with different ratios of the 
neutral DOPE and cholesterol helper lipids, were made to produce cationic liposomes 
that had similar +ve surface charges (≈ 50mV) [197]. When the nanoparticles were 
complexed to siRNA at nanoparticle nitrogen (N) to siRNA phosphate (P) molar ratios 
(N/P) ratio of 2.5, 5 and 10, all nanoparticles had similar rates of transfection and gene 
knockdown effect, but the groups of nanoparticles with less helper lipid (DOPE and 
cholesterol) ratios were more cytotoxic compared to the DOTAP/Chol/DOPE liposome 
with the highest helper lipid ratio. Cell cytotoxicity was also shown to be influenced by 
siRNA concentration (40nM and 100nM) and the N/P ratio of (2.5, 5 and 10). All four 
cationic liposome formulations at any N/P ratio were cytotoxic when 100nM siRNA was 
complexed to the nanoparticle, whilst at lower 40nM siRNA concentration, only the 
nanocomplexes at higher N/P of 10 and consequently a high cationic charge were more 
cytotoxic compared to lower N/P ratios 2.5 and 10 with lower cationic charge [197].  
This in vitro study demonstrated the effects of cationic liposomes’ physicochemical 
properties, lipid composition, cationic liposome and siRNA concentration on cell 




cytotoxicity. In this case, a lower concentration of siRNA and liposome had to be used in 
order to achieve non-cytotoxic gene knockdown effect. Cationic liposomes incorporate 
negatively charged siRNA via electrostatic interactions easily and they demonstrate 
great potential candidate nanoparticles for in vivo gene knockdown. However because 
of the potential immune trigger and cytotoxic effect they are likely to induce, special 
consideration of the nanocomplexes overall charge and siRNA concentrations to be used 
is required to ensure optimal efficacy. 
The cationic lipids in liposomes effectively condense nucleic acid with the negatively 
charged siRNA molecules via electrostatic interaction to form multiple structural 
conformational possibilities (Fig.4) such as lipoplexes, lipopolyplexes, membrane/core 
nanoparticles (MCNP) and stable nucleic acid lipid particles (SNLPs) [2]. Lipoplexes are 
formed when the lipids form multiple bilayers and the siRNA is embedded within the 
adjacent lipid bilayers [2]. Lipopolyplexes are single bilayer liposomes containing 
polyplexes (a cationic-polymer / siRNA complexation) [2]. MCNP are made of a single 
bilayer as a shell encasing an inorganic core loaded with siRNA molecules [198].  
 
 
Figure 4: Possible structural conformations made from complexing siRNA to cationic liposomes. 




SNALPs are also single bilayered membranes with a neutral surface charge and their 
siRNA is encapsulated in the interior of the liposome interacting with the inner wall of the 
bilayer which is positively charged. This is made possible because the liposomes are 
composed of titrable pH-sensitive lipids, that is, cationic at pH=4 and neutral at pH 7.4 
[2, 199]. SNALPs include PEGylated lipids in their composition for enhanced 
nanocomplex stability and evading mononuclear phagocyte system [43, 200]. There are 
a number of examples of efficient siRNA delivery in vivo by SNALPs that have been 
reported [43, 201-203]. The initial SNALP formulation for RNAi in hepatitis B virus (HBV) 
therapy was developed by Morrissey et al 2005 [204]. In a mouse HBV model, the 
SNALP achieved siRNA delivery which resulted in persistent HBV inhibition, in a dose 
dependent manner [43]. Since then SNALPs have emerged as one of the leading 
liposome formulations under clinical development and are in different stages of clinical 
trials for diseases such as hypercholesterolemia, hereditary transthyretin (TTR)-
mediated amyloidosis and various cancers  [200]. Patisiran is an example of SNALP 
liposome produced by Alnylam® Pharmaceuticals that was recently approved by the 
FDA. Patisiran (ALN-TTR02) is an RNAi SNALP, the first and only approved RNAi 
nanoparticle being applied in the clinic for the treatment TTR-mediated amyloid 
polyneuropathy in adults. TTR-mediated amyloidosis is a slowly progressive disease 
caused by TTR gene mutations and the deposition of hepatocyte-derived TTR amyloids 
in the peripheral nerves and heart [31, 205]. The cationic liposomal SNALP complexes 
are introduced intravenously into patients and contain siRNA molecules against TTR 
mRNA. This RNAi drug reduces hepatic synthesis of TTR protein in patients and 
therefore improves multiple polyneuropathy and cardiomyopathy clinical manifestations 
of TTR amyloidosis [31, 206].  
In another study, a group again in association with Alnylam® developed a SNALP-ApoB 
siRNA formulation that was used to reduce LDL cholesterol levels for 
hypercholesterolemia therapy in non-human primate animal models [203]. The SNALP 
was composed of the lipids [methoxypoly (ethylene glycol)2000)carbamoyl]-1,2-
dimyristyloxy-propylamine (PEG-C-DMA),  cationic lipid 1,2-dilinoleyloxy-N,N-dimethyl-
3-aminopropane (DLinDMA), and helper lipids 1,2-distearoyl-sn-glycero-3-
phosphocholine and cholesterol, in a 2:40:10:48 molar ratio. A single systemic injection 
of the SNALP-siApoB formulation resulted in ApoB gene silencing (in a dose dependent 
manner) in the liver of cynomolgus monkeys, 48hrs after administration, with maximal 
silencing of over 90%. 
In later studies they developed more lipid nanoparticles termed lipidoids, similar to their 




of 1200 structurally diverse lipidoids was synthesised and used to formulate lipidoid 
particles that could be either complexed with siRNA or miRNA. Using a luciferase 
screening assay in HeLa cells, they selected lipidoids that resulted in high levels of gene 
silencing in vitro after cells were treated with firefly luciferase targeting siRNA-lipidoid 
complexes [207]. Seventeen lipidoid formulations composed of various types of amine-
alkyl-acrylate/acrylamide lipidoid conjugates, cholesterol and mPEG2000-DMG (Alnylam® 
product) in a 42:10:48 molar ratio, was selected from in vitro assays for further in vivo 
screening. The lipidoid formulations were complexed to serum Factor VII siRNA (siFVII) 
and systemically introduced into mice to target serum FVII protein. Seven lipidoids were 
identified to achieve significant reduction of FVII with the largest reduction being caused 
by the 98N12-5 (5-tailed) lipidoid. The 98N12-5 lipidoid was complexed with various 
siRNAs and miRNAs to test for efficacy in various animal and disease models when 
locally or systemically delivered. For example, siFVII and siApoB were intravenously 
injected into rats and resulted in significant gene knockdown of the respective gene 
targets in the liver compared to lipidoids formulated with siControl. The lipidoid was also 
complexed to anti-miR122 (which targets miR122 and results in target gene 
upregulation) and was systemically delivered which resulted in repressed miR122 
(compared to mismatched anti-miR122 control) in the liver. In non-human primates 
cynomolgus monkeys were given i.v injection of lipidoid-siApoB formulation and 
monitored up to 30 days post treatment. Serum ApoB reduction was observed 
(compared to animals treated with lipidoid-siControl) in a dose dependent manner with 
the lowest levels achieved rapidly by day 3, >50% silencing still maintained at 2 weeks 
and full recovery of expression achieved 1 month later. Silencing duration extended their 
previous reports for systemic RNAi in nonhuman primates where the study terminated at 
11 days [203]. In a separate study, they used the same 98N12-5 lipidoid particle to 
complex siRNA against proprotein convertase subtilisin/kexin type 9 (PCSK9) for 
hypercholesterolemia using rat and mice models [208]. PCSK9 protein regulates LDL 
receptor (LDLR) protein levels. Reduction of PCSK9 causes increased LDLR levels in 
the liver and reduction of plasma LDL cholesterol. Lipidoid-siPCSK9 reduced PCSK9 
mRNA levels in the liver by 50–70% which was associated with up to a 60% reduction in 
plasma cholesterol levels compared to lipidoid-siControl. This liposome has entered and 
completed phase I clinical trial as ALN-PCS02 with a positive outlook where the drug 
reduced LDL cholesterol in healthy participants with raised cholesterol concentrations 
[209]. Further progress on this is yet to be reported and it may have been hindered by 
the competing FDA approved modRNA drug, mipomersen (discussed in prior section 
1.3.1), used in the clinic for therapy in patients with homozygous and severe 




outlook on efficacy of cationic liposomes, SNALP in particular, in vivo for various targets 
when systemically injected. 
Other cationic lipid particles that are not SNALPs, have been able to illustrate their use 
in various therapeutic miRNA and siRNA delivery in vivo. A liposome nanoparticle 
composing DODMA/egg-PC/Cholesterol/PEG-cholesterol at molar ratios of 45:15:35:5, 
with a slight +ve charge (≈ 4mV) at pH 7.4 and a slight –ve charge (≈ 4mV) when 
complexed to siRNA was developed for gene knockdown in murine tumor xenografts 
model. The nanoparticles were again complexed with miR-122, a liver-specific tumor 
suppressor miRNA sequence commonly downregulated in hepatocellular carcinoma 
(HCC), and injected intratumorally twice a week over 26 days in nude mice xenografts. 
The experimental groups yielded efficient miR-122 knockdown of its target genes by 
>95% in the liver and tumor xenografts, as well as reduced angiogenesis and tumor 
growth reduction by 50% compared to a control siRNA group without causing systemic 
cytotoxicity. This liposome nanoparticle demonstrated therapeutic potential, in particular 
for HCC therapy, and it demonstrated efficient miRNA mimics delivery and gene 
knockdown in vivo [210]. The use of cationic lipid nanoparticles in various in vivo studies 
and the approval of patisiran application in the clinic shows the advancement of cationic 
liposome nanoparticles as RNAi delivery vehicles. 
Lipofectamine® RNAiMAX and Invivofectamine® 3.0 are examples of very widely used 
commercial cationic lipid transfection reagents developed to optimise siRNA/gene 
delivery and efficacy in vitro and in vivo. The structures and formulations of these 
liposomes are proprietary but direct communication with the manufacturer indicated that 
post siRNA complexation, Lipofectamine® RNAiMAX remains cationic whilst 
Invivofectamine® 3.0 has a neutral charge. Lipofectamine® RNAiMAX has mainly been 
used in multiple in vitro studies but has also been utilised in a few in vivo studies [211-
213]. It was used in a study that demonstrated intracardiac injection of pro-regenerative 
miRNA mimics for cardiac repair [213]. In this study, Lipofectamine® RNAiMAX was 
used as delivery vehicles of miRNA mimics (has-miR-199a-3p, has-miR-1590a-3p) in a 
mouse MI model. These miRNAs were previously shown when expressed in the heart 
using viral vectors to stimulate cardiomyocyte proliferation and thus induce cardiac 
regeneration post MI [214]. One dose of 1.4ug miRNA complexed to Lipofectamine® 
RNAiMax nanoparticles were directly injected to the infarct border zone of the mice. 
Results showed improved cardiac function and repair compared to control untreated 
mice, reduced infarct size 8 weeks post MI and increased the number of cardiomyocytes 
in a proliferative state. This is an important study were liposome nanocomplexes were 




Invivofectamine® 3.0 is a newer and more costly transfection reagent that has been 
shown in a number of studies to be an effective transfection reagent for RNA delivery in 
various tissues in vivo when injected systemically [38, 215-219]  but studies that show 
direct injection of this liposome in solid tissue at the site of action is limited [213, 220]. A 
recent study that investigated vascular lung-targeted delivery of miRNA (with no 
mammalian homologue) complexed to PEI and Invivofectamine® 3.0 showed that, 
systemic i.v injection via the jugular vein of rats with both miRNA nanocomplexes 
resulted in a lack of pulmonary selectivity and led to broad elevated miRNA levels in the 
lungs, heart and excretory organs (spleen, liver and kidneys), 2 and 24hrs post injection 
[216]. Preferential transfer of miRNA was observed in the spleen and liver, and less in 
the kidneys for both PEI and Invivofectamine® 3.0 nanocomplexes. The study shows the 
potential ability to deliver miRNA in various tissue when delivered intravenously however 
it also emphasised that off target gene knockdown may occur in various tissues where 
the nanocomplexes accumulate, which may not necessarily be the intended target. 
Another study utilised Invivofectamine® 3.0 in the delivery of miR-302d nanocomplexes 
into peritoneal cells of adult mice with induced lupus-like phenotype, a model of 
systematic lupus erythematosus (SLE) [219]. miR-302d was established as a therapeutic 
target in this study where it was shown that miR-302d levels negatively correlated with 
disease severity in SLE patients and that miR-302d down regulated interferon regulatory 
factor (IRF)-9 thus decreasing expression of interferon stimulated genes. Lupus induced 
mice were given an intraperitoneal injection of miR-302d mimics and control miRNA 
complexed with Invivofectamine. Seven days post injection, results showed significant 
downregulation of IRF-9 and interferon-stimulated genes expression in the extracted 
peritoneal cells, kidneys, lungs and blood of the miR-302d treatment group with a 
concomitant reduction in inflammation in comparison to the control miRNA group. In this 
study, it was shown that inhibition of the type I interferon pathway through miR-302d 
delivery via Invivofectamine has potential benefits for SLE patients. 
It is important to note that multiple studies illustrate the use of cationic liposomes and 
show great prospective as nanoparticles to use for RNAi in vivo when introduced 
systemically. Other than the discussed cancerous tissue and a few intramyocardial 
injection studies, there is limited evidence of these nanoparticles being applied in solid 
tissue. Hence the use of liposomes to demonstrate targeted gene knockdown at the site 





1.3.3.2.2.2  Neutral Liposomes 
 
Neutral liposomes are made from lipids with a neutral charge such as zwitterionic  1,2-
dioleoyl-sn-glycero-3-phosphocholine (DOPC) and 1,2-dioleoyl-3-dimethylammonium-
propane (DODAP) to improve blood circulation and reduce the potential toxicity and 
immunogenicity arising from the charged cationic liposomes [2, 193, 221]. Neutral 
liposomes function by entrapping siRNA in their hydrophilic core [222]. However, the lack 
of interaction between the oligonucleotides and the neutral lipids at physiological pH 
results in low siRNA entrapment efficiency by passive loading resulting in complex siRNA 
incorporation processes [223]. Among other methods, the use of ionisable pH-sensitive 
lipids such as DODAP with a pKa of 6.6 and ethanol dialysis, to allow siRNA interaction 
in the lipid’s cationic state has been shown to improve siRNA entrapment [223]. In 
addition, the cellular uptake of neutral liposomes is less efficient in comparison to that of 
cationic liposomes [224]. 
Despite this, a variety of neutral liposomes have been investigated for RNAi and shown 
efficacy in vivo.  Examples of such a study include the use of DOPC neutral liposomes 
in cancer therapy. The liposome was used in the delivery of siRNA in orthotopic xenograft 
mice models for ovarian cancer targeting EPH Receptor A2 [225] and breast cancer 
targeting B-cell lymphoma 2 (Bcl-2) [221]. Systemic injection of the DOPC liposomal 
nanocomplexes with their respective siRNA in these studies showed localisation of 
siRNA in target tumors and consequentially resulted in tumor growth suppression [221, 
225]. Another example of a neutral liposome used in vivo is a PEGylated DOPE derived 
neutral liposome composed of (DOPE, N-(carbon-methoxypolyethylene-glycol-2000)-
1,2-distearoyl-sn-glycero-3-phosphoethanolamine and cholesterol lipids) which was 
formulated and complexed to siRNA against Myeloid cell leukaemia-1 (MCL1) with high 
encapsulation efficiency [226]. MCL1 is an anti-apoptotic protein in macrophages 
responsible for disease progression in rheumatoid arthritis. The in vitro gene knockdown 
experiments showed MCL1 mRNA (60%) and protein (90%) knockdown and resulted in 








1.4 Barriers of nanoparticle efficacy 
 
Though nanoparticle based approaches have shown good transfection efficiency and 
RNAi efficacy in vitro, the majority of them are in their formative stages and there are 
relatively few that have reached the pre-clinical stage and very few are being investigated 
clinically [41, 97, 98]. Their clinical translation and FDA approval success rate is still 
limited owing to a variety of systemic barriers which include: eliciting an immune 
response, lack of targeted and localised tissue delivery of the RNAi nanoparticles 
resulting in off target effects, accumulation in clearance organs (liver, kidneys and 
spleen) which potentially results in cargo dependent toxicity in those tissues and 
concomitant failure at the intended peripheral target tissues  [38, 227-231].  
One approach to overcome the above issues is the development of a RNA delivery 
vehicle/system to localise and sustain release of siRNA in the targeted tissue. This 
siRNA delivery system should holistically address the barriers encountered by siRNA or 
nanocomplexes namely: RNAse attack and consequential short plasma life span, off 
target delivery, immunogenicity, cytotoxic effects as well as satisfactory efficacy [232]. 
Increasing siRNA availability at the required site and preventing off target effects should 
reduce the dosage and frequency of delivery required to achieve gene knockdown effect 
before RNase attack and systemic clearance by both phagocytic cells and secretory 
organs. A promising approach that has begun recently to receive significant attention is 
the delivery of RNAi nanoparticles in combination with scaffolds [232, 233].  
 
1.5    Scaffolds and nanocomplex delivery 
 
Scaffolds can be defined as biologically compatible biomaterials and are currently used 
in tissue engineering for a wide range of purposes which include structural support, 
adhesion, and as sealant and surface coatings [234]. Most importantly scaffolds are 
increasingly being investigated as an efficient way of providing localised and sustained 
therapeutic effect of drugs, cells, growth factors and nucleic acids in vivo [234, 235]. The 
combination of RNAi and scaffolds is a relatively new but growing offshoot of this 
research. As for other drugs and biomolecules, sustained and localised release of RNAi 
molecules encapsulated in a scaffold is expected to improve efficacy, specifically by 
achieving a more prolonged gene silencing effect than the transient effect of 2-4 days 




or siRNA nanocomplexes in target tissue as opposed to systemic delivery, scaffolds may 
limit exposure to RNases, circumvent global immune response and prevent off target 
effect and systemic clearance by excretory organs  [233, 235].  
Factors that need to be considered in scaffold design for RNAi purposes not only include 
tissue biocompatibility and biodegradability into non-toxic by-products but also include 
injectability, biomaterial type (synthetic or natural), scaffold structure (pore size and 
connectivity), degradation time and electrostatic/reactive inertness [235, 237]. The latter 
might reduce nanocomplex interaction and/or cause aggregation which may result in 
nanocomplex inactivity.  
Some of the scaffolds being used for RNAi and previously reviewed include macroporous 
scaffolds [238, 239], microparticles [240, 241], electrospun nanofibres [242-245] and 
hydrogels [246]. Pre-crosslinked scaffolds such as microparticles, electrospun fibers and 
surface coating scaffolds for medical devices and implants have a pre-conceived shape 
and size and will require surgical implantation [233, 234, 246, 247]. As they are more 
invasive, they are less ideal for siRNA delivery in vivo. Injectable and in situ forming 
scaffolds such as hydrogels on the other hand carry the advantage of having the ability 
to mould to the required shape, access unreachable areas and importantly they have the 
potential to be delivered in a minimally invasive fashion, therefore, allowing for possible 
shorter recovery time for patients [234]. Nonetheless, mild gelation conditions and 
gelation rates during the crosslinking process of these in situ forming hydrogels are 
essential to prevent overheating and tissue damage, to allow injecting and retention of 
the gel precursors and therapeutics at the site of action before diffusion occurs [235]. 
Another unique feature of hydrogels that makes them advantageous and highly favoured 
in research for clinical application as a biomaterial compared to other scaffold types 
mentioned above is that they characteristically retain a high volume of water content 
identical to human tissue and provide cells or tissue with structural support emulating 
that of the ECM [248, 249]. Therefore hydrogels and their use in the controlled delivery 




Hydrogels are water swollen 3D networks of porous and hydrophilic polymers that are 




demonstrated to permit cellular invasion and provide cues for surrounding tissue to 
regenerate [250-253]. They have also been shown to allow for entrapment of 
biomolecules and cells as well as offer controlled release of the encapsulated cargo 
without destroying tissue structure or function [235, 251-253]. Hydrogels can be 
engineered in ways that promote degradation/porosity and drug release. This 
improvement in adjustable biodegradability and porosity of the scaffold would 
theoretically equate to improved localised release of nanocomplexes over the required 
time at the injected site, therefore providing sustained release of RNAi molecules at the 
target site. Wang and Burdick 2017 [235] extensively reviewed the various types of 
modifications that can be applied to the hydrogels’ design to enhance their degradability 
in response to surrounding stimuli in vivo such as pH, temperature, hydrolysis, and 
enzymatic degradation and hence improve cargo delivery [235].  
Hydrogels used in sustained release of RNA molecules can be made by synthetic 
polymers, naturally derived polymers or combinations thereof [237, 254]. Most synthetic 
biomaterials, without any modifications, lack the inherent ability to provide cues for 
cellular interaction and tissue regeneration, but they do allow for greater tunability of 
properties compared to natural polymer hydrogels [237]. RNAi molecules require optimal 
integration into scaffolds without significantly reducing their gene silencing effect. A 
summary of the various hydrogels that have been used in preclinical RNAi studies is 
given in Table 2. As reflected in the table PEG based hydrogel scaffolds are one of the 
most commonly used scaffolds for in vivo siRNA delivery. PEG hydrogels are favourable 
because they are electrostatically inert and they can easily incorporate nanocomplexes 
during their formation and gelation process and will not directly interact with charged 
nucleic acids or nanocomplexes. In addition, PEG hydrogels are injectable, have the 
ability to crosslink in situ and they can be designed to have various engineerable 
physical, mechanical and chemical properties. Therefore they will be deliberated upon 
further in sections to follow. 
 
Table 2: Summary of in vivo scaffold mediated RNAi in therapeutics. 
Condition Hydrogel Nanoparticle Target Observations  Ref 
Cancer      
 Chitosan Naked siRNA TG2 Inhibition of tumor growth in 
melanoma and breast cancer 




PEI/pDNAshRNA Akt1 Reduced Akt1 expression, 





inhibited tumor growth in breast 
cancer mice model. 
 PLGA-PEG-PLGA PEI/pDNAshRNA PLK1 PLK1 expression inhibition, 
enhanced cell cycle regulation, 
apoptosis and tumor growth in 
osteosarcoma mice model. 
[257] 
 PAMAM-Dextran  PEI/siRNA Luciferase Improved transfection efficiency 
and luciferase silencing in mice 







Tumor size reduction in breast 
cancer mice model. 
[259] 
 Collagen-PEG Naked siRNA 
& pDNAeNOS 
Interleukin-6 Reduced inflammatory cells, 
increased blood vessel density, 
growth factor binding,  
[260] 
 Collagen PEI/siRNA Id1 Improved siRNA delivery, 
prolonged Id1 expression 
suppression, inhibition and 
reduced tumor growth in gastric 
cancer xenograft mice model. 
[261] 
 PEI-PEG-PP Naked siRNA cyclin B1 Reduced cyclin B1 expression 
(30 days) and decreased tumor 
volume in prostate cancer mice 
model. 
[262] 
 PEI-PEG-fPP Naked siRNA VEGF Extended VEGF gene silencing 
(21 days) and reduced tumor 
sizes in breast cancer mice 
model. 
[263] 
 PEI-PEG-PP Naked siRNA Bcl-2 Reduced Bcl-2 expression 
(30days) and tumor volumes in 
mice cancer xenografts.  
[264] 
Inflammation      
 Alginate/chitosan 
biomaterial 
PEI/siRNA CD98 CD98 expression and colitis 
reduction in mouse colic tissue. 
[265] 
 Chitosan Naked siRNA VEGF Hydrogel extended siRNA 
retention, reduced VEGF 
expression, decreased mucosa 
thickness in rats. 
[266] 
 Sericin silk protein Naked siRNA RelA Reduced ear thickness and 
clinical skin severity in AD-
induced ear skin of mice. 
[267] 
 Collagen-PEG Naked siRNA 
& pDNAeNOS 
Interleukin-6 Reduced inflammatory cells, 
increased blood vessel density, 




     
 PLA-DX-PEG  
 
Naked siRNA BMP-2 BMP-2 induced Noggin gene 
expression suppression and 







Naked miRNA miR-26a 
targets 
System led to increased 
vascularization and complete 
bone repair in rats with calvarial 
bone defect  
[269] 
 PEG-b-PLA-b-DM Diblock cationic 
polymer/siRNA 
 
Wwp1 Wwp1 silencing at fracture, 
accelerated bone formation and 
increased biomechanical 
strength in mice 
[270] 





Noggin and miR-26a targets 
reduction, accelerated bone 





     
 Cationised pullulan Naked siRNA MMP2 siRNA uptake, and reduced 






pDNAshRNA ACE Reduced ACE expression, 
inhibited cell apoptosis, reduced 
infarct size, and improved 
cardiac function in rat MI model. 
[273] 
 PEI-PEG hydrogel Naked  
siRNA-Cy5.5 
GFP Improved siRNA uptake and 
reduced GFP fluorescence in 
GFP-expressing rat hearts.  
[274] 
 HA-PEG hydrogel Naked miRNA miR-29B 
targets 
Decreased elastin, less collagen 
deposition, increased 
vascularisation and improved 
myocardial function in mice.          
[275] 
 HA Naked miRNA miR-302 Sustained local cardiomyocyte 
proliferation and improved 
myocardial function in mouse MI 
model. 
[276] 
 HA Naked siRNA MMP2 Improving myocardial thickness 
and myocardial function in a rat 
MI model. 
[1] 
      
TG2=transglutaminase, Akt1=serine/threonine-protein kinase, CLA=Conjugated linoleic acid, PLK1=Polo-
like kinase 1, PLGA=poly(d,l-lactide-co-glycolide), pBAE=oligopeptide-terminated poly(β-aminoester), 
Id1=Inhibitor Of DNA Binding 1,PEI-PP=Polyethyleneimine-poly(organophosphazene), fPP=folate PP,PLA-
DX-PEG=poly-D,L-lactic acid-dioxanone-poly(ethylene glycol), BMP=Bone morphogenetic proteins, HP-
HA-PEG=heparin-thiol- hyaluronic acid-poly(ethylene glycol), PEG-b-PLA-b-DM = EG-b-poly(lactide)-b-
dimethacrylate, Wwp1=WW domain-containing E3 ubiquitin protein ligase 1, PEG-PLA-DM=poly(ethylene 
glycol)-poly(lactic acid)-dimethacrylate, PEI=polyethylenimine, ACE=angiotensin-converting enzyme, Dex-
PCL-HEMA/PNIPAAm=dextran-poly(e-caprolactone)-2-hydroxylethylmethacrylate-poly(N-
isopropylacrylamide),RelA= NF-κB subdomain, MMP=matrix metalloproteases, VEGF=Vascular endothelial 





Compared to synthetic polymers, fewer natural polymer derived hydrogels have been 
investigated for siRNA delivery both in vitro and in vivo and these include carbohydrate 
based (chitosan, hyaluronic acid (HA), alginate) and protein based (gelatin, collagen, 
fibrin) hydrogels [249, 254, 277]. Of the mentioned natural polymers, fibrin based 
hydrogels have not been adequately evaluated in vitro and they have not been 
demonstrated in vivo therefore further investigation of this scaffold material is desirable 
as it offers advantages that will be discussed and explored further. Hydrogels made of 
naturally derived polymers have an added advantage over synthetic based scaffolds 
because they play a role in cell interaction, signaling and adhesion. However, without 
modifications, they tend to lack adequate mechanical properties and engineerability that 
is afforded by synthetic hydrogel polymers, thereby compromising their application in 
vivo [234, 278]. The combination of synthetic and natural polymers to develop hybrid 
hydrogel scaffolds with improved combined properties for sustained delivery is now 
being widely investigated. Hence synthetic PEG hydrogels, naturally derived fibrin 
hydrogels and their modifications with potential for RNAi molecules delivery will be 
discussed. 
 
 PEG hydrogels 
 
PEG hydrogel scaffolds are inert, biocompatible, water swollen synthetic polymer 
networks. They are made of reactive PEG polymer molecules with reactive linear or 
branched structures (referred to as arms) and reactive crosslinker segments [234, 277]. 
PEG polymers are one of the most advantageous synthetic biomaterials to use for 
hydrogel formation in tissue regeneration because, in addition to what was discussed 
above (section 1.5), PEG is an FDA approved conjugate molecule with various 
biomedical applications in the clinic which include many FDA approved protein-PEG 
conjugates for treatment of diseases such as cancer and hepatitis [279, 280]. PEG 
hydrogels can be engineered to be degradable or non-degradable by adding crosslinker 
segments with various characteristics during polymerisation [277] and the hydrogel 
crosslinking process is easily achieved in response to conditions such as heat, pH, 
radiation and photopolymerisation [254, 277, 281-283]. In addition to degradability other 
characteristics such as pore structure and hydrogel function can be achieved by altering 
(i) PEG polymer type (ii) crosslinker type (iii) the ratio of these reaction components (that 
is PEG polymer, crosslinker) used during the hydrogel polymerisation and (iv) 




requirements [234, 277, 284-286]. These functional bioactive groups that can be added 
include heparin, RGD peptide motif and growth factors, they can also be used to 
engineer the hydrogels for specification of function [277, 284, 287, 288]. 
There are various types of PEG polymers that are determined by the kind of functional 
group they consist of on their reactive arms, for instance: amine, thiol, carboxyl, acrylate 
(AC) and vinyl sulfone (VS) functional groups [277]. Some of the crosslinker types 
include hydrolytically degradable poly (lactic acid) (PLA), polyglycolic acid molecules, 
and reactive enzyme sensitive peptide sequences such as matrix metalloprotease 
(MMP) [277, 284, 286]. 
An example of a particularly useful and widely explored form of PEG hydrogel system 
that is a powerful synthetic ECM mimic is an enzymatically degradable PEG hydrogel 
initially developed by the Hubbell group [289]. A representation of such an enzymatically 
degradable PEG hydrogel formation is shown in Fig.5. Where a multi arm (typically 4 or 
8-arm) PEG with acrylate (AC) or sulfhydryl (VS) reactive end groups is crosslinked with 
a reactive bis-cysteine protease sensitive peptide. This protease sensitive sequence can 
be tailored to be MMP sensitive and there has been a wide range of applications and 
studies using the MMP sequence GCREGPQGIWGQERCG developed by the Hubbell 
group containing the MMP1 enzyme cleavage motif GPQG↓IWGQ (arrow indicates 
cutting site for the MMP1 enzyme) [285, 290].  
The advantage of enzymatically degradable hydrogels over hydrolytically degradable 
ones is that non-enzymatic hydrolysis is uncommon in vivo. Naturally, the ECM is 
degraded by migrating cells that secrete proteases such as, serine proteases,	
collagenase, plasmin, MMPs, and ECM proteolysis is essential for cell migration and 
invasion [289, 291]. The peptide sequence incorporated within the hydrogel is sensitive 
to degradation by the corresponding protease, therefore the degradation rate of the 
hydrogel (as well as the release of encapsulated drugs) adjusts to the rate of cell 
infiltration as well as the specific enzymes secreted by those migrating cells [291]. 
Enzyme sensitive PEG hydrogels have not been used for RNAi but have been used for 
plasmid delivery in vitro [292]. In this study, they explored the use of a 4-arm PEG-VS 
hydrogels in the delivery of PEI complexing a pDNA (carrying various reporter 
transgenes) to clusters of MSCs cells also encapsulated within the hydrogel prior to 
crosslinking. Cells were either suspended as a cluster within a fibrin clot or as a 
homogenous mix of single cells throughout the gel. The PEG-VS was functionalised for 
cell adhesion with RGD and the gel crosslinking was facilitated by the bis-cysteine MMP1 




fluorescence of the reporter gene microscopically. Results showed cell clusters produces 
cumulative increasing gene expression over 21 days whereas homogenous cells 
produced a plateauing cumulative gene expression by day 7. The study showed that the 
gel was capable of maintaining viable transfecting polyplexes over time and cells could 











As discussed hydrogels have the ability to control the delivery and release of growth 
factors [252, 253], siRNA [293], cells [294], and other biodrugs [233, 251]. In addition, 
the design principles of hydrogels have been influenced by their ability to mimic the ECM.  
Since the ECM has been demonstrated to play a vital role in cell interaction, signal 
transduction and providing mechanical support to tissue [295, 296], developing scaffolds 
that provide similar functions has become an emerging research area. The use of an 
injectable engineered hydrogel without therapeutic biomolecules or cells in MI therapy is 
one classic example where hydrogels are being applied for their discussed injectability, 
tunable degradability, engineerability and ECM mimic characteristic features to provide 
cardioprotective function [247, 297].  
 
 
 Scaffold mediated RNAi in therapeutics.  
 
Figure 5: A schematic representation of an 8-arm PEG- VS/AC hydrogel formation crosslinked with 




Currently, there are no injectable scaffold based RNAi for targeted delivery strategies 
being used in clinics or in clinical trials as determined by using the key search words 
siRNA and RNAi in the Clinical Trials database  [179]. There is however one study in 
phase I/II  trials, where a surgically implanted miniature biodegradable polymer Local 
Drug EluteR containing siRNA against an oncogene K-RasG12D (siG12D), is being 
tested as a treatment for pancreatic cancer therapy [298-300]. As outlined in Table 2, 
there is a relatively low number of early stage preclinical applications of engineered 
hydrogels for local and sustained delivery of RNAi [235]. RNAi through controlled release 
from hydrogel scaffolds has primarily been applied in cancer therapy studies [255-259, 
261-264], but also in inflammation [260, 265-267], bone regeneration [268-271], 




The majority of the studies on sustained localised delivery of siRNA or nanocomplexes 
has been towards targeting cancer cells. This is because in part most of the 
subcutaneous xenograft tumour models used in the studies can be directly and simply 
intratumorally injected. In addition, the enhanced permeability and retention effect 
associated with cancerous tissue allows for ready uptake of siRNA or nanocomplexes 
and therefore facilitating targeted delivery and accumulation of therapeutics in this tissue 
[134, 303].  
One of the earliest proof-of-concept studies to investigate the delivery of localized RNAi 
molecules for cancer therapy was by Han et al. [255]. The delivery of siRNA against the 
oncogene transglutaminase (TG2), which is highly expressed in multiple cancers, was 
done with a temperature sensitive chitosan hydrogel. Initially to show localisation of 
siRNA they intratumorally injected mice once with the in situ gelling chitosan hydrogel 
containing Alexa 555-fluorescently labelled siRNA. Tumor explants 24 and 48hrs post 
injection showed that the gel was capable of releasing siRNA to surrounding tumor cells 
as well as being invaded by tumor cells. It was noted that the gel they used degraded 
within 3-4 days, hence to show efficacy, melanoma and breast cancer murine tumor 
models received a single intratumoral injection per week of hydrogel containing siTG2 
and Docetaxel (DTX) drug over a 30 day period. Their results indicated that one month 
post treatment this combinatorial treatment had a significant reduction in tumor growth 




treatment controls. This study showed localisation of siRNA and improved efficacy when 
siRNA and drug are delivered using the chitosan hydrogel. 
A collagen hydrogel was used for localised and sustained delivery of siRNA against 
oncogene Id1 responsible for cell proliferation and migration in gastric cancer [261]. The 
siRNA was mixed in the collagen gel either alone or complexed to PEI nanoparticles and 
its release profile and bioactivity was determined in vitro. It was shown that PEI-siRNA 
nanocomplexes were released more slowly (50%) than siRNA alone (100%) over 10 
days, and that proliferation of cells within hydrogels containing PEI-siRNA  or naked 
siRNA was significantly lower than gel only controls with a more substantial gene 
knockdown effect seen in the PEI-siRNA group. In a gastric cancer xenograft tumour 
animal model, gastric cancer cells were mixed with either media only or siRNA only 
controls, siRNA-gel or PEI-siRNA-gel and injected into nude mice. They found reduced 
tumor weight, size and cell proliferation in siRNA-gel or PEI-siRNA-gel treated groups 
and an enhanced effect in PEI-siRNA-gel. The study showed the feasibility of using 
collagen hydrogel for localised and sustained delivery of siRNA in cells incorporated 
within the gel. Though a proof of concept, it should be noted that pre-mixing of siRNA 
with cancer cells prior to injection might create an artificially favourable environment for 
siRNA uptake. 
A sophisticated approach has been extensively investigated by the Song group since 
2012 [262]. They developed a linear PEI - conjugated poly(organophosphazene) (PP) 
hydrogel that was modified with hydrophobic isoleucine ethylester and a hydrophilic 
thermosensitive  amino PEG such that the polymer would electrostatically interact with 
siRNA (via PEI interaction) and also transition to a hydrogel upon exposure to 37OC. The 
hydrogel can through both dissolution and degradation release siRNA polyplexes for 
efficient uptake. This sustained delivery thermosensitive gelling approach has great 
potential for minimally invasive delivery and their findings suggested that the PP hydrogel 
delivery. With this PP hydrogel system they encapsulated various RNAi molecules such 
as PEI-siCyclin B1 [262] and PEI-siVEGF [263] for cancer therapy. In another study, they 
encapsulated protamine (a potent transfection reagent) complexed with siVEGF within 
the thermosensitive PP hydrogel system without PEI conjugation (Fig.6) [3]. When the 
hydrogel was administered intratumorally or subcutaneously in murine models, it 
demonstrated anticancer effect caused by RNAi and gene knockdown of the oncogenes 
in question at the tumor sites. In a more recent study [264] they co-delivered siBcl-2 and 
Docetaxel (DTX) drug via the PEI and hydrophobic isoleucine ethylester interaction 




showed successful delivery of drug and siRNA as well as efficacious Bcl-2 gene 
knockdown. They showed enhanced tumor size and weight reduction in the PP-DTX-
siBcl-2 treated groups (in a dose dependent manner) when compared to DTX and PP-
siGFP negative controls over 30 days. Here, they demonstrated the potential use of the 
gel in cancers that require combinatorial therapy.  
In addition to the discussed, there are several other hydrogel based approaches that 
have utilised a mouse subcutaneous xenograft model and intratumoral injection of RNAi 
molecules [256-258, 261]. Given that this is the most investigated disease for RNAi 
application and although promising results have been observed, there has not been 
translated to the clinic as of yet. This may reflect the novelty of this approach but also 
that the animal model may not be ideal [304]. Therefore finding other ways to model the 
disease as well as broadening the spectrum of disease focus for RNAi therapeutic 














Figure 6: Schematic diagram of a thermosensitive poly(organophosphazene) nano-polyplex 







Hydrogels are also being investigated as delivery vehicles for RNAi molecules in chronic 
inflammatory diseases such as rhinosinusitis [266], atopic dermatitis where the treatment 
is topically applied on the skin [267], and inflammatory bowel disease. In a combinatorial 
approach, controlled release from a hydrogel was used to target inflammation in the 
colon of an induced colitis mouse model [265]. PEI-siRNA nanocomplexes against a pro-
inflammatory	 glycoprotein (CD98) gene were encapsulated in an alginate chitosan 
hydrogel that would release the nanocomplexes at pH 5-6 thus avoiding the stomach 
and small intestines (with pH lower than 4 and higher than 6 respectively) and targeting 
the colon. Colitis mice received daily gavages of the nanocomplex-hydrogel over 8 days, 
and then their colons were excised and analysed for pro-inflammatory cytokines. 
Efficient uptake of nanocomplexes by macrophages and epithelial cells in the colon, 
reduction of CD98 expression, inflammatory cytokines and weight loss was observed 
relative to scrambled siRNA negative control. Results from this study demonstrated the 
ability of the nano-hydrogel system to locally release nanocomplexes in the colon and 
decrease colitis in a pH depended manner. Though not an injectable hydrogel depot 
approach, this study demonstrated a novel manner in which hydrogels can target a 
specific organ. 
An injectable collagen sphere-in-hydrogel system was designed to target transplant 
rejection problems that result from the foreign body response against tissue engineered 
organs and implants during organ replacement [260]. Endothelial nitric oxide synthase 
(eNOS) pDNA, encoding for a pro-angiogenic enzyme eNOS, was complexed to partially 
degraded PAMAM dendrimer to form polyplexes. The polyplexes were loaded into hollow 
1µm collagen microspheres by agitating the mixture of negatively charged collagen 
microspheres and positively charged polyplexes. The polyplex loaded microspheres 
were then resuspended in a collagen/pentaerythritol poly(-ethylene glycol) ether 
tetrasuccinimidyl glutarate solution containing free Interleukin-6 (IL-6) siRNA. The 
collagen sphere-in-hydrogel system with eNOS-pDNA and IL-6 siRNA (a pro-
inflammatory cytokine involved in inflammatory cascade and increase in inflammatory 
cells) was subcutaneously injected into the rat dorsum and at 7 and 14 days post 
treatment the animals were sacrificed and implants excised and analysed. Results from 
the explants confirmed a reduction in inflammatory cells and an increase in the length 




+eNOS pDNA+IL-6 siRNA compared to scaffold+IL-6 siRNA. They also showed that this 
therapeutic eNOS-pDNA delivery system caused temporary changes in the ECM 
composition as seen by the increase in the binding capacity of the sulfated 
glycosaminoglycan to growth factors VEGF165 and fibroblast growth factor (bFGF) at day 
7 which returned to baseline by day 14. The increase in binding capabilities of growth 
factors may cause the increase in angiogenic inducing capabilities of the ECM in the 
treated area. This study showed that the developed injectable collagen sphere-in-
hydrogel system could deliver nucleic acids over a period of 2 weeks, modulate 
inflammation and increase angiogenesis in vivo. 
   
1.5.1.2.3 Bone regeneration 
 
There are presently few reports on scaffold mediated RNAi in bone regeneration. In one 
study, siRNA against WW domain-containing E3 ubiquitin protein ligase 1 (Wwp1), was 
complexed via electrostatic interaction with polymer diblock nanoparticles (NP) 
composed of dimethylaminoethyl methacrylate [270]. The NP-siWwp1 nanocomplexes 
were encapsulated within a hydrolytically degradable hydrogel formed from ultraviolet 
(UV)-photopolymerization of photo-initiator, lithium arylphosphanate, with poly(ethylene 
glycol)-b-poly(lactide)-b-dimethacrylate (PEGa-b-PLA-b-DM). The hydrogels were 
precast with NP-siWwp1 prior to assessment. In vitro assays showed that the hydrogels 
released 75% of NP-siRNA over 30 days compared to 100% release of non-complexed 
siRNA in 1 day. When cells were seeded in wells with NP-siWwp1 hydrogels placed 
above in transwell inserts, knockdown of Wwp1 was found to be maintained for at least 
12 days relative to the 3 days achieved by siRNA/NP alone. The localization and release 
of NP-siRNA hydrogels, using near-infrared (Cy5) labelled siRNA and their gene 
silencing efficiency (using siWwp1), was investigated in vivo in a murine mid-diaphyseal 
femur fracture model. Hydrogels encapsulating NP- siRNA Cy5 labelled were implanted 
at the fracture site and localised NP-siRNA was observed at the fracture site over 28 
days compared to free siRNA which was only present for 3 days. 2 and 3 weeks post 
NP-siWwp1 hydrogel treatment, mice were sacrificed and real time polymerase chain 
reaction (RT-PCR) showed a significant 77% reduction of Wwp1 mRNA expression at 
the fracture callus and accelerated bone formation and improved biomechanical strength 
of the harvested femur specimens in the treatment group relative to NP-siWwp1 only 
injections and untreated fractures which had no significant effect. This study indicates 




fracture healing, but because their hydrogel is prepared and set outside the body and 
requires surgical implantation, this approach may be limited in applicability for other 
pathologies such as CVD as the involved organs may be less amenable to the 
implantation of precast hydrogels. 
In situ forming hydrogels offer substantial advantages as they can be less invasively 
delivered and can take the form of complex 3D shapes and have been investigated for 
the controlled delivery of RNAi nanoparticles in bone regeneration [271]. In an initial in 
vitro study, sustained delivery of PEI-siNoggin and PEI-miRNA-20a nanocomplexes to 
human derived MSCs (hMSCs) that were encapsulated within an 8-arm-PEG-acrylate 
(8-arm-PEG-AC) hydrogels was observed. The 8-arm-PEG-AC was crosslinked with 8-
arm-PEG-SH. Results indicated increased osteogenic differentiation of the hMSCs over 
a 28 day period compared to PEI-control siRNA [305]. It should be noted that the siRNA 
nanocomplexes and cells were premixed during hydrogel formation which does allow for 
direct interaction of the cells with siRNA whilst the hydrogel is still liquid thus it is not 
entirely clear that this setup reflects a sustained delivery of siRNA to the cells.  
More recently the same 8-arm-PEG-AC hydrogel system was modified by covalently 
attaching a GRGDSPC cell adhesion peptide through their cysteine thiol prior to 
crosslinking. They encapsulated hMSCs + siNoggin and/or miRNA-20a to assess their 
ability to accelerate bone formation in a rat model with calvarial bone defect [271]. The 
thiolated cell adhesion peptide sequence containing RGD was used to enable the 
encapsulated hMSCs’ attachment and survival in the hydrogel microenvironment. 5mm 
bilateral circular defects were drilled on both sides of the sagittal suture on the rats’ 
cranium and the hydrogels encapsulating human bone marrow derived MSC cells and 
PEI-RNA complexes were implanted in the defects. Rats were sacrificed 2 and 12 weeks 
post-surgery and the implants were excised and analysed for cell differentiation, RNA 
analysis (at 2 weeks) and bone formation at 12 weeks. Their results showed sustained 
significant knockdown of Noggin and miRNA-20a target in hMSCs encapsulated in the 
hydrogel 2 weeks post-surgery as well as an increase in osteogenic markers in those 
samples compared to siRNA negative controls. At 12 weeks histology showed that 
explants treated with hydrogels containing hMSCs and miRNA-20a-nanocomplexes 
resulted in more bone formation than the hydrogels containing hMSCs without siRNA or 
with negative control siRNA. It was concluded that the hydrogel system developed in this 
study may provide a platform for filling and healing bone defects, additionally, it is a 
promising system for localised and sustained gene delivery in a variety of tissue 
applications. Though the hydrogel system developed has in situ forming capabilities, the 




gel discs, as well as mixing the cells being targeted for transfection with the 
nanocomplexes occurred within the hydrogel prior to polymerisation. It would be of 
interest to investigate its systemic capability when injection of a hydrogel and release of 
nanocomplexes to knockdown genes in surrounding tissue is required. 
 
1.5.1.2.4 Muscular dystrophy 
 
RNAi is being applied to enhance and accelerate skeletal muscle regeneration as a 
therapeutic measure for skeletal muscle injuries and muscular dystrophy therapy 
targeting proteins such as myostatin [306-308]. Myostatin is an important key regulatory 
protein in muscle regeneration as it acts as a negative regulator of skeletal muscle 
growth. In brief, myostatin is a protein that belongs to the transforming growth factor – 
Beta family and it is also referred to as growth differentiation factor (GDF-8) [309]. It is a 
secreted protein whose precursor form goes through two proteolytic processes in the cell 
to produce a biologically active 12-14 kDa active C terminal fragment [310, 311]. 
Myostatin gene sequence is conserved across various species such as fish, cattle, mice 
and humans. In adult tissue, it is almost exclusively expressed in skeletal muscles and 
adipose tissues, though the expression levels vary in each muscle [309]. The function of 
myostatin was first elucidated in mice and cattle with mutated myostatin, where it was 
observed that the absence of functional myostatin results in increased muscle fibre mass 
through hyperplasia and hypertrophy [310, 311]. The mice and cattle with mutant 
myostatin presented with a double muscle phenotype compared to wild-type animals 
[309-312]. Understanding the mechanism by which myostatin regulates muscle growth 
has become important in developing new strategies for human therapeutics in treating 
muscular atrophy diseases and as well as agricultural function in livestock production 
[301, 309, 311]. One of the therapeutic measures being explored as therapy for diseases 
such as muscular dystrophy is the inhibition of myostatin to increase muscle mass. 
Atelocollagen (ATCOL) is a cationic naturally derived polymer that has been used for 
local myostatin siRNA (siMstn) delivery in skeletal muscle for muscle mass increase and 
muscle function recovery [301, 302]. It is a collagen derivative produced by pepsin-
treatment of collagen type I to remove telopeptides on the C and N terminals of the 
collagen molecule [313]. ATCOL was developed and optimised for siRNA delivery in vivo 
and is commercially available in two forms depending on the desired method of 




siRNA in the form of a hydrogel with gelation capabilities for local injection or it can be 
used as a solution for systemic administration that does not gel [302].  
The effect of ATLCOL-siMstn complexes in three murine models using ATLCOL-
scrambled siRNA as control was investigated. In their first investigation, ATLCOL-siRNA 
was injected into the masseter and bicep femoris of normal mice. These nanocomplexes 
were also injected into the masseter and tibial muscles of dystrophin deficient mice, a 
muscular dystrophy animal model. In both these animal models, muscle morphology was 
examined 2 weeks post treatment. Their third animal model involved systemic injection 
4 times over 3 weeks of the ATLCOL-siMstn complex into normal mice to show global 
silencing effect of myostatin. In this animal study, muscle morphology was examined on 
lower limbs and masseter muscles 3 weeks post treatment. In all their animal models 
they observed similar results which included significant increase in muscle mass and 
muscle fibre (larger myofibrils) as well as a decrease in myostatin protein in the ATLCOL-
siMstn compared to the scrambled siRNA control group. In a follow up study, ATLCOL-
siMstn and similar control nanocomplexes were injected in masseter muscles of 
transgenic mice expressing mutant caveolin-3, an animal model for muscular dystrophy 
showing severe myopathy [301]. In addition to determining muscle mass and fibre size; 
the Mstn protein, myogenic transcription factors (MyoD and Myogenin) and adipogenic 
transcription factors (CCAAT/enhancer-binding protein, glitazone receptor) RNA levels 
were quantified. Both adipogenic transcription factors and Mstn RNA levels were found 
to be downregulated whilst the myogenic transcription factors were upregulated, this 
would result in the replacement of adipose cells with skeletal muscle growth. Supporting 
this conclusion was the observation that Mstn treated tissue was found to be lean and 
had reduced connective tissue compared to the ATLCOL-scrambled siRNA control. In 
addition, they showed that muscle activity in the treatment group was increased 
compared to the negative control. The results from both their studies indicated that local 
and systematic application of ATLCOL-siMstn stimulated muscle growth and could 




There has been a recent increase in research into the application of scaffolds for RNA 
delivery in MI therapy. RNAi has shown promising outcomes with improvements in a 
wide range of MI therapeutic targets such as fibrosis, infarct size, apoptosis, hypertrophy, 




cardiomyocytes [214, 314, 315]. There is now interest in using various injectable 
scaffolds to deliver many of these RNA interfering molecules for MI therapies.  
One of the earliest studies to demonstrate the use of a scaffold in sustained efficacious 
gene knockdown in vivo with siRNA targeted neointimal hyperplasia or restenosis of 
coronary stents [272]. Reduction of MMP2 was the goal as the expression of this 
protease by vascular cells is upregulated during restenosis of the stented vessel. A rabbit 
model which was subjected to balloon carotid artery injury had metal stents coated with 
unmodified pullulan and dextran polysaccharides crosslinked with sodium-
trimetaphosphate to form a hydrogel and then impregnated with cationised-pullulan-
siRNA nanoparticles implanted 15 days post injury. This study used surface coated 
stents into which nanocomplexes were swollen and they illustrated localised delivery and 
uptake of Tamra-tagged siRNA in the carotid artery 24hrs post implantation and a 
notable 30% decrease in pro-MMP2 activity [272]. In this very preliminary study, no 
assessments were carried out at more relevant later time points and can be viewed as a 
proof of concept. In a later study, a modified thermosensitive biodegradable dextran 
hydrogel encapsulating shRNA plasmids complexed to Lipofectamine 2000 was used to 
inhibit angiotensin converting enzyme (ACE) in a rat MI model [273]. Post MI, 
angiotensin-converting enzyme (ACE) has been shown to enhance myocardial cell death 
and increase infarct size [316, 317]. When the shRNA-hydrogel was injected directly into 
the infarct zone, an improved cardiac function at 30 days was observed with a 
concomitant decrease in ACE mRNA, apoptosis and the infarct size compared to the 
negative control shRNA-hydrogel group [273].  
The use of a scaffold based delivery system for RNAi molecules as a therapy for MI has 
been most intensively investigated by the Burdick group. The overall approach 
incorporates degradable guest host hydrogels with shear-thinning properties that rapidly 
self-heal for controlled delivery of miRNA mimics and siRNA. In one of their initial studies, 
GFP silencing siRNA was locally delivered by a self-eroding hydrogel into rat 
myocardium [274]. Here, PEI was modified with guest molecule β-cyclodextrin (CD) and 
PEG with host molecule adamantine (Ad). siRNA was complexed to the CD-PEI to form 
polyplexes, and these polyplexes were combined with Ad-PEG to form an injectable, 
shear thinning, guest-host PEI-PEG hydrogel encapsulating siRNA that self-erodes into 
smaller spherical PEI-PEG polyplexes in a size range of 20-300nm (Fig.7). The 
polyplexes were capable of transfecting HT1080 and GFP expressing C166 endothelial 
cells in vitro as assessed with Cy3-labelled siRNA and siGFP siRNA respectively. They 
encapsulated GFP-Cy5.5 labelled siRNA into the self-eroding-hydrogel system and 




Cy5.5 signal by thresholding confocal micrographs of frozen sections suggested 40% 
GFP knockdown in proximity to Cy5.5 labelled siGFP siRNA and not the control siRNA 
containing gel at 24hrs. Knockdown was also suggested at 7 days from qualitative 
observation (no quantification). When delivered in a hydrogel there was significantly 
more Cy5.5 label retained at 2 and 7 days though the label had substantially dispersed 
by day 7. This study indicated the potential of this type of siRNA delivery system for 














In a later study, a guest host injectable HA hydrogel was used to deliver a cholesterol 
modified miR-302, a cardiomyocyte proliferation regulator [276]. HA was modified with 
CD and Ad molecules to again interact and form a shear thinning and self-healing 
hydrogel that entrapped siRNA due to its cholesterol modifications affinity to CD. A single 
injection of this hydrogel system was delivered to the infarct in a mouse MI model and 
optical imaging of explanted hearts showed that 90-95% of siRNA was lost by 7 days 
with the remainder dissipating over the next 3 weeks. Improved cardiac function was 
observed and an increase in cardiomyocytes in the infarct border zone 28 days post 
treatment relative to PBS and gel-siRNA negative control miRNA [276]. In their most 
Figure 7: Schematic representation of CD-PEI/Ad-PEG polyplex. Figure reprinted and adapted with 




recent study, cholesterol modified siMMP2 was investigated as MMP2 is implicated in 
deleterious heart remodeling post MI [1]. Here the siMMP2 was delivered into infarct 
cardiac tissue of a rat using a guest-host HA hydrogel that had been further modified to 
be protease sensitive. The HA was modified with guest molecule CD to react with the 
cholesterol modified siRNA, additionally guest molecule aldehyde (ALD) and 
heterobifunctional MMP-cleavable peptide with host molecule hydrazide (which reacts 
with ALD via an hydrazone bond to form the protease responsive aspect of the shear-
thinning, self-healing hydrogel) were added to the HA polymer [1] . Controlled release of 
siRNA was observed over 15 days and 4 weeks post injection in the infarcted area, 
reduced wall thinning and improved cardiac function was seen in comparison to PBS 
and gel/negative siRNA controls. This powerful and modifiable system has great 
potential to be delivered via catheter based approaches. It would be of interest to 
determine whether the short term loss of siRNA could be alleviated through greater 
protection against RNase activity and tighter entrapment. 
In another recent study, a miRNA mimic to miR-29B was delivered to an infarct in a 
controlled release fashion [275]. A thiolated hyaluronic acid polymer (Glycosan 
HyStem®) was crosslinked with thiol-reactive PEG diacrylate to form a hydrogel that 
encapsulated miRNA-29B (miR-29B), a miR-29 mimic. The miR-29 family is known to 
target inhibition of multiple ECM genes which include fibrillins, elastin, collagens type I 
and III [318]. Adult mice were subjected to ischemia/reperfusion and immediately 
received 5 X 10µl injections of gel mixture on the border zone of the infarcted 
myocardium. At 2 and 5 weeks following MI myocardial function was maintained and, 
increased vasculature and decreased elastin protein expression and collagen fibre 
deposition at the border zone of the infarct were observed [275]. Furthermore, using 
Raman microscopy they managed to show location specific alteration of ECM 
organisation and maturity in areas were the miRNA-hydrogel was loaded.  Hence, in this 
case, improved functional recovery of the myocardium through modification of ECM was 
achieved through sustained delivery of siRNA.   
 
 Fibrin hydrogels 
 
Fibrin is an FDA approved naturally derived scaffold which is desirable in regenerative 
medicine due to its elasticity, minimal immunogenicity, permeability and biocompatible 
degradation products [235, 319]. Fibrin hydrogels are formed from the major components 




role in several pathologies and its biological functions are homeostasis and wound 
healing [321]. Considering the advantages of fibrin as a biomaterial, it has not been 
sufficiently explored as a potential scaffold candidate for localised and sustained delivery 
of siRNA. 
1.5.1.3.1 Fibrinogen structure and fibrin clot formation in vivo. 
 
Fibrinogen is a soluble fibrous 340 kDa glycoprotein made primarily in the liver. It is 
present in human blood at 1.5 - 4mg/ml concentration. This concentration increases 
dramatically when an injury occurs in the body [321]. Human fibrinogen is made up of 3 
pairs of polypeptide chains (AαBβγ)2, that is, α,β and γ chain pairs with small 
fibrinopeptide proteins A and B (FpA, FpB). The fibrinopeptides attach the 2 α chains to 
the (middle) E region [322-325]. The 2 sets of βγ chains are linked to form two dimers 
(D regions), that sit on either side of the middle E region. The two D regions (made of βγ 
chains) are then linked to the middle E region by an α-helical coiled segment. All 6 chains 
of the fibrinogen are linked together by 29 disulphide bonds [326]. In fibrin synthesis post 
vascular injury, thrombin, a protease enzyme in the plasma is activated to cleave off FpA 
and FpB in a pH and Ca2+-dependent manner via a complex enzymatic activation 
cascade [327, 328]. Thrombin first cleaves FpA off the fibrinogen monomers causing 
conformational changes in the monomer structure allowing them to spontaneously join 
and lengthen to form double stranded protofibrils. Thrombin subsequently cleaves off 
FpB from the protofibrils releasing α chains allowing the protofibrils to aggregate laterally 
and longitudinally forming insoluble fibrin fibres and a 3D fibrin network clot or gel.  The 
gelation or formation of the fibrin clot occurs when 15-20% of the fibrinogen has been 
converted to fibrin, new branch points and fibres continue to form within the clot network 
[321, 329]. The clearing of fibrin clots in vivo after completing their haemostatic function 
follows a controlled proteolytic degradation process termed fibrinolysis by the plasmin 
protease [330, 331].  
 
1.5.1.3.2 Fibrin clot (hydrogel) formation in vitro 
 
Formation of fibrin gels in vitro mimics the in vivo fibrinogen cleavage process which 
leads to fibrin hydrogel formation [234]. When formed, fibrin hydrogels also follow the 
natural in vivo fibrinolytic systemic degradation process, which makes them highly 




as a whole, fibrin hydrogels have demonstrated their potential in skin, cartilage, neural 
and cardiac tissue repair [319, 320, 334-340]. In addition fibrin hydrogels are widely used 
in surgery as a bioadhesive and sealant in wound closure [320, 341-343]. 
There is extensive investigation into the use of fibrin hydrogels for the delivery of growth 
factors such as transforming growth factor (TGF), bFGF, and VEGF [234, 332, 337, 344-
347], and fibrin hydrogels have also been utilised for cell delivery both in vitro and in vivo 
[320, 332, 348-353]. However, there are a limited number of studies investigating the 
delivery of nucleic acids with the majority assessing gene (pDNA) delivery [348, 354, 
355] and only one to our knowledge that examined siRNA delivery [356].  Uptake and 
expression of lipoplexes of plasmids carrying GFP (Lipofectamine 2000 [348]) or 
luciferase (Transfast™ [354]) were found to be highly efficient when cells and DNA-
lipolexes were mixed during polymerisation and less so when cells were seeded upon 
DNA containing fibrin hydrogels. It was noted that the highly efficient transfection 
observed upon mixing was most likely due to the proximity of lipoplexes and cells when 
incubated together during polymerisation [348]. Knockdown of noggin expression was 
observed when lipofectamine 2000 complexes with noggin siRNA were layered onto 
preformed fibrin hydrogels [356]. In a form of reverse transfection, cells were seeded 
onto the hydrogel surface which was decorated with lipoplexes thus ensuring direct 
contact. Therefore, though this study was an initial proof that fibrin could allow for RNAi 
agent delivery, it was not designed to examine controlled release. The above studies 
demonstrate the potential of fibrin as a nucleic acid delivery vehicle but have only 
assessed its suitability in vitro. A concern with the use of fibrin in vivo is its limited duration 
after implantation due to proteolytic degradation [357]. One relatively gentle modification 
that has been shown to limit proteolytic degradation in vitro is the crosslinking of fibrin 
with bivalent PEG molecules [337]. This approach has also shown utility in vivo [358, 
359]. 
 
1.5.1.3.3 PEGylated fibrin hydrogel  
 
The PEGylation of fibrin by bivalent PEG crosslinkers has been most extensively 
developed by the Suggs group [337, 351, 358-362]. In their early studies, they showed 
that reaction of fibrinogen with benzotriazole carbonate derivative of PEG (PEG-BTC2) 
to form a PEGylated fibrin patch consisting of pig bone marrow MSCs in vitro improved 




phenotypes [351]. They then in another study injected this PEG-BTC2 PEGylated fibrin 
gel type in a mouse MI model with or without hepatocyte growth factor (HGF), cells or 
both. It was shown that 2 to 4 weeks post treatment, animals that received gel-HGF-cells 
had high cell retention, low cell apoptosis and improved cardiac function compared to all 
other groups. 
In a later study they showed that reaction of fibrinogen with bivalent succininimidyl 
methylbutonate PEG (PEG-SMB2) significantly delayed degradation by plasmin relative 
to the unmodified fibrin [337]. The in vitro release study kinetics showed that release of 
TGF-β1 from the fibrin gels was dependent on the degree of PEGylation and that the 
release rate of growth factors correlated with gel degradation rate (which is controlled by 
PEGylation degree). Bioactivity of the released growth factor up to 8 days was 
maintained as they observed a reduction in cell proliferation rate versus untreated cells. 
In earlier in vivo studies, they PEGylated fibrin with another different bivalent PEG 
derivative, succinimidyl glutarate (PEG-SG2) [360]. It was found that when combined with 
insulin-like growth factor-I (IGF-I), it improved skeletal muscle function and structure in 
the rat hind limb ischemic reperfusion injury model relative to PEGylated fibrin or IGF 
alone. The behavioural effects of the PEG-SG2 PEGylated fibrin gel versus unmodified 
fibrin or collagen gels on encapsulated adipose derived stem cells (ASCs) was 
determined in vitro [358]. They demonstrated that the PEGylated fibrin gel enabled cells 
to have an elongated interconnected morphology compared to other gels. The gel also 
caused increased expression of a haemostasis glycoprotein (von Willebrand factor) and 
secretion of angiogenic factors from the ASC cells compared to the other gel types. Their 
results suggested the PEGylated fibrin matrix provided better mechanical and 
biochemical support to cells, therefore, offering a better therapeutic angiogenic 
advantage. More recently in 2016, two studies utilised the same PEG-SG2 PEGylated 
fibrin in delivering stem cells in vivo  [359, 362]. In both instances the PEGylated-fibrin 
groups resulted in	significantly increased vascularisation when (i) ASCs were delivered 
in a rat burn injury model [362] and (ii) when bone marrow MSC were delivered in rat 
hind limb ischemic model [359] relative to the no treatment, PEGylated fibrin gel only and 
MSCs only controls. 
Thus PEGylation of fibrin in this manner reduces protease degradation and appears to 
increase its functionality in vivo although a direct comparison to unmodified fibrin in vivo 





2 Research aim  
 
The overall aim of this study was to develop a novel RNAi delivery system with utility for 
delivery to soft tissue based on hydrogel entrapment of siRNA-nanocomplexes. 
Two commercial cationic lipid nanoparticles	 Lipofectamine® RNAiMAX and 
Invivofectamine® 3.0, a  commercial cationic polymeric nanoparticle G(4)-PAMAM 
dendrimer nanoparticle and it’s modified triblock G(4)-D-PEG2k-DOPE version previously 
developed by Biswas et al. [140] were assessed for their sustainability for scaffold based 
delivery with particular emphasis on their ability to protect their siRNA cargo from serum 
RNase cleavage, as it is considered a critical aspect for prolonged delivery in vivo.  
Two variants of a synthetic based PEG hydrogel and natural fibrin and a PEGylated fibrin 
hydrogel were assayed in vitro with respect to controlling release of the mentioned 
siRNA-nanocomplexes, and supporting transfection of cells in a 3D model assay 
developed to more closely resemble in vivo delivery to soft tissue.  
Finally, the delivery of siRNA against GFP and myostatin into the TA of mice was used 















3 Results and discussion 
 
3.1   Characterisation of nanoparticles for scaffold based delivery  
 
3.1.1 Dendrimer nanoparticles In vitro characterization 
 
The initial nanoparticle vector assessed as a vehicle for siRNA delivery from a hydrogel 
scaffold was a PAMAM dendrimer-based nanoparticle, due to its good biocompatibility 
and potential for protection from RNases [140]. RNA protection from degradation by 
ribonucleases is an important factor in vivo for prolonged RNAi efficacy to be achieved. 
Cationic particles have the ability to condense and protect siRNA from serum RNases 
and therefore this warrants further exploration. Modifying nanoparticle surfaces with 
molecules such as PEG and lipid molecules improves biocompatibility by reducing 
chances of nanoparticle agglomeration, protein absorption to their surfaces that makes 
them targets for opsonisation, improve stealth circulation in the system (avoiding eliciting 
innate immune response), improve RNA complexing and protection, cell penetration, 
endosomal escape and siRNA release into the cytoplasm [33, 137-139, 143].  Hence the 
PAMAM dendrimer nanoparticle was modified with a nitrophenyl carbonate derivative of 
PEG (PEG2K-NPC2) and DOPE molecules to form a triblock PAMAM dendrimer-based 
copolymer previously developed by Biswas et al. [140]. The initial focus was towards 
replicating the findings of Biswas et al. and the examination of the potential of their 
modified dendrimer to protect siRNA from serum RNases in greater depth. 
 
 MD synthesis  
 
The 4th generation PAMAM dendrimer G(4)-D (referred to further as D), with 64 free 
reactive primary amines was modified as described in 5.1 by coupling of PEG2K-NPC2 
and DOPE molecules to form a triblock G(4)-D-PEG2k-DOPE modified dendrimer (MD) 
nanoparticle at a stoichiometry that would reduce primary amines in D to 63. D and the 
schematic synthesis reaction of MD is shown in Fig.8A. To confirm the successful 
modification of the dendrimer, starting materials D, modifying tail group PEG-DOPE and 
the final product MD were analysed by 1H nuclear Magnetic Resonance (NMR) (Fig.9). 




methyl (-CH3) groups give rise to the peaks at δ 0.91 ppm (j). Peaks at 1.33-1.35 ppm 
(i), 1.62ppm (h), 2.05 ppm (g), 3.32 ppm (f) and 3.48 ppm (e) are from methylene (-CH2-
) protons in the lipid chains.  CH2 peaks from the PEG are indicated at 4.55-4.57 ppm 
(m), 3.82-3.84 ppm (n) and 3.54-3.80 ppm (p). The peak at 5.38 ppm (a) represents the 
vinylic protons (-CH=CH-). Doublets at 8.34-8.36ppm and 7.51-7.53 ppm (k and l) are 
indicative of protons in the nitrophenyl group. Successful coupling of PEG-DOPE to D to 
form MD are confirmed by a) the disappearance of CH-proton signals (present in 
nitrophenyl groups of PEG-DOPE) from the MD spectrum, and b) presence of 
characteristic CH2-proton signals from both PEG and D, as well as CH2- and CH3-proton 

























Figure 8: Schematic representation of (A) MD synthesis and (B) Dendriplex formation by complexing 
siRNA to D and MD nanoparticles. DMF (N, N-Dimethylformamide),TEA (Triethylamine), RT (room 
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Figure 9: 1H NMR spectra of the starting materials G(4) PAMAM-Dendrimer (D) and NPC-PEG2K-DOPE 














































 siRNA binding and dissociation capacities of D and MD nanoparticles. 
 
The abilities of D and MD nanoparticles to bind siRNA were assayed by agarose gel 
shift. The D and MD dendriplexes were formed by complexation with a negative control 
sequence siRNA (siNegative) at different nanoparticle to siRNA ratios (N/P ratios) as 
described in section 5.2. When positively charged nanoparticles bind to negatively 
charged siRNA, they prevent the siRNA migrating in the electric field. Hence the siRNA 
complexing abilities were analysed by gel shift assay a method commonly used to 
assess siRNA binding affinity to [363]. MD was capable of fully complexing siRNA at an 
N/P ratio as low as 0.5 whilst D formed complexes from N/P of 1 (Fig.10). Thus both 
nanoparticles condensed siRNA effectively at low N/P ratios. These results confirm the 
findings of Biswas et al. [140]. 
 
 
Subsequent to establishing the binding capacity of the various N/P ratios, the nature of 
the siRNA binding to the dendrimers was further characterised using a RiboGreen™ 
RNA fluorescent label exclusion quenching assay followed by a heparin sulphate 
dissociation assay (Fig.11). 
Figure 10: The siRNA binding abilities of nanoparticles (D and MD). This was assessed by agarose gel 
shift.  Dendriplexes were formed at different N/P ratios of 0 to 20.  siRNA concentration was kept constant at 
200ng. The image of unbound siRNA recovered after dendriplex formation and electrophoresis on 2% 





Figure 11: The siRNA binding abilities of D and MD assessed by quenching assay. D and MD at N/P 
ratio of 0-20 were formed using 200ng siFITC scramble siRNA. The quenching of fluorescence from siRNA 
bound RiboGreen™ RNA label was determined. Subsequently reversal of quenching after addition of 
heparin sulphate was quantified. (A) and (B) siRNA fluorescence quenching for D and fluorescence recovery 
after addition of 10 and 50U/µg siRNA  of heparin sulphate respectively. (C)  siRNA fluorescence quenching 
and  recovery  for MD in the presence of 10U/µg siRNA  of heparin sulphate. Graphs represent three 




A maximum quenching of siRNA fluorescence from N/P ratios of 1 and 0.5 for D and MD 
nanoparticles respectively was observed, corresponding to the gel shift assay findings 
above. When 10U/µg siRNA of heparin sulphate was added to disrupt the ionic bonds 
between the negatively charged siRNA phosphate backbone and the positively charged 
surface of the nanoparticles, fluorescence quenching of MD was reversed. At the same 
concentration of heparin, siRNA dissociation from D appeared incomplete at higher N/P 
ratios from 8 upwards and it required addition of 50U heparin per µg siRNA to reverse 
quenching at all ratios. This finding suggests that though siRNA is complexed at similar 
ratios for D and MD, D complexation is tighter. 
The siRNA complexing abilities of D were comparable with what has been previously 
observed [140] however, in this study MD was found to be slightly more effective at 
binding siRNA (from N/P 0.5) compared to binding only being observed at N/P 2 in the 
original report. Another discrepancy was observed with heparin sulphate induced 
dissociation of the dendriplexes. Dissociation of D in this study required 5 times higher 
concentration of heparin sulphate to achieve complete siRNA recovery than that 
previously reported for D. Particularly this inconsistency observed for heparin sulfate 
dissociation might reflect the necessary use of different batches of reagents though this 
does not entirely explain the same concentration achieving dissociation of MD in both 
studies. 
 
 siRNA protection ability of dendriplexes from degradation in serum 
 
In the original study, complete protection over 24hrs from serum RNases was observed 
for both particles at an N/P 10 ratio [140]. Protection of siRNA from RNases is a critical 
area for any vehicle that will carry siRNA within an implanted scaffold for extended 
periods and therefore was explored with a serum protection assay over a longer period. 
D and MD-siNegative dendriplexes were incubated in 50% FBS over a period of 10 days. 
The ability of the dendriplexes to protect siRNA from RNases at different N/P ratios in 
serum was determined by agarose gel after 0.5% sodium dodecyl sulfate (SDS) 
decomplexation (Fig.12). Naked siRNA (N/P ratio 0) was completely degraded in less 
than 24hrs. This is expected and has been reported in many other studies [43, 140, 204, 
364, 365]. There was limited protection observed for both D and MD at N/P ratios 0.5 
and 1 whilst substantial siRNA presence was detected up to 10 days in both D and MD 
samples for higher ratios (N/P 2-20). The results suggest that the higher N/P ratios 




studies have generally considered serum protection/stability of siRNA over a short time 
period (24hrs) [140, 204, 364, 365]. siRNA appeared to be protected slightly more 
effectively in the D samples which correlates with the stronger interaction with siRNA 
that was observed in the heparin stability assay (Fig.11). As the higher N/P ratios (2-20) 
for both D and MD provided siRNA protection for longer compared to the lower N/P ratios 
(0.5-1), these ratios were included in follow up experiments. These findings suggest that 
dendrimer based protection of siRNA is suitable for controlled release studies in vivo. 
 
 
 Cytotoxicity analysis of D and MD dendriplex  
  
The potential cytotoxicity of D and MD dendriplexes was assayed with HT1080 cells 
(Fig.13). Both D and MD dendriplexes at N/P ratio of 2-8 showed no cytotoxic effect 
relative to siRNA alone. MD at N/P ratio of 10 and 20 showed a non-significant reduction 
in viable cells by 5% and 19% respectively. The inherent cytotoxicity effect of the 
dendriplexes alone, with no siRNA complexation, on C166-GFP and A549 cells, was 
previously shown to be non-cytotoxic [140]. In this study dendrimers complexed to siRNA 
were shown to have a similar effect. 











Figure 12: siRNA protection from degradation by D and MD nanoparticles. Dendriplexes formed with 
200ng siNegative, at N/P ratio of 0-20. D and MD dendriplexes were incubated with 50% FBS over 10 days. 
After denaturation in 0.5% SDS, 100ng equivalent siRNA was resolved on 2% agarose gel. Fresh siRNA 





 Cellular uptake and transfection efficacy of dendriplexes 
 
Initially, the ability of dendriplexes at different N/P ratios to deliver siRNA into cells was 
determined with a fluorescently labelled scrambled siRNA sequence with fluorescein 
isothiocyanate (siFITC), procedure described in section 5.7. Fluorescent micrographs 
(Fig.14) showed that there was no discernible uptake of naked siFITC but that D and 
MD-siFITC dendriplexes were equally capable of efficiently delivering siRNA into cells 
for all N/P ratios as evidenced by the bright fluorescence of all cells which was more 
pronounced in N/P 8. In comparison to the previous report where only N/P=10 
dendriplexes made with siRNA-Cy5 were considered for transfection efficiency, and it 
was observed then that D showed less internalization of D dendriplexes compared to 
MD [140].  The reason for the apparent reduction in uptake at N/P 20 is not clear but 
possibly reflects a tighter interaction of the siRNA with the dendrimer such that 
dissociation in the cytoplasm is inhibited. 
 
Figure 13: The cytotoxic effect of dendriplexes D and MD on HT1080 cells. D and MD were complexed 
with scrambled siNegative at N/P ratios of 2-20. After 4hr transfection and 48hr incubation cells were assayed 
for cell survival using the Cell Titre Glo® assay. Untreated cells (cells only) and free siNegative (siRNA only) 
treated cells were included as controls. Percentage cell survival is represented as standard error mean of 





Figure 14: Uptake of siFITC D and MD dendriplexes at N/P of 2-20. Dendriplexes were made with 200ng 
siFITC scramble siRNA. Hoechst stained nucleus (blue) and siFITC (green). Untreated cells served as 




Though uptake is of course necessary for delivery, the siRNA delivered into the cell must 
be efficiently released to interact with its target mRNA sequences in the cytoplasm. The 
efficacy of delivery was assayed using a mixture of commercial siRNA sequences 
(siDeath) that have been shown to elicit cell death after their cellular delivery allowing for 
efficacy to be determined by measuring cell viability after transfection. When naked 
siRNA or D dendriplexes at any N/P ratio were delivered as described in section 5.8.1, 
cell viability relative to untreated cells or those receiving the scrambled siNegative 
sequence did not decrease (Fig.15A).  MD dendriplexes elicited significant decreases in 
cell viability at N/P ratios of 4 and 8 relative to their equivalent siNegative complexes 
reaching a maximum at 8 with a 36 ± 2% reduction in viable cell number (p<0.05 vs 
siNegative) (Fig.15B). At the higher N/P ratios of 10 and 20, similar levels of cell death 
to N/P ratio of 8 were observed but significance against their siNegative controls were 
lost. This presumably reflects the cytotoxicity observed above (Fig.13) with reductions 
in viability for the MD dendriplexes with siNegative at N/P ratios 10 and 20   of 12 ± 7% 
and 24 ± 13% respectively. Because N/P of 8 showed the most efficient siRNA delivery, 
no cytotoxic effect and most efficacious delivery of the siDeath, it was the chosen ratio 
to use throughout the following experiments that further characterized the dendrimers. 
 
 TEM analysis of D, MD and dendriplexes 
 
Structural analysis of the D and MD nanoparticles at N/P ratio of 8 by transmission 
electron microscope (TEM) was carried out (Fig.16A). MD nanoparticles were larger 
than D with diameters of 33 ± 2nm and 18 ± 1nm respectively (Fig.16B). When 
complexed to siRNA the size of D increased significantly to 24 ± 1nm, and that of MD 
increased to 44 ± 4nm (p<0.01 vs uncomplexed dendrimers). The sizes of D and MD 
nanoparticles without siRNA complexation are similar to what was previously seen in the 
original study [140]. Additionally, it was observed in this present study that when 







Figure 15: Transfection efficacy of D and MD dendriplexes determined by cell death assay. D (A) and 
MD (B) nanocomplexes at N/P ration of 2-20 were formed with either 200ng siDeath (+ve siRNA) or siDeath-
Negative control (-ve siRNA). Cells only and siRNA only cells treated with free +ve siRNA or -ve siRNA 
served as negative controls. After transfection, cell viability was determined with the Cell Titre Glo® assay.  
Percentage cell survival is represented as standard error mean of three biological repeats with 3 technical 









Figure 16: Transmission electron microscopy of dendrimer nanoparticles. TEM micrographs (A) of D, 
MD and their respective siNegative dendriplexes formed at (N/P ratio of 8) using 200ng siRNA. (B) The 
nanoparticles average diameter in nm. 20 nanoparticles were analysed per group. *p<0.0005 vs D, 




 Complementary assays of D and MD dendriplex uptake and efficacy 
 
D and MD dendriplexes at N/P ratio of 8 were further investigated for siRNA delivery 
efficiency by flow cytometry to assay uptake of siFITC by HT1080 cells. It can be clearly 
seen (Fig.17A) that naked siRNA is not taken up at a detectable level but is when 
complexed to both D and MD, 24hrs after transfection. There was no significant 
difference noted in the uptake amount between D and MD. When A549 cells were 
transfected with siFITC-dendriplexes and analysed 1hr and 4hrs post transfection by 
Biswas et al [140] a higher siRNA up take with MD than D was reported which was not 
observed in this study.  
An alternative reporter assay was established to confirm the above findings of the cell 
death assay. A stably transfected cell line of HT1080 cells expressing green fluorescent 
protein (HT1080-GFP cells) under the control of the CMV promoter (Appendix 1) was 
generated following the procedure described in 5.5.1. The HT1080-GFP clones with 
varying levels of GFP expression were made (Appendix 2A). Clone 9 with the highest 
GFP expression was chosen for use in in vitro GFP expression experimental analysis 
throughout this study.   
The established HT1080-GFP cells were used to analyse the knockdown of the GFP 
gene by dendriplexes made with siGFP at N/P of 8. Both flow cytometry and immunoblots 
were employed to quantify the knockdown. The geometrical mean analysis determined 
by flow cytometry (section 5.8.2.1) showed a reduction of GFP based fluorescence by 
both D and MD dendriplexes in the HT1080-GFP cells by 25% and 37% 48hrs post 
transfection as seen in Fig.17B (p<0.05 and p<0.01 vs their respective D and MD-
siNegative dendriplexes). 72hr knockdown effect was included to determine any further 
decrease in GFP KD effects that may occur over time. The transfection efficacy had 
started to reduce slightly by 72hrs after transfection with 24.5% and 32% for D and MD 
(Appendix 3) however the GFP knockdown remained significant (p<0.01).  As the D 
particle showed no efficacy of gene knockdown when assessed with the cell death assay 
(Fig.15) and a weaker effect when assayed for GFP inhibition (Fig.17), it was decided 




























The GFP knockdown by MD was further confirmed by immunoblot in Fig.18. Initially 
before western blot analysis of GFP expression could occur the co-probing of GFP and 
loading control β-Tubulin, as well as the amount of protein to load for detection, was 
optimised (see section 5.10 and Appendix 2B). Once the western blot was optimised, 
Figure 17: The transfection efficiency and efficacy of D and MD nanocomplexes (N/P of 8). (A) The 
ability of D and MD to efficiently deliver siFITC into HT1080 cells.  Dendriplexes were made with 200ng 
siFITC. (B) The efficacy of the delivered siGFP with D and MD on HT1080-GFP cells. Here dendriplexes 
were made with 500ng siGFP (pos D/MD groups) or siNegative (neg D/MD groups). Results were analysed 
by flow cytometry three biological repeats with 3 technical repeats per experiment. * p<0.05 vs siRNA only 





HT1080-GFP cells were transfected with siGFP- dendiplexes and 48hrs post transfection 
whole cell lysate was probed with an anti-GFP monoclonal antibody (following procedure 
in section 5.8.2.2). Two bands were observed at 27 and 30 kDa which accords with the 
molecular weights reported for GFP according to the manufacturer’s product description 
[366, 367]. Both bands were quantified by densitometry and showed a significant 32% 
knockdown of GFP protein by MD (p<0.05 vs naked siRNA) and a 69% knockdown with 
Lipofectamine® RNAiMAX (p<0.01 vs naked siRNA). Thus, the knockdown efficacy of 
MD was shown to be reproducible with the two different assays (cell death assay and 
GFP knockdown) but also that the commercial liposomal carrier used as a positive 















Figure 18: GFP knockdown in GFP-HT1080 cells with MD (N/P of 8) dendriplexes 48hrs post 
transfection with siGFP. (A) Immunoblot of GFP with β-tubulin as a loading control. (B) Densitometric 
analysis of GFP levels normalised to β-tubulin levels. HT1080-GFP cells were either untreated or treated 
with naked siGFP Lipofectamine® RNAiMAX as a positive control or MD dendriplexes made with 200ng 
siRNA. Image and graph represents three biological repeats with 3 technical repeats per experiment.  * 





Both D and MD dendrimers have the ability to efficiently deliver siRNA in HT1080 cells 
with minimum cytotoxicity, however this high siRNA delivery efficiency does not translate 
to efficacious gene knockdown with the D dendrimer, as shown by the nanoparticle’s 
inability to cause cell death with siDeath and achieve a lower GFP knockdown compared 
to that of MD. When D and MD siGFP dendriplexes were used on a stably expressing 
GFP C166 cell line in the original study, a 10 and 22% GFP knockdown respectively was 
observed [140]. A similar but more pronounced knockdown with MD of around 35% ± 
3% was observed across all assays in this study. This may reflect the use of HT1080 
cells. As noted above, the low efficacy of D can possibly be attributed to the stronger 
interaction of siRNA with D as indicated by the requirement of high levels of heparin 
sulphate to achieve dissociation. This may have resulted in the failure of D dendriplexes 
to effectively disassociate and release siRNA into the cytoplasm to for efficacious 
knockdown in contrast to its counterpart MD.  
Adding the PEG and lipid DOPE modification to the dendrimer achieved adequate siRNA 
condensation/binding, non-cytotoxicity, improved siRNA delivery and siRNA dissociation 
capabilities as well as gene knockdown effect compared to D. In addition, it is possible 
that this modification improved the endosomal escape ability of MD dendriplexes and 
therefore played a role in the improved gene knockdown efficacy compared to D. Even 
though MD achieved higher efficacy, it is important to note that the GFP knockdown 
effect was of lower magnitude when compared to Lipofectamine® RNAiMax. Thus 
though it was considered viable to proceed with MD due to its good biocompatibility and 
pronounced protection against RNase degradation as a potential vehicle for sustained 
delivery from a hydrogel, it was considered prudent to also assess commercial liposomal 
vehicles due to their high efficiency. Therefore Lipofectamine® RNAiMAX and another 
related liposome based carrier (Invivofectamine® 3.0.) were also assessed in 
downstream experiments.   
MD was theoretically modified with PEG-DOPE in a 1 to 1 molar ratio, because of the 
multivalent nature of PAMAM (64 free reactive amines) other molar ratios, different 
conjugates as well as different lipid molecule lengths, can be explored to possibly 
optimise the efficacy of this G(4)-PAMAM-D. The effects of varying lengths of 
hydrophobic alkyl lengths on G(3) dendrimer’s efficacy was tested in vitro by one group 
[177]. Another looked at the toxicity effects of a variety of PAMAM to lipid ratios as well 
as PAMAM to PEG molecules was tested by another group however no biological effects 
of these modifications on the nanoparticle was verified in vitro [169], suggesting that 




dendrimer. It should also be noted at this stage the work reported by Biswas et al. [140] 
was confirmed by the findings described above with only minor differences. 
 
3.1.2 Lipid nanoparticles In vitro characterization 
 
The two lipid based vehicles Lipofectamine® RNAiMax and Invivofectamine® 3.0 had 
recently been shown to have substantial efficacy after direct delivery to the mouse heart 
in vivo by Giacca et al. 2016 [213].  Although Lipofectamine and Invivofectamine® 3.0 
are established transfection reagents commonly used in research as positive controls in 
in vitro transfection assays, characterizing their siRNA binding, RNase protection, toxicity 
and confirming their efficacy in vitro in our hands was essential prior to exploring their 
utility for encapsulation in and release from hydrogels. 
 




Lipofectamine® RNAiMAX and Invivofectamine® 3.0 nanoparticles’ siRNA binding 
abilities were assayed by gel shift assay as was done for the dendrimers and as 
described in 5.3.1. The amount of Lipofectamine® RNAiMAX used in transfections in this 
study (0.6µl Lipofectamine® RNAiMAX / 200ng siRNA communicated with Giacca 
laboratory for the ratios used in their in vivo study [213]) and the commercially 
recommended undiluted concentration of Invivofectamine® 3.0 (0.36µl Invivofectamine® 
3.0 / 200ng siRNA) were tested. The agarose gel shift Fig.19A and quantified in Fig.19B 
shows that Lipofectamine® RNAiMAX does not stably condense siRNA whilst 
Invivofectamine® 3.0 complexed 70% of the loaded siRNA. However, when increasing 
amounts of Lipofectamine® RNAiMAX (in the range of 0.6-5µl / 200ng siRNA) were used 
to complex the siRNA, stable siRNA condensation begins to occur from 3µl / 200ng 
siRNA with full complexation at 5µl/200ng siRNA (Appendix 4). Unfortunately, in this 
study, these high concentrations of Lipofectamine were found to be cytotoxic to the 
HT1080 cell line substantial cytotoxicity of cells was observed and therefore the 0.6µl / 
















 siRNA protection ability of nanocomplexes from degradation in serum 
	
The ability of the lipid nanocomplexes to protect siRNA from serum RNases was again 
assayed by incubation of complexes in 50% FBS over 10 days following the protocol in 
section 5.4. Lipid nanocomplexes were formed by complexing 200ng siNegative with 
0.6µl siRNA for Lipofectamine® RNAiMAX and with the recommended 0.1mg/ml 
Invivofectamine® 3.0.  Lipofectamine® RNAiMAX at the concentration used did not 
provide siRNA protection in serum as siRNA was completely degraded in 24hrs, thus at 
least the same rate as naked siRNA indicating no meaningful protection (Fig.20). The 
Lipofectamine® RNAiMAX serum protection of siRNA seen here supports the siRNA 
complexing data (Fig.19) confirming that because of the weak siRNA condensation 
ability it is unlikely to effectively protect siRNA from degradation. Invivofectamine® 3.0 
had a curious pattern of protection. A substantial proportion of the siRNA was degraded 
by 24hrs but ≈10% of siRNA remaining at that time point persisted over the entire period 
assayed.	The RNA binding assessment by gel shift and their protection against RNase 
for Lipofectamine® RNAiMAX and Invivofectamine® 3.0 particles has not to our 
knowledge been reported before. Others have shown the complexing	ability [368]	of 
different types of lipid nanocomplexes as well as their ability to protect siRNA in serum 
for periods up to 24hrs [369, 370] and 48hrs [371] whereas here extended 10 day period 
was considered. This study’s findings show that the binding and the protection against 
RNase of the lipid based particles is much more reduced relative to the MD. However, it 
Figure 19: The siRNA binding abilities of Lipofectamine® RNAiMAX and Invivofectamine® 3.0: This 
was assessed by agarose gel shift. To show siRNA  complexation  image of unbound siRNA recovered after  
electrophoresis of Lipofectamine® RNAiMAX and Invivofectamine® 3.0 nanocomplexes made with  200ng 
siNegative on 2% agarose gel was taken (A). (B) shows quantification of  the siRNA bands. Image and graph 





was not clear what level of knockdown from the RNase resistant siRNA from 





























Figure 20: siRNA protection from degradation by Lipofectamine® RNAiMAX and Invivofectamine® 
3.0 nanoparticles.  Nanocomplexes were made with 200ng siNegative, and incubated with 50% FBS over 
10 days. After denaturation in 0.5% SDS, 100ng equivalent siRNA was resolved on agarose gel and imaged 
(A). Fresh siRNA (100ng) was loaded as a control at each time point. (B) Shows quantification of the 
remaining siRNA. Image and graph represent 2 experimental repeats. Lipo and Invivo = Lipofectamine® 




 Cytotoxicity analysis of Lipofectamine® RNAiMAX and Invivofectamine® 3.0 
nanocomplexes  
 
Nanocomplexes made with siNegative were tested for cytotoxicity on HT1080 cells 
Fig.21. Invivofectamine® 3.0 showed no signs of cytotoxicity whilst Lipofectamine® 
RNAiMAX showed a very minimal (6.5 ± 1%) but significant reduction in cell viability 
(p<0.001 vs untreated cells). Cationic transfection reagents such as Lipofectamine with 
a high transfection efficiency have been associated with high cell cytotoxicity [372, 373]. 
Lipofectamine® RNAiMAX has been shown in one particular study to have cell type 
dependent cytotoxicity [374]. When Lipofectamine® RNAiMAX nanocomplexes made 
according to manufacturer specifications complexing single-stranded oligonucleotide 
were used to transfect various cells it displayed a relative high transfection efficiency as 
well as cytotoxicity of 20% [374]. An interesting observation in this study is that of the 10 
cell lines were considered in the study, 7 of the cell lines where Lipofectamine® 
RNAiMAX exposure resulted in various levels of cytotoxicity were cancer cells. It is also 
important to note that single stranded nucleotides were used in this screening study. 
Given that the cells used in this study are also cancer cells and a low of toxicity was 
observed, it may suggest though Lipofectamine® RNAiMAX is efficacious it may have 
toxic effects in cancer cells.  
 
 
Figure 21: The cytotoxic effect of Lipofectamine® RNAiMAX and Invivofectamine® 3.0 
nanocomplexes on HT1080 cells. Cells were treated with nanocomplexes made with 200ng siNegative. 
After 4hr transfection and 48hr incubation cells were assayed for cell survival using the Cell Titre Glo® 
assay. Untreated cells (cells only) were included as control. Percentage cell survival is from three biological 




 Gene knockdown effects, Lipofectamine® RNAiMAX and Invivofectamine® 3.0 
nanocomplexes 
  
The efficacy of Invivofectamine® 3.0 and Lipofectamine® RNAiMAX nanocomplexes 
made with siGFP-Cy3 (1000ng) was determined by GFP knockdown in HT1080-GFP 
cells. MD knockdown was repeated in this experiment for direct comparison with the lipid 
nanoparticles. The GFP levels measured by flow cytometry (Fig.22) shows that MD, 
Lipofectamine® RNAiMAX and Invivofectamine® 3.0 resulted in 25%, 70% and 43% 
GFP knockdown (p<0.01) when compared to their respective nanocomplex negative 
controls. Though Lipofectamine® RNAiMAX has the lowest level of siRNA binding and 
serum protection capacity (Figs.19 to 21), it was the most efficacious at gene knockdown 
in these 2D in vitro assays. MD has better siRNA condensation and serum protection 
however compared to lipid nanocomplexes it is less effective at gene knockdown but 
more effective than D. Invivofectamine® 3.0 showed some degree of binding and 
protection and an intermediate level of gene knockdown. As all three nanocomplexes 
displayed efficacy with minimal cytotoxicity as well as varying degree levels of serum 
protection, they were all investigated in scaffold release experiments.     
			
Figure 22: GFP knockdown in HT1080-GFP cells with the MD, Lipofectamine® RNAiMAX and 
Invivofecatamine nanoparticles. HT1080-GFP cells were transfected by nanocomplexes made with 500ng 
siGFP-Cy3 or siNegative for 4hrs with and incubated for 48hrs post transfection. Flow cytometry was used 
to measure the GFP geometric mean. siNegative control was included. Data represents of an experiment 
done with 3 technical repeats per experiment.  ** p<0.005 vs neg Invivofectamine and *** p<0.0005 vs 




3.2   Hydrogel optimisation  
 
3.2.1 Fibrin and PEG hydrogel characterisation 
 
Due to their potential for controlled and localised delivery of RNAi agents, hydrogels have 
begun, as detailed in chapter 1.5, to be increasingly investigated. Synthetic PEG based 
hydrogels have been assessed by a number of investigators in pre-clinical small animal 
studies with a particular emphasis on targeting cancer, bone regeneration, inflammation 
and MI [257, 260, 262-264, 268-271, 274, 275]. One form of PEG hydrogel has been 
developed to function as an ECM mimic containing cell adhesion peptides and 
enzymatically degradable crosslinkers [285, 290, 375]. Our laboratory has refined these 
hydrogels to control their interactions with cells and tissue [284, 290, 375] and utilised 
them to mechanically reinforce the infarcted heart [376, 377] and deliver growth factors 
and mesenchymal stem cells to the heart [287, 378]. Thus it was thought relevant to 
explore this type of hydrogel that is centered on the PEG-VS 8-arm 20 kDa molecule that 
allows for stable crosslinks to thiol containing compounds. Further to this, the utility of a 
PEG-Ac variant [379] that allows for the formation of hydrolytically degradable crosslinks 
with thiols was investigated.  
In addition, it was deemed useful to consider the natural FDA approved fibrin hydrogel. 
Fibrin has been widely used to deliver proteins such as growth factors and to a lesser 
extent DNA [337, 348, 354, 355] and only one in vitro study to our knowledge examining 
RNAi [356]. It was considered likely that chemical modification of fibrin, such as 
PEGylation as pioneered by the Suggs group [337, 351, 359, 380] to increase it's in vivo 
stability might be required. Thus initially, PEGylation of fibrin hydrogels needed to be 
established in our hands. 
 
 Fibrinogen PEGylation 
 
Fibrinogen was PEGylated (described in section 5.12) by reaction with the succinimidyl 
carboxymethyl ester derivative of PEG (PEG-SMC2) at PEG to fibrinogen molar ratios of 
5:1 (lane 2) and 10:1 (lane 3).  The use of this homo-bifunctional PEG allows for 
crosslinks to be forms with positive amine groups in the protein. It can be clearly seen 




molecular weights (Fig.23). The shift is more pronounced for the 10:1 ratio. The 
presence of bands at molecular weights higher than 250 kDa are suggestive that there 
is a portion of the fibrinogen molecules that have intermolecular crosslinks. These 
findings are similar to those reported by others [351, 380]. 
 
 
 Fibrin and PEGylated fibrin hydrogel structure  
 
It has been observed by the Suggs group [381] that PEGylation of fibrinogen at ratios 
similar to those reported here resulted in changes in structure from the entangled fibrillar 
nature of unmodified fibrin to an amorphous sheet-like structure as visualised by 
scanning electron microscope (SEM). The fibrin hydrogels in this study were polymerised 
within highly porous polyurethane foams (150-180 µm diameter pores with 80-90 µm 
diameter interconnections [382] that allowed for support of the hydrogels during SEM 
processing (section 5.2.1.4). A SEM micrograph of an empty foam is given in Fig.24A. 
It can be seen that similarly to what was observed by the Suggs group, upon PEGylation, 
even at the lower level of 5:1 PEGylation (Fig.24C), a fibrillar structure of unmodified 
fibrin Fig.24B was replaced by a flat sheet-like morphology. It is possible that this 
structural change is in part desirable for a hydrogel to be utilised for controlled release 
as this change was correlated with slower diffusion through the PEGylated fibrin by a 10 
Figure 23: PEGylation of fibrinogen at 5:1 and 10:1, PEG to fibrinogen molar ratio. Image of SDS-
PAGE gel stained for protein with Coomassie Brilliant Blue R-250. M lane=molecular weight marker in kDa. 
Lane 1 is unmodified fibrinogen. Its PEGylation with PEG-SMC2 was at ratios 5:1 (lane 2) and 10:1 (lane 




kDa dextran and thus might allow for a more prolonged release of siRNA-nanoparticles 
[381]. PEGylation also increased the gelling time after activation with thrombin from 
3minutes for unmodified fibrin to ≈20minutes (mins) for the 10:1 ratio and the 5:1 
intermediate in time. This again is not necessarily a disadvantage for an injectable 
hydrogel as it allows for more time to set up an experiment. Furthermore, PEG hydrogels 
injected into rat hearts showed that a formulation that took 20mins to polymerise was 





Figure 24: Fibrin gel characterisation by scanning electron microscope. SEM micrograph images           
of unmodified fibrin (B), 5:1 PEGylated fibrin (C) and 10:1 PEGylated fibrin gels (D) that were polymerised 





 Stability of fibrin hydrogels in aqueous buffers.  
	
Fibrin hydrogels spontaneously degrade in aqueous buffers as previously observed by 
the Suggs group [337]. This could be due to the presence of proteases and in 
communication with the Suggs laboratory, they indicated that aprotinin stabilizes fibrin 
under these conditions. This shows that the protection against degradation that the group 
observed after PEGylation was due to protection against proteases and might translate 
to greater longevity in vivo. It is intended that PEGylation of fibrinogen increases the 
hydrogel duration in vivo, therefore, a simple assay to determine the rate of the fibrin 
hydrogels degradation over time was employed. Following the procedure in section 
5.12.1.5, 50µl (10mg/ml) fibrin hydrogels were formed and incubated in Hepes buffered 
saline (HBS) pH 7.4 buffer at 37o under sterile conditions. The eluents of the fibrin 
hydrogel were collected at various time points over 18 days until the gels completely 
degraded, and the breakdown products were quantified by Bradford’s assay. Unmodified 
fibrin hydrogel degraded faster showing complete degradation by day 3 (Fig.25) an 
observation similar to Suggs’ group that showed complete degradation by day 4 [337]. 
5:1 PEGylated fibrin hydrogel degraded by day 10, however,	macrosegments of the fibrin 
were possibly lost during sample collection therefore 100% protein was not recovered	
as assayed by Bradford’s protein quantification. 10:1 PEGylated fibrin hydrogel took the 
longest to degrade as it was still present by day 18. These results are comparable to 
previous observations [337]. It was shown here that there is an inverse relationship 
between the degree of fibrin PEGylation and rate of degradation. The Drinanan et al. 
study [337] showed that mono-functionalised PEG-(succinimidyl α-methylbutanoate) 
(PEG-SMB) had generated similar protection to PEG-SMB, suggesting steric hindrance 





3.2.2 Controlled and sustained release of nanocomplexes from PEG and Fibrin 
hydrogels. 
 
 siRNA and nanocomplex release from PEG-AC and PEG-VS hydrogels  
 
Successful scaffold based controlled and sustained delivery of RNAi molecules requires 
a reasonable release profile of molecules as well as maintenance of active RNAi 
molecules over time. Hydrogels encapsulating free siNegative or nanocomplexes were 
eluted in HBS and eluents were collected and quantified following the procedure in 
section 5.13. In aqueous buffers, PEG-AC hydrogels begin to visibly break up after 7 
days [288], whilst the PEG-VS hydrogels are hydrolytically stable [376]. Both free siRNA 
and Lipofectamine® RNAiMAX nanocomplexes show up to 30% release in the initial 
30min wash, almost complete elution by day 1 and elution appears complete by day 3 
from PEG-AC hydrogel (Fig.26). Though there may be a stable proportion of 
Lipofectamine® RNAiMAX nanocomplexes entrapped that were released whilst the 
PEG-AC degraded from day 7 to day 10. MD and Invivofectamine® 3.0 nanocomplexes 
show slow release over the first 7 days then approximate full release by day 10 which 
again coincides with hydrogel degradation. Very similar release behavior was observed 
Figure 25: non-PEGylated, 5:1 and 10:1 PEGylated fibrin gel degradation rate measured by fibrin 
release from the hydrogel. 50µl (10mg/ml) fibrin hydrogels were formed and incubated at 37OC over 18 
days.  The release of the hydrogel/protein breakdown in HBS pH 7.4 over 18 days was measured and 





from stable PEG-VS hydrogel. Free siRNA and Lipofectamine® RNAiMAX 
nanocomplexes essentially show fast release by day 1 with a small proportion on MD 
released upon the enzymatic degradation of the peptide crosslinked PEG-VS hydrogel 
with Proteinase K on day 10. Again there was limited release of ≈20% of MD and 
Invivofectamine® 3.0 nanocomplexes until degradation of the PEG-VS.  Thus it appears 
that naked siRNA and Lipofectamine® RNAiMAX nanocomplexes are not sterically 
hindered from rapidly diffusing out of the PEG hydrogels. For Lipofectamine® RNAiMAX 
this may reflect weak binding of siRNA as indicated by the gel shift assay (Fig.19). It 
appeared that ≈70-80% of MD and Invivofectamine® 3.0 nanocomplexes were 
entrapped until hydrogel degradation. Certainly for MD the particle would be sterically 
entrapped as 4% 8-arm hydrogel is expected to have a mesh size of less than 25nm 







Figure 26: siRNA and nanocomplex release from PEG-AC and PEG-VS hydrogels over 10 days. 
1000ng siNegative nanocomplexes encapsulated in PEG-AC (A) or PEG-VS (B) were incubated in HBS and 
collected over 10 day period. Collected nanocomplexes were denatured (0.5% SDS), resolved on a 2% 
agarose gel and the siRNA bands were quantified. PEG-VS gels were digested over night from day 10 to 11 




 Effects of animal derived fibrin hydrogel components on siRNA degradation 
 
The fibrin hydrogel components used in this study (fibrinogen and thrombin) are animal 
derived and therefore could potentially contain RNases. Before conducting siRNA 
encapsulation experiments with this hydrogel type, naked siRNA was incubated under 
sterile conditions with human serum derived fibrinogen and bovine plasma derived 
thrombin in HBS at 37oC (as prescribed in section 5.14). The samples were collected 
over 5 days for siRNA detection. In Fig.27 the gel components showed no degradation 
effect on the free siRNA which is normally observed within 24hrs in the presence of 
serum as seen in this study (Figs.12 & 13). In fact, siRNA was persistently present over 
the tested 5 day period, through signs of degradation were apparent at day 5. The result 
here suggested that the fibrin gel components were essentially RNase free and could be 
used in siRNA release assays.  
 
Figure 27: Effects of fibrin gel components (fibrin and thrombin) on siRNA degradation over time. 
200ng of siNegative was incubated over 5 day period with fibrinogen (10mg/ml final concentration) in HBS 
buffer and 0.624U/ml thrombin in 40mM CaCl2 HBS buffer. Fibrinogen, thrombin and fresh 200ng siRNA 
were included in the 2% agarose gel electrophoresis as controls. Throm: thrombin. Image is a representation 




 siRNA and nanocomplex release from fibrin hydrogels  
 
Unmodified fibrin hydrogels also showed a more rapid release of naked and 
Lipofectamine® RNAiMAX nanocomplexes than MD and Invivofectamine® 3.0 
nanocomplexes. However, unmodified fibrin hydrogel released most of the siRNA 
formulations by day 3 when there was breakup of the hydrogel. Because this hydrogel 
degraded rapidly controlled siRNA release over a lengthier time period was not feasible.  
The PEGylated fibrin gels however degraded slowly over time, as shown in Fig.28. 
Consequently they slowly released MD and Invivofectamine® 3.0 nanocomplexes over 
time and therefore showed improved siRNA release over 10 days compared to the PEG-
AC and PEG-VS hydrogels. Again naked siRNA and Lipofectamine® RNAiMAX were 
essentially completely released by day 3. The PEGylated fibrin hydrogels showed 
sustained release of MD and Invivofectamine® 3.0 nanocomplexes over 10 days. From 
day 1-10, 5:1 PEGylated fibrin released Invivofectamine® 3.0 nanocomplexes at 
≈48ng/day and MD nanocomplexes at ≈56ng/day. 10:1 PEGylated fibrin released 
Invivofectamine® 3.0 nanocomplexes at ≈42ng/day and MD nanocomplexes a 
≈40ng/day. The release of both nanocomplexes was more linear in nature for the 5:1 
than observed in 10:1.  
 What was apparent in all the release studies is that naked siRNA had a similar fast 
release profile as Lipofectamine® RNAiMAX. As speculated above, Lipofectamine® 
RNAiMAX at the nanoparticle/siRNA ratio used in this study, did show weak siRNA 
condensation abilities in prior siRNA binding assays (Fig.19), it is possible that the 
Lipofectamine® RNAiMAX nanocomplexes fell apart in the HBS within a day and hence 
produced a release pattern similar to that of naked siRNA. PEG-AC, -VS and non-
PEGylated fibrin hydrogels had less optimal release profile relative to PEGylated 
hydrogels which showed gradual siRNA release in an aqueous environment over at least 






Unmodified fibrin hydrogels have a known fibrous structure [356, 383] and since it is 
recognized that adding modifications to fibrin polymer changes their structure, 
Figure 28: siRNA and nanocomplexes release from non-PEGylated and PEGylated fibrin hydrogels 
over a period of 10 days. 1000ng siNegative nanocomplexes encapsulated in unmodified (A), 5:1 (B) and 
10:1 (C) PEGylated fibrin were incubated in HBS and eluents collected over a 10 day period. Collected 
nanocomplexes were denatured (0.5% SDS), resolved on a 2% agarose gel and the siRNA bands were 





viscoelasticity, gelation time and degradation rate of the resulting hydrogel [320, 321, 
331], it was shown here that the addition of PEG in fibrin hydrogels affects the fibrous 
structure of fibrin into a flat sheet-like structure altered its gelation, degradation time and 
may have variably influenced their nanocomplex release rates. Findings in this study 
indicate that naturally derived fibrin polymers without modifications lack the adequate 
stability and tunable properties that are required for sustained release, but introducing 
modifications and forming hybrid gels by adding a synthetic polymers such as 
PEGylation improves the hydrogels characteristics, function and stability particularly and 
improve controlled release of their cargo [337, 351, 359, 361, 384-387]. Certainly, it was 
clear from these release studies that the PEGylated fibrin hydrogel had the most 
promising controlled release of MD and Invivofectamine® 3.0 nanocomplexes in vitro. 
Subsequently, the bioactivity of the releasates from these hydrogels was analysed. 
 
 Bioactivity of eluted nanocomplexes from PEGylated fibrin hydrogels in vitro  
 
The free siRNA nanocomplex release experiment was repeated using 1000ng siGFP 
and 5:1 or 10:1 PEGylated fibrin hydrogels (section 5.15.1 no serum). The initial 30min 
wash eluent was discarded and the rest collected after 0-5 day and 5-10 day incubation 
periods.100ng siGFP equivalent nanocomplexes released from each 0-5 day and 5-10 
day pool was used to transfect HT1080-GFP cells. It can be seen from Fig.29 that only 
Invivofectamine® 3.0 nanocomplexes from both PEGylated fibrin hydrogels showed 
efficacy at both time points. siRNA, MD and Lipofectamine® RNAiMAX evidenced no 
efficacy. Eluents from 5:1 PEGylated fibrin (Fig.29A) consistently knocked down GFP 
expression by around 45% ± 10% (0-5 days) and 42 ± 13% (5-10 days), p<0.05 against 
cells only control. 10:1 PEGylated fibrin (Fig.29B) knocked down GFP expression by 56 
± 34% from 0-5 days and the knockdown was reduced to 36 ± 1% from 5-10 days, 
suggesting a possible decline in efficacy over time. It is clear that Invivofectamine® 3.0 
appears to maintain stability and efficacy. This may result from the nanoparticles’ 
development for in vivo delivery. It is curious that the other nanocomplexes showed no 
efficacy at either time points. For Lipofectamine® RNAiMAX it does again suggest that 
the nanocomplexes were unstable. It is not clear why MD nanocomplexes have lost all 
efficacy as these nanocomplexes were shown to be relatively stable up to 10 days 





3.2.3 In vivo degradation of 4% 8-arm PEG-VS, PEG-AC, fibrin and PEGylated 
fibrin hydrogels  
 
In order to assist in choosing the most promising hydrogel candidate, the in vivo rate of 
degradation of all the hydrogels was qualitatively assayed. The tibialis anterior (TA) 
muscle of mice was chosen as the target soft tissue due to its small size (to facilitate 
Figure 29: Bioactivity of eluted siRNA and siRNA-nanoparticles over 0-5 and 5-10 days from 
PEGylated fibrin gels in HBS. The pooled eluted and quantified nanocomplexes (100ng siGFP  
equivalent) from 5:1 (A i-ii) and 10:1 PEGylated fibrin gel (Bi-ii) over 0-5 and 5-10 days was used to transfect 
HT1080-GFP cells for 4hrs. 48hrs post transfection flow cytometry was used to measure the GFP geometric 
mean shift. Untreated cells only and PEGylated fibrin only eluents (PEG fibrin) were included as negative 
controls. The % GFP knockdown represents three biological repeats with 3 technical repeats per 




downstream analysis) and ease of access for injection. It was established by assessing 
the spread of Coomassie Brilliant Blue R-250 stained PBS in the injected tissue, that to 
achieve optimal TA muscle coverage with one injection of the hydrogel, 30µl volumes of 
the gels were to be injected parallel to the long axis of the TA muscle. The procedure is 
fully described in section 5.17.2.  
All gels were conjugated with a Cy5 fluorescent tag, PEG gels were labelled via Fluor® 
660 C2-maleimide as described before [376] and in section 5.12.3. This procedure had 
been shown effective for verifying PEG hydrogels in rat hearts for up to 3 months with 
non-degradable 8-arm-PEG-VS gel [376]. Purchased fibrinogen with Alexa Fluor™ 647 
conjugate was used in combination with the natural human fibrinogen (with no Alexa 
label) as described in section 5.12.1.1&2. This resulted in highly fluorescent fibrin gels 
that polymerised at equivalent rates. Pilot injections in the TA muscle of BALB/c mice 
with the optimised injections of the Cy5 labelled PEG and fibrin hydrogels was shown to 
result in effective fluorescence in the tissue (Appendix 5).  
To determine the distribution and degradation rate of the PEG and fibrin hydrogels in 
vivo over 7 days, the mice were injected in their TA with the hydrogels (2 legs per gel) in 
a randomised manner. The animals were euthanised at 30mins, 2, 4 and 7 day time 
points post injection. At 30mins all hydrogels are clearly visible throughout the muscle 
tissue. It is possible that fibrin is more effectively retained as evidenced by the high 
fluorescence intensity and greater coverage (Fig.30). However, this may also reflect 
different staining efficiencies. By day 2 PEG-AC (Fig.30B) hydrogel was no longer visible 
[288] and unmodified fibrin gel (Fig.30C) at this time showed only minor traces of the gel 
present. H&E stain (data not shown) found no evidence of PEG-AC presence suggesting 
that the absence of fluorescence is not simply indicative of loss of fluorescent label. Such 
a loss is possible as the label will also detach from the PEG-AC due to hydrolysis, but 
here it seemed that the loss of hydrogel was complete. This suggests that hydrolysis 
coupled with enzymatic degradation of peptide crosslinker caused a much more rapid 
degradation in vivo compared with what was seen in vitro where only hydrolytic 
degradation takes place. Rapid unmodified fibrin degradation was not unexpected as its 
stability was found to be limited in vitro (Fig.25).  
PEG-VS (Fig.30A) showed a gradual degradation over the 7 day period with still 
significant PEG gel left at day 7. This accords previous experience in the laboratory with 
injection into rat hearts [377]. 5:1 (Fig.30D) and 10:1 (Fig.30E) PEGylated fibrin also 




degradation for the 5:1 PEGylated gel. This might be expected as degradation in vitro 
was more rapid for this hydrogel. 
Thus this first in vivo study allowed for the clear exclusion of PEG-AC and unmodified 
fibrin gels as potential delivery vehicles due to rapid degradation. Of the remaining 3 gels 
it was decided that the 5:1 PEGylated fibrin gel was the optimal candidate to proceed 
with. PEG-VS allowed minimal nanocomplex release in vitro though it had a promising 
degradation rate in vivo. This hydrogel can be investigated in the future to study the 
delivery of siRNA or nanocomplexes in invasive cells. It was considered that the trial 
period for determining the scaffold mediated siRNA-nanoparticles delivery in the 
selected TA muscle was to be 7 days in these initial proof of concept studies. The 5:1 
PEGylated fibrin gel showed perhaps a more controlled release over a 10 day period 
(Fig.28), faster degradation rate in vitro and possibly in vivo, and represented less 
modification of natural fibrinogen and therefore was chosen over the 10:1 PEGylated 















Figure 30: PEG and fibrin hydrogel degradation time in the TA muscle of BALB/c mice over 7 days. 
30µl hydrogels of 4% 8-arm PEG VS (PEG-VS) (A), 4% 8-arm PEG-AC (PEG-AC)(B), unmodified  fibrin 
gel (C), 5:1 (D) and 10:1(E)  PEGylated fibrin gel was imaged 30mins to 7 days post injection. All hydrogles 
were Cy5 labelled (pink) and whole TA muscle tissue nuclei is 4’,6-diamidino-2-phenylindole (DAPI) stained 
(blue).  The images of the whole TA muscle tissue are a representation of n=2 legs per group. Scale bar 
=500µm. 
2 days  
4 days  
7 days  
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 Bioactivity of eluted Invivofectamine® 3.0 nanocomplexes in serum   
 
Prior to establishing a 3D assay for investigating efficacy of nanocomplexes delivered by 
5:1 PEGylated hydrogel and subsequent in vivo analysis, the bioactivity of the eluted 
Invivofectamine® 3.0 nanocomplexes was assayed in the presence of serum. This was 
considered necessary as the nanocomplexes will be exposed in vivo to serum 
components. The release of nanocomplexes, was repeated in the presence of 10% FBS 
in media rather than HBS (section 5.15). Invivofectamine® 3.0 nanocomplexes were 
eluted in 10% serum containing media and collected at day 2, 4 and 7 time points. 
Transfections with the collected releasates were carried out in serum rich media (10% 
FBS) for 24hrs (2 day releasates) or 72hrs (4 and 7 day releasates).  
It can be seen that there was a highly effective knockdown as determined by flow 
cytometry (Fig.31). The nanocomplexes collected at day 2, 4 and 7 resulted in 76.4%, 
86.5% and 82.4% GFP knockdown effect. This result not only confirms the sustained 
bioactivity of Invivofectamine® 3.0 in previous observations (Fig.29) but also show a 
substantially more effective knockdown efficacy compared to the knockdown effects 
observed in the previous 4hr transfection experiments carried out in the absence of 
serum. This again may reflect the design of the Invivofectamine® 3.0 for systemic in vivo 
use. In addition, there was no significant knockdown difference between 48hr and 72hr 
transfections as established prior by dendriplexes (comparing Fig.17 and Appendix 3). 
The result here does indicate probable protection against RNase degradation. There was 
a prolonged protection of a limited quantity of siRNA when the nanocomplexes were 
incubated in 50% FBS (Fig.20) and it may be that this protection effect is more 
pronounced in less serum/FBS concentration.  
Even though the nanocomplex release and bioactivity data thus far shows that 
Invivofectamine® 3.0 nanocomplexes are efficacious in 2D assays all three 
nanocomplexes, however, were investigated for bioactivity upon release from the 
PEGylated fibrin hydrogels in further 3D assays because each nanoparticle displayed its 
own advantages prior. MD dendriplexes are the most effective at siRNA complexing and 
serum protection compared to lipid based nanoparticles but the least efficacious. At the 
concentrations used in this study Lipofectamine® RNAiMAX is the least effective at 
forming stable nanocomplexes and serum protection, however the most efficacious in 
2D in vitro assays (4hr transfections in the absence of serum), compared to 




nanocomplexes in the 3D assays to compare how the three would compare in an 
environment that best mimics the tissue microenvironment. 
 
 
3.3 Controlled and sustained release of nanocomplexes in Fibrin 
hydrogels 
 
3.3.1 3D RNAi in vitro assays  
 
In order to advance to in vivo assays of scaffold base RNAi, it was necessary to develop 
a 3D model that mimicked the in vivo scenario. It was considered important that the cells 
and RNAi agents were not exposed to each other whilst the hydrogel scaffold 
polymerised and was in liquid form. Hence in this study, two 3D in vitro assays were 
developed to investigate controlled sustained release of nanocomplexes from 5:1 
PEGylated fibrin hydrogels.  
 
Figure 31: Bioactivity of Invivofectamine® 3.0 nanocomplexes eluted from 5:1 PEGylated fibrin 
hydrogel gel in the presence of serum. Invivofectamine® 3.0 nanocomplexes (1000ng siGFP-Cy3) in 
PEGylated fibrin were incubated in media (10% serum) and eluted over 7 days. The eluted nanocomplexes 
were used to transfect HT1080-GFP cells in the presence of 10% serum for 48-72hrs. Post transfection flow 
cytometry was used to measure the GFP geometric mean. Untreated cells and siNegative Invivofectamine® 
3.0 nanocomplexes (siNegative-In vivo) were included as negative controls. Data represents 3 technical 





 3D chemotaxis Transwell assay  
	
The initial approach investigated was a variation of a standard transwell chemotaxis 
assay. Here a layer of fibrin hydrogel containing MD, Lipofectamine® RNAiMAX and 
Invivofectamine® nanocomplexes made with siGFP-Cy3 was polymerized in fibrin 
hydrogels, onto the membrane of transwell with 8 micron pore size as illustrated in Fig.32 
(procedure described in section 5.16.1). Onto this was layered another fibrin hydrogel 
containing HT1080-GFP cells. The transwell was placed into media in the lower chamber 
containing 10% FBS as a chemoattractant. Unfortunately, it was found that both the 
PEGylated fibrin hydrogels limited the cell invasion to an extent that very minimal cells 
were seen to navigate through the transwell membrane or on the surface of the lower 
chamber. This observation did not change significantly over 10 days and therefore there 
were insufficient cells to allow for analysis. The fast degrading non-PEGylated fibrin gel 
however allowed faster cell migration through the transwell membrane to the surface of 
the lower chamber that allowed sufficient cells to be analysed. Though this was not the 
hydrogel formulation that was targeted, the ability of this type of assay to determine 3D 
RNAi was assessed. The efficacy of the nanocomplexes was determined 48hrs post cell 
seeding, a day earlier than the hydrogel has been shown to completely degrade in vitro 
(Fig.25 and 29) This was so it could be ensured that the nanocomplexes being assessed 
for efficacy were from hydrogel release.  
 
 
Figure 32: Schematic representation of the 3D chemotaxis Transwell assay. A layer of 50µl fibrin 
hydrogel encapsulating HT1080-GFP cells was seeded on top of a layer of 50µl fibrin hydrogel encapsulating 




It can be seen from the micrograph of the underneath of the transwell membrane 
(Fig.33A) that uptake of siGFP-Cy3 could be seen for all complexes but not the free 
siGFP-Cy3. However, a clear drop in GFP cells could be seen for Lipofectamine® 
RNAiMAX and Invivofectamine® 3.0 treated cells. It was also apparent that fewer cells 
as determined by DAPI stain can be seen on Lipofectamine® RNAiMAX nanocomplexes 
suggesting a level of toxicity by the nanocomplex. As Lipofectamine was found to be 
minimally cytotoxic in the previous 2D assay (Fig.21), this might reflect a more prolonged 
exposure of cells to the nanocomplex therefore may result in more cell loss. These 
micrograph images confirm previous results that although MD is efficient at cell 
transfection (indicated by more cells with siGFP-Cy3 compared siGFP-Cy3 only group) 
it has the least gene knockdown effect indicated by the presence of more green cells 
compared to Lipofectamine® RNAiMAX or Invivofectamine treated cells. Lipofectamine® 
RNAiMAX though highly efficacious (less green cells present) is more toxic, indicated by 
less live DAPI stained cells compared to the other nanoparticles. This result 
demonstrated that Invivofectamine® 3.0 is the optimal nanoparticle as it is efficient at 
transfecting cells and causing significant gene knockdown without being toxic. The 
qualitative GFP gene knockdown shown by the images was confirmed by GFP 
expression analysis of cells from the bottom well by flow cytometry in Fig.33B. MD, 
Lipofectamine® RNAiMAX and Invivofectamine® 3.0 nanocomplexes caused 42 ± 8%, 
69 ± 5% and 72 ± 6% GFP knockdown ( p<0.01 against positive siGFP-Cy3 only control 
group).   
Although somewhat limited in applications to hydrogels that the cells can invade through 










Figure 33: GFP knockdown in a 3D chemotaxis Transwell assay. A non-PEGylated fibrin gel containing  
500ng free siNegative-Cy3 (neg siRNA) or free siGFP-Cy3 (pos siRNA) or  MD/Lipofectamine® RNAiMAX/ 
Invivofectamine® 3.0-siGFP nanocomplexes was polymerised onto the Transwell membrane. It was 
overlaid by another non-PEGylated fibrin gel encapsulating HT1080-GFP cells. 72hrs post incubation, (A) 
cells that migrated to the bottom of the transwell membrane were DAPI stained and imaged by fluorescent 
microscopy (i-vi) representing untreated cells, siNegative-Cy3, siGFP-Cy3, MD, Lipofectamine® RNAiMAX 
and Invivofectamine® 3.0 treatments respectively. (B) Cells that migrated to the bottom of the well were 
tripsonized and quantified for GFP knockdown by flow cytometry. Untreated cells were included as controls. 
Data represents three biological repeats with 2 technical repeats per experiment. ** p<0.005 and *** 




 3D embedded cell cluster assay   
 
Thus an additional 3D assay was developed. Here a droplet of 5:1 PEGylated 
encapsulating HT1080-GFP cells was overlaid with 5:1 PEGylated fibrin containing 
nanocomplexes made with 500ng siRNA as illustrated in Fig.34 (and described in 
5.16.2). GFP expression was considered as evidence of cell viability (green cells) and 
dead cells were stained red with ethidium homodimer-1 (EthD-1). Limited cells were 
seen to migrate out of the PEGylated fibrin into the surrounding 5:1 PEGylated fibrin 
similar to their behavior in the Transwell assay (data not shown). However, it was 
surmised that release of siGFP into the cell droplet could be assessed.   
 
 
Uniform distribution of GFP expressing cells could be seen at day 0 for all groups, 
(Appendix 6). Cells in the central droplet were visualised by fluorescent microscopy 
Fig.35. and the imaged live (green) or dead (red) cells were quantified by image analysis 
Fig.36. At day 3 there was no significant change in the number of GFP expressing cells 
in all groups. However, an increase in dead cells was observed for cells surrounded by 
PEGylated fibrin containing MD-siDeath and Invivofectamine® 3.0-siDeath with 8 and 6 
fold increase relative to MD-siDeath-Negative or Invivofectamine® 3.0-siDeath-Negative 
respectively (p<0.01).  
At 7 days there was a 69% reduction in GFP expressing cells in the central droplet 
surrounded by Invivofectamine® 3.0-siDeath relative to Invivofectamine® 3.0-siDeath-
negative (p<0.01). There was also a significant reduction in GFP expressing cells in the 
Figure 34: Schematic representation of 3D embedded cell cluster assay. HT1080-GFP cells were 
encapsulated in 5µl 5:1 PEGylated fibrin hydrogel and a layer of 50µl 5:1 PEGylated fibrin hydrogel 





Invivofectamine® 3.0-siDeath group compared to all other groups (p<0.01).  When 
assessing the number of dead cells, Invivofectamine® 3.0-siDeath was again 
significantly increased by 7 fold relative its negative control group, Invivofectamine® 3.0-
siDeath-Negative, and also against both Lipofectamine® RNAiMAX groups and cells 
only (p<0.01) but not relative to  MD-siDeath group (p=not significant). Both MD-siDeath 
and siDeath-Negative treated groups for live cells showed significant reduction relative 
to cells only group (p<0.01). Dead cells were significantly increased for both MD groups 
relative to cells only (p<0.01) and MD-siDeath showed a significant 2 fold increase 






Figure 35: Transfection efficacy of HT1080-GFP cells in 3D embedded cell cluster assay. Maximum 
projection Z-stack images of cells encapsulated in 5ul 5:1 PEGylated fibrin droplet  covered with a  layer of 
50µl 5:1 PEGylated fibrin gel containing: MD/Lipofectamine® RNAiMAX/ Invivofectamine® 3.0 
nanocomplexes made with 500ng siDeath (pos siRNA groups) or siDeath-Negative control (neg siRNA 
groups).  3 days (A) and 7 days (B) post incubation EthD-1 (2mM) from the Live/Dead™ cell viability assay 
was used to stain dead cells red and imaged by confocal microscopy. Green indicates viable/live HT1080-
GFP cells. Cells only were included as negative controls. Micrograph images are representation of three 
























This assay allows for the relatively simple quantification of the efficacy of the release of 
siRNA into cells in 3D. It was clear that Lipofectamine® RNAiMAX nanocomplexes again 
had no efficacy when released from PEGylated fibrin hydrogel. This is in contrast to the 
positive effect observed when assayed in the previous Transwell assay (Fig.33). A major 
difference between these two assays is the presence of serum in the 3D cluster assay. 
Manufacturers recommendations are to transfect in serum free media and this may have 
Figure 36: Efficacy quantification of the 3D embedded cell cluster assay z-stack images. 3 days (A) 
and 7 days (B) post incubation EthD-1 (2mM) staining and confocal microscopy  imaging  (Fig.32), the 
average number of living (green) and dead (red)HT1080-GFP cells were counted by Image J cell counter (4 
fields/well). Data represents three biological repeats with 4 technical repeats per experiment.  In (A) *p<0.05 
for dead cells: pos MD vs neg MD and all groups except pos Invivofectamine. #p<0.05 for dead cells: pos 
Invivofectamine vs neg Invivofectamine and all groups except pos MD. In (B) #p<0.05 for dead cells: pos 
Invivofectamine vs neg Invivofectamine and all groups except the MD groups. $p<0.05 for live cells: pos 
Invivofectamine vs all groups. &p<0.05 for live cells, pos MD vs cells only, %p<0.05 for live cells, neg MD vs 
cells only. *p<0.05 for dead celsl: neg MD vs posMD and cells only. @p<0.05 for dead cells: pos MD vs neg 











impacted Lipofectamine® RNAiMAX efficacy. However, Lipofectamine® RNAiMAX 
nanocomplexes released from fibrin hydrogels were assayed for efficacy (Fig.29) in 2D 
transfections under serum free conditions. The lack of efficacy in that study suggests 
that Lipofectamine® RNAiMAX nanocomplexes at the concentration used in the study 
are relatively unstable. In a previous study, Lipofectamine® RNAiMAX nanocomplexes 
absorbed on the surface of unmodified fibrin hydrogel were shown effective at noggin 
gene knockdown in a 3D in vitro assay when MC3T3-E1 pre-osteoblasts cells were 
directly seeded on top of the hydrogel [356]. In another study, these nanocomplexes 
were injected into the myocardial tissue and showed effective RNAi [213]. However, in 
this study, the release assay and the 3D assays showed that Lipofectamine® RNAiMAX 
nanocomplex eluents either failed to demonstrate efficacy or showed signs of toxicity. In 
the studies mentioned, cytotoxicity of the nanocomplexes in vitro was not assessed as 
they were in this present study. 
The lipid nanoparticles used here vary in overall charge post siRNA complexation 
according to their manufacturer. Lipofectamine® RNAiMax has an overall positive 
charge whilst Invivofectamine® 3.0 has an overall neutral charge when complexed to 
siRNA. It has been reported that nanoparticles with an overall neutral charge are optimal 
carrier nanoparticles compared to cationic particles when in the presence of serum as 
cationic nanoparticles are prone to aggregation [388-390].  
The apparent efficacy of MD-siDeath at 3 days was surprising as MD had not shown 
efficacy in the release studies. However, the conditions of the experimental set up were 
different which could possibly impact efficacy. Nanocomplexes were incubated 5 days in 
the release assay prior to use, whereas in the 3D assays nanocomplexes could start 
transfecting as soon as the experiment was set up. The reduction in GFP expressing 
cells and increases in dead cells over 7 days observed for both the MD-siDeath and MD-
siDeath-Negative (negative control), suggests cytotoxicity of MD nanocomplexes when 
exposed to cells for longer periods of time. In the previous 2D	cytotoxicity assay (Fig.13) 
experiment the cells were only exposed to nanocomplexes for 4hrs whereas in the 3D 
cell cluster assay cells were incubated with the nanocomplexes up to 7 days.  
The 3D cell cluster assay showed Invivofectamine® 3.0 was the most consistent with 
cell death occurring at both 3 and 7 days and no sign of toxicity in the Invivofectamine® 
3.0-siDeath-Negative group. This finding confirmed it is the optimal candidate for 




This is the first study to attempt dendrimer, Lipofectamine® RNAiMax and 
Invivofectamine® 3.0 encapsulation in a PEGylated fibrin hydrogel for gene knockdown 
in vitro. The scaffold studies in literature, fibrin hydrogel included, show controlled siRNA 
release and prolonged gene silencing mostly in in vitro studies using 3D assays that 
have in vivo mimicking limitations [239, 293, 305, 391-395]. For instance, a commonly 
used 3D approach to demonstrating gene knockdown efficacy of RNAi scaffolds involves 
mixing single cells and nanocomplexes in the gel components prior to polymerisation 
[293, 305, 391] or 2D assays were cells are seeded directly on top of a layer of 
nanocomplexes on the scaffold [395]. In both these methods, cells are immediately in 
contact with the nanocomplexes which is not always the case when hydrogel-
nanocomplexes are injected in solid tissue. Other studies use transwell experiments 
were gels with nanocomplexes are set in the well and single cells seeded in 2D on the 
top side of a transwell [393] or vice versa [270]. This approach effectively assays release 
but does not incorporate a 3D aspect for the cells. The 3D assays developed in this study 
were designed to limit the immediate contact of cells with the nanocomplexes and allow 
cell transfection to occur via the release and diffusion of nanocomplexes through the 
separate hydrogel layers or by means of cell migration through the hydrogel layers past 
the nanocomplexes towards the serum rich media. 
Collectively the 2D and 3D nanocomplex release and gene knockdown assay results 
with the tested three nanocomplexes have shown that Invivofectamine® 3.0 is the 
optimal nanoparticle which consistently showed minimal toxicity, high transfection 
efficacy, and when encapsulated in 5:1 PEGylated fibrin hydrogel over 7/10 days, 
maintained bioactivity compared to MD and Lipofectamine® RNAiMAX. Therefore 
Invivofectamine® 3.0 nanocomplexes encapsulated in 5:1 PEGylated fibrin hydrogel 
were used in in vivo model to knockdown GFP protein and myostatin mRNA in TA 
muscle. 
 
3.3.2 In vivo RNAi assays 
 
The mouse hind limb is technically attractive as it allows for easy minimally invasive 
access with low potential of harm to the animal. However skeletal muscle has generally 
been reported to be challenging tissue to gene transfect with non-viral nanocomplexes 
[396-398]. To assist in transfection a number of studies suggest the use of 




electrical pulse to the muscle tissue to make the cells more permeable and susceptible 
to transfection [398-405]. Earlier studies showed that the use of electroporation to 
transfect interleukin-5 pDNA into TA mice skeletal muscle [400] and pDNA expressing	
β-galactosidase in soleus or	extensor digitorum longus muscles of adult rats [402] was 
more efficient than simple intramuscular DNA injection. Later studies showed 
electroporation effectively transfect TA muscle with shRNA against inositol 1, 4, 5-
triphosphate receptor [405], 5′-Nucleotidase (NT5C1A) [403]and myostatin [404]. This, 
therefore, suggested that evidence of knockdown using PEGylated fibrin-nanocomplex 
system would be a strong indication of its ability. 
As the mice used in this study expressed enhanced GFP (eGFP) ubiquitously, siGFP 
used in the above experiments was employed. GFP is a common gene knockdown 
reporter in 2D in vitro experiments and it was used in this study for the same purpose, to 
investigate downstream effects of gene knockdown at a protein level both in vitro and 
now in vivo using BALB/c GFP transgenic mice. However, GFP would not result in a 
measurable functional effect in vivo hence myostatin was additionally investigated to 
show gene knockdown effect as well as providing the possibility of measuring physical 
changes in the mouse muscle after gene knockdown. As previously discussed  (section 
1.5.1.2.4), myostatin is an important key regulatory protein in muscle regeneration and 
has been investigated in developing new strategies for human therapeutics in treating 
muscular atrophic diseases [301, 309] including the use of hydrogel based Mstn RNAi 
to knockdown its expression in vivo [301, 302]. Hence in this study, it was considered 
advantageous to employ the siRNA sequence that had been shown previously by Magee 
et al. [312], Noji group [301, 302, 406] and Mosler et al. [308] to knockdown myostatin in 
the masseter,	gastrocnemius and quadriceps femoris muscles. 
 
 Establishment of in vivo model 
	
Prior to commencing the in vivo study, there were a number of aspects of the RNAi and 
downstream analysis that required characterisation. As it was clear from the literature 
that skeletal muscle gene knockdown was demanding it was deemed that a maximal 
amount of siRNA that could be feasibly loaded in the 30µl injection volume of the TA 
muscle should be used. Direct communication with the manufacturer indicated that 
dialysis of the nanocomplexes prior to animal delivery due to lack of dilution was 
desirable. This was tested for its influence on cytotoxicity and efficacy as described in 




after dialysis but as these experiments were to be carried out in vivo and no negative 
influence of dialysis was observed, this dialysis modification was retained. 
 
 Detection of GFP and Mstn gene knockdown 
 
In an initial study with total RNA extracted from TA of a BALB/c GFP transgenic mice, it 
was used to identify the optimal housekeeping gene primer to use in conjunction for RT-
PCR analysis (procedure described in section 5.18.3). It was decided that GAPDH 
primers gave the least variation in cycle threshold (Ct) values and were therefore used 
in data analysis (Appendix 8). Mstn primers generated an acceptable Ct value at 32 
cycles and the amplification efficiencies of the primers was accounted for through the 
analysis of RT-PCR data with the LinRegPCR software program [407]. Immunoblotting 
of Mstn with the purchased anti-myostatin primary antibody [404] was unsuccessful in 
our hands. The purchased myostatin antibody was optimised by dot blotting and western 
blotting to reduce background and unspecific binding (Appendix 9), however, analysis 
of myostatin from muscle tissue sample produced multiple unspecific bands rendering it 
impossible to discern the right size bands for myostatin. Therefore it was decided to rely 
on RT-PCR data of mRNA levels to determine myostatin gene knockdown. Gene 
knockdown of GFP by siGFP for potential protein knockdown was carried out by western 
blotting. GFP could be effectively extracted from TA muscle tissue and showed a higher 
level of expression relative to β-Tubulin as compared to HT1080-GFP (clone 9) levels 
(Appendix 10). The expression pattern also appeared different as the GFP from the 
BALB/c transgenic mice extract was predominantly 27 kDa whereas the HT1080-GFP 
extract mainly contained the 30 kDa band.  
Once knockdown analysis assays were in place, an in vivo study looking at PEGylated 
fibrin hydrogel based RNAi was carried out. siMstn-Cy3 and siGFP-Cy3  complexed to 
Invivofectamine® 3.0 was injected alone or with 5:1 PEGylated fibrin hydrogel into the 
TA of BALB/c GFP transgenic mice as described in 5.18. 
 
 Nanocomplex retention in TA over 7 days 
 
GFP transgenic BALB/c mice were treated with Cy3 labelled siRNA Invivofectamine® 




following the procedure fully described in 5.18. In short 16 mice were randomly injected 
in both their TA hind limbs with four groups of treatments of PEGylated fibrin hydrogel 
encapsulated or free siMstn-Cy3 Invivofectamine® 3.0 and siGFP-Cy3 Invivofectamine® 
3.0 nanocomplexes. 7 days post treatment, TA muscles were dissected and a central 
≈1mm cross section was assessed for siRNA content and the rest was used for protein 
and mRNA analysis. As the 1mm cross-sectional tissue samples were small (to allow 
maximal tissue to be made available for RNA and protein extraction in further 
experiments) some difficulty was experienced with processing for histology and 3 tissue 
samples were lost from the PEGylated fibrin-nanocomplexes (Invivofectamine® 3.0-
siGFP-Cy3 and siMstn-Cy3) group and 3 samples from free nanocomplexes 
(Invivofectamine® 3.0-siGFP-Cy3 and siMstn-Cy3) group were lost. Cy3 labelled siRNA 
could be detected in the stitched micrographs in Fig.37. siRNA was only detected in 5 
out of 14 explants for free nanocomplex group represented in Fig.37A and 11 out of 13 
for PEGylated fibrin-nanocomplexes group represented in Fig.37B. Blinded image 
analysis showed that significantly more siRNA was present in the TA muscle tissue per 
total area of muscle tissue in the PEGylated fibrin nanocomplexes group by 87% versus 
the free nanocomplexes group (Fig.37C) (p<0.05). The results not only indicating that 
muscles injected with encapsulated nanocomplex localised and retained more 
nanoparticles in the muscle by day 7, but also that a portion of the siRNA was kept 
protected from RNase cleavage. This finding is in line with others who have shown that 
siRNA retention at the site of delivery improved in tumors, sinus mucosal lining and bone 
fracture targets sites when a scaffold is used in the siRNA/nanocomplex delivery [255, 
262, 263, 266, 270]. Scaffold mediated nucleic acid retention in cardiac muscle tissue 
has also been seen in two studies where rat MI models were intramyocardially injected 
with either gel-siRNA-Cy5.5 or gel-pDNA [273, 274]. siRNA was detected to be more in 
the gel-siRNA group compared to siRNA alone 24hrs post injection. In this present study 
siRNA retention of nanocomplexes was seen to be increased in mouse skeletal muscle 


































Figure 37: Tibialis Anterior muscle tissue retention of free Invivofectamine® 3.0 nanocomplexes or 
encapsulated in 5:1 PEGylated fibrin gel. 16 mice (32 legs) were randomly injected in their left and right 
TA muscle with Invivofectamine ® 3.0 nanocomplexes made with 5µg siMstn-Cy3 or siGFP-Cy3 with or 
without 5:1 PEGylated fibrin hydrogel encapsulation. For nanocomplex retention analysis, 7 days post 
treatment mice were then grouped into free nanocomplexes group and nanocomplexes in 5:1 PEGylated 
fibrin group (16 legs per group). 1mm crossections extracted from each TA muscle was used for fluorescent 
imaging of the retained siRNA in the tissue without (A) or with (B) 5:1 PEGylated fibrin hydrogel. Blue is 
DAPI stain, green is GFP and red is the Cy3 labelled siRNA. Arrows indicate some of the areas with 
nanocomplexes. (C) Quantification of the % area covered by Cy3 labelled nanocomplexes relative to total 
tissue by Visiopham image analysis software. Data is representation of 14 tissues samples without fibrin gel 






 GFP knockdown in vivo over 7 days  
	
It was considered reasonable to use siMstn treated tissue as control for their siGFP 
treated counterparts and siGFP nanocomplex alone treated tissue as control for the 
influence of fibrin as Mstn knockdown would not be expected to influence GFP 
expression. The converse was used for analysis of Mstn expression. The siGFP/Mstn- 
nanocomplex treated tissue samples were analysed for GFP knockdown by western blot 
analysis in Fig.38. No significant protein reduction was observed in the siGFP 
experimental groups against their siMstn treated negative control groups or for siGFP in 
PEGylated fibrin against siGFP nanocomplex alone. However, there was a decrease in 
GFP expression of 24% for Invivofectamine® 3.0-siGFP versus Invivofectamine® 3.0-
siMstn (p=0.91) and 13% versus Invivofectamine® 3.0-siMstn nanocomplexes in 
PEGylated fibrin (p=0.98). Furthermore, Invivofectamine® 3.0-siGFP nanocomplexes in 
PEGylated fibrin had a reduction in GFP expression relative to all other groups: 52% vs. 
free Invivofectamine® 3.0-siMstn (p=0.46), 37% vs free Invivofectamine® 3.0-siGFP 
(p=0.85) and 46% vs Invivofectamine® 3.0-siMstn in PEGylated fibrin (p=0.67).  
 
Figure 38: In vivo GFP knockdown with or without PEGylated fibrin over time. Mice were injected in 
their TA muscle with Invivofectamine ® 3.0 nanocomplexes of siMstn-Cy3 or siGFP-Cy3 with or without 
PEGylated fibrin hydrogel encapsulation. 7 days post treatment GFP expression was determined by western 
blot analysis. A.  GFP levels at day 7 (B) Quantification of GFP normalised to β-Tubulin, n=8. Statistical 





GFP is a protein that is commonly used as a visual and quantitative reporter for 
monitoring gene expression in biological assays [408, 409]. It is clear from literature that 
quantification of GFP knockdown is easily achieved on single cells by flow cytometry and 
by western blots in in vitro assays. eGFP protein is a stable variant of GFP that has a 
longer half-life which presents a challenge in studies where quantifying protein levels 
after transient GFP knockdown studies over a limited time period is required [409-411]. 
Indeed many studies investigating siRNA knockdown in vitro use a destabilized form of 
the GFP that possibly renders knockdown more detectable [52, 293, 408, 412-416]. 
There is a relative scarcity of in vivo RNAi knockdown of GFP expression studies 
reported in literature [274, 293, 417-422] and all were conducted using eGFP.  
In an early study, 14 days after implantation of GFP expressing glioblastoma cells in the 
flanks of mice, siGFP attached to magnetic nanoparticle carrying a membrane 
translocation peptide was delivered systemically [422]. Tumor accumulation of siRNA 
was observed 48hrs after delivery and a significant drop in GFP fluorescence (% 
decrease not given) was observed with optical imaging. In a more recent but similar 
study, GFP expressing T-lymphoma cell tumors in mice were targeted with siGFP 
complexed to acid-degradable ketalized PEI were delivered systemically 10 days after 
cell implantation. 3 days post treatment, flow cytometry indicated a 30% reduction in 
GFP expressing cells from the tumors but a GFP ELISA indicated a non-significant drop 
in GFP expression and RT-PCR was not conclusive with respect to mRNA knockdown 
[419]. As noted above, tumors with their leaky vasculature may be more susceptible to 
RNAi reagents than soft tissue. 
In skeletal muscle studies, GFP expression was achieved through plasmid transfection 
where GFP plasmid was delivered in conjunction with naked siGFP to TA of mice 
followed by electroporation [421]. An 80% knockdown in GFP expression, as determined 
by whole body imaging, was observed over 23 days when the plasmid was delivered in 
conjunction with the siRNA. Interestingly if siRNA was delivered 2 days after plasmid 
delivery only ≈40% knockdown was observed and this was only significant transiently at 
day 5, suggesting that established GFP expression and translation may make 
knockdown more challenging.  In another skeletal muscle based study, GFP expression 
was achieved in mice limb through transfection with a recombinant adenovirus that 
expresses GFP [417]. Delivery of siGFP in a cationic nanogel achieved a 58% 
knockdown as determined by fluorescence of the limb. However, it should be noted that 




In a study that used transgenic mice expressing GFP under control of the β-actin 
promoter (heterozygotes as compared to homozygotes used in this present study), 
delivery to mouse bronchial epithelial cells was undertaken through nasal spray of 
siGFP/chitosan nanoparticles daily for 5 days [420]. These particles were observed to 
knockdown GFP expression in vitro by 80% whilst bronchial epithelial cell knockdown in 
mice was observed by fluorescent microscopy to achieve ≈40% knockdown. A limited 
number of replicates (2-3) were used in this study. Transgenic rats expressing GFP from 
the CAG promoter in their cardiac tissue  (see section 1.5.1.2.5)  had guest host 
assembled PEI hydrogel carrying siGFP-Cy5.5 injected into heart tissue [417]. Here 
cardiac GFP expression was assayed with confocal microscopy whereby GFP 
fluorescence intensity that co-localised with siGFP-Cy5.5 signal was determined. At 
24hrs a 40% reduction in GFP fluorescence was observed when siGFP-Cy5.5 signal 
was present.  
RNAi knockdown of GFP expression in vivo appears to be in the majority assayed by 
fluorescence based methodologies which are more quantitatively challenging than 
methods such as western blot and Elisa. In one study described above, significance 
observed with flow cytometry was lost when analysed with ELISA suggesting that this 
latter type of analysis should be employed more frequently. 
The mice used in this study were eGFP expressing mice with expression driven by a 
ubiquitin C promoter and the mice were homozygotes. Therefore, there were potentially 
high levels of expression of the more stable variant and consequently, it is possible that 
the turnover of the protein may not have been rapid enough to reliably detect protein 
reduction.  
The observation above that knockdown was more effective when carried out in parallel 
with the initiation of GFP expression in skeletal muscle than when knockdown was 
delayed by only 2 days further suggests that the stability of the eGFP variant  may render 
GFP knockdown detection challenging [421]. Though not significant, a reduction in GFP 
protein levels was observed with the most pronounced reduction in the hydrogel group.  
 
 Myostatin knockdown in vivo over 7 days 
 
The knockdown of Mstn in TA tissue samples treated with the free or PEGylated fibrin 
encapsulated siMstn-Cy3 or GFP-Cy3 Invivofectamine® 3.0 nanocomplexes was 




GAPDH taking into account the individual primer efficiencies acquired from LinRegPCR 
program output (determined from averaging primer efficiencies for each sample run) 
[407].    
RT-PCR analysis (Fig.39 amplification curves in Appendix 11) showed that only delivery 
of siMstn-Cy3 complexed on the 5:1 PEGylated fibrin hydrogel resulted in a significant 
knockdown against all groups that is, 91 ± 17% versus free Invivofectamine® 3.0-siGFP-
Cy3, 93 ± 22% versus free Invivofectamine® 3.0-siMstn-Cy3 and 86 ± 62% versus 5:1 
PEGylated fibrin hydrogel encapsulating Invivofectamine® 3.0-siGFP-Cy3 groups 
(p<0.01). All other changes were not significant. This result indicates that the entrapment 
and release of Invivofectamine® 3.0-siMstn-Cy3 nanocomplexes in PEGylated fibrin 
hydrogel over the 7 days was effective. 
 
 
Since Mstn is known to promote muscle growth through muscle cell hypertrophy and 
hyperplasia [423], the mass of the excised TA was quantified (Fig.40). Only the fibrin 
hydrogel encapsulating Invivofectamine® 3.0-siMstn-Cy3 group showed a significant 
increase in mass of 26% and 25% against the free Invivofectamine® 3.0-siGFP-Cy3 and 
Invivofectamine® 3.0-siGFP-Cy3 nanocomplexes groups respectively. There was only a 
non-significant 9% increase against the fibrin hydrogel encapsulating Invivofectamine® 
Figure 39: Myostatin knockdown with Invivofectamine® 3.0   nanocomplexes in the presence or 
absence of 5:1 PEGylated fibrin over 7 days.  Mice were injected in their TA muscle with Invivofectamine 
® 3.0 nanocomplexes of siMstn-Cy3 or siGFP-Cy3 with or without PEGylated fibrin hydrogel encapsulation. 
7 days post treatment, Mstn expression was quantified by RT-PCR normalised to GAPDH. n=8. * p<0.05 vs 




3.0-siGFP-Cy3 group. This suggests that retention of fibrin and associated fluid might 













There have been several studies investigating the influence of siMstn sequence used in 
this present study on skeletal muscle mass. They all examine mass gain after 2-4 weeks. 
In the original study that identified the sequence as being an effective Mstn mRNA 
inhibitor, the sequences incorporated in a shRNA plasmid was electroporated in the TA 
of rats and the muscle excised after 2 weeks [312].  Only a 25% mRNA knockdown was 
achieved but this resulted in a 10% increase in muscle mass. In two related studies 
where the sequence was delivered with atelocollagen into masseter muscles [301] and 
biceps femoris [302] of mice, a 20-60% increase in muscle size was observed in the 
earlier study in the biceps femoris and around 35% increase in masseter mass with a 
75% knockdown of mRNA at 2 weeks. In a study that examined the effect of combining 
mice exercise with RNAi, the siRNA sequence was delivered systemically using a mini-
osmotic pump [308]. After 28 days, only the combination of siRNA and exercise resulted 
in an increase of the mice’s gastrocnemius muscle mass of 8%. This was associated 
with a knockdown of Mstn mRNA of approximately 30-40%. Interestingly for both this 
and the first Mstn RNAi study above, in a comprehensive Cre recombinase study in mice 
with floxed Mstn genes, it was found that a 60% knockdown of Mstn mRNA was required 
 Figure 40: Effects of Mstn knockdown over 7days on TA muscle tissue weight. Mice were injected in 
their TA muscle with Invivofectamine ® 3.0 nanocomplexes of siMstn-Cy3 or siGFP-Cy3 with or without 
PEGylated fibrin hydrogel encapsulation were analysed for muscle weight gain 7 days post treatment. The 




to achieve an increase in muscle mass [424]. In a recent study using an alternative 
sequence conjugated to a highly chemically modified cholesterol, systemic 
administration in mice achieved 85-95% knockdown of Mstn mRNA [425]. Here an ≈8% 
increase in mice gastrocnemius muscle size (as determined by microcomputed 
tomography) was observed after 7 days. The apparent increase in mass of the TA in this 
present study coupled with a 90% mRNA knockdown is comparable to the findings 
discussed above, suggesting that delivery from PEGylated fibrin hydrogel is 
advantageous. It should be noted that the level of knockdown observed in vivo was 
similar to that achieved in the experiments above where cells were transfected with 
siRNA complexed with Invivofectamine® 3.0 in the presence of serum. 
In total, the results reported above for delivery of siRNA into the challenging environment 
of the skeletal muscle is efficacious when encapsulated within PEGylated fibrin. This 
improved efficacy most likely resulted from the improved retention and controlled release 
of the lipid nanocomplexes. 
Future work to further investigate this system should consider longer implant periods 
whereby a potentially more pronounced increase in muscle mass might be achieved. 
Additionally, the impact of delivery into a muscle damage model where the impact on 
















The present study confirmed the observations shown in literature that the PAMAM 
dendrimer effectively condenses siRNA, and efficiently delivers siRNA in in vitro 2D cell 
culture with minimal cytotoxicity. Efficacy of the dendrimers in this study was 
demonstrated in two ways, by GFP knockdown and using a cocktail of siRNA sequence 
that result in cell death. It was confirmed that the unmodified version of the nanoparticle 
was not as effective in GFP knockdown in HT1080 cell line compared to the modified 
version, additionally, it was observed to have no effect at all when cell death was 
assessed. This highlights the importance of using various assays to show efficacy of 
nanoparticles. These siRNA interactions and gene knockdown were improved when the 
nanoparticle was modified with PEG polymer and DOPE lipid molecule, again confirming 
the work from the original study. In an extension to previous work, both dendrimers were 
shown to effectively protect against RNase attack for at least 10 days. Even though the 
dendrimer nanoparticles could effectively knockdown genes, when compared to the 
commercial lipid nanoparticles their efficacy paled in comparison. As these lipid based 
nanoparticles were intended for sustained delivery in vivo from scaffolds, which has 
never been reported in literature, their siRNA binding capacity and RNase protection 
capacity was also examined. Invivofectamine® 3.0 was verified to be non-cytotoxic and 
to effectively bind around 70% of its siRNA. Although the majority of complexed siRNA 
was degraded within 24hrs, the nanoparticle persistently protected 10% of its siRNA over 
10 days.  
Enzymatically degradable PEG and fibrin hydrogels have not been comprehensively 
investigated for controlled siRNA delivery thus they were assessed here. The 
modification of fibrin by adding PEG molecules to stabilise degradation of fibrin in vitro 
and allow sustained release of cargo has been shown by the Suggs group. They also 
showed a structural change of the fibrin from a network of fibrillary structure to sheet-like 
morphology. This study confirmed these well-defined effects of fibrin PEGylation in vitro 
and went further to show for the first time the comparisons of non-PEGylated and 
PEGylated fibrin degradation rate in vivo. Unmodified fibrin degraded in vivo by day 2 
whilst the PEGylated fibrin gradually degraded and was still present in tissue after 7 
days. The hydrolytically and enzymatically degradable PEG-AC hydrogel had a much 
faster degradation rate in vivo compared to that in vitro, and this was presumably due to 




 PEG-AC, like unmodified fibrin, was completely degraded by day 2 and therefore would 
not be useful for in vivo sustained release, however, PEG-VS showed similar 
degradation rate to the PEGylated fibrin gels. Because PEG-VS did not degrade in vitro 
and release siRNA or nanocomplexes, the efficacy of those releasates could not be 
verified in vitro. This type of gel may be an interesting candidate for nanocomplex 
delivery to invasive cells in the future. This present study proceeded with the PEGylated 
fibrin hydrogel which did release siRNA nanoparticles in a sustained manner in vitro and 
whose efficacy could be verified. It was determined that of the nanoparticles used in the 
study, Invivofectamine® 3.0 nanocomplex releasates remained effective over 10 days of 
release.  
A 3D assay was designed to more closely mimic in vivo delivery to soft tissue, whereby 
PEGylated fibrin hydrogels containing cells or nanocomplexes were polymerised 
separately were employed. Though other variations of these assays have been used, it 
is the first time they were used for a RNAi assay. The 3D assays showed that 
Invivofectamine® 3.0 nanocomplexes were consistently efficacious with no evidence of 
cytotoxicity. It was also found in these assays that though the modified dendrimer 
nanocomplexes were effective at gene knockdown at early time points, with longer 
exposure to cells there were evident signs of toxicity. Based on these results, it was 
determined that Invivofectamine® 3.0 and PEGylated fibrin hydrogels were the optimal 
siRNA delivery combination and were investigated in vivo. 
To our knowledge, PEGylated fibrin hydrogel has not been used for sustained in vitro or 
in vivo RNAi. Furthermore to this, RNA interfering lipid nanocomplexes specifically have 
not been shown to be delivered in a sustained manner by any scaffold. This study is the 
first to show in vivo RNAi in mouse skeletal muscle, which is considered a challenging 
tissue to transfect, via localised and sustained delivery of lipid based nanocomplexes 
encapsulated in PEGylated fibrin hydrogel.  The direct injection of this novel hydrogel-
lipid nanocomplex (PEGylated fibrin hydrogel- Invivofectamine® 3.0 nanocomplex) RNAi 
system into the TA muscle resulted in (1) improved siRNA or nanocomplex retention at 
the target site compared to free nanocomplexes (2) the knockdown of target Mstn mRNA, 
and a significant muscle weight increase as well as  an observed reduction in GFP level 
(through this reduction was not significant) compared to free lipid nanocomplexes or the 
hydrogel-lipid nanocomplex control groups within the 7 day period. Future work will 
investigate the effect of Mstn knockdown over a longer period on muscle growth.   
In this present thesis, Invivofectamine® 3.0 nanocomplexes were shown to be the 




Encapsulating the lipid nanocomplexes in PEGylated fibrin hydrogel improved the 
efficacy of free lipid nanocomplexes in skeletal muscle gene knockdown. A novel 
PEGylated fibrin hydrogel- Invivofectamine® 3.0 nanocomplex RNAi system established 
in this preliminary proof of concept study, is potentially a delivery system for RNAi 
molecules for various human diseases and presents further opportunity for possible 























5.1 Modified dendrimer nanoparticle formation  
 
5.1.1 G(4)-D-PEG2K-DOPE Polymer synthesis 
 
Synthesis of G(4)-D-PEG2K-DOPE was prepared following the procedure previously 
detailed by Torchilin et al. and Biswas et al. with minor modifications described below 
[140, 426]. 
 
 Synthesis of NPC-PEG2K-DOPE (starting polymer)  
 
PEG2K-NPC2 (1g, 0.5mmol) was dissolved in 5ml chloroform (≈10 fold molar excess to 
DOPE).  20μl tris base, acetic acid and EDTA (TAE) buffer solution was added to 
50mg/ml solution of DOPE (37.2mg, 0.05mmol) in chloroform [37.2mg DOPE +744µl 
chloroform + 20μl TAE]. The DOPE-TAE mixture was added dropwise to the PEG2K-
NPC2 solution. The reaction mixture was incubated at room temperature (RT) overnight 
with stirring. Chloroform was removed with a rotary evaporator and freeze dried. The 
crude reaction mixture was dissolved in 1 ml 0.01 M hydrochloric acid (HCl) solution with 
water bath sonication to form NPC-PEG2K-DOPE micelles. The micelles were purified 
from the unbound PEG2K-NPC2 and released -NPC by dialysis of the mixture against 
0.01 M HCL using cellulose ester dialysis membrane with 12-14000 kDa molecular 
weight (MW) cut off. Dialysis was carried out with changes of HCl three times at 2X1.5hrs 
and overnight. The purity of NPC-PEG2K-DOPE product was determined by thin layer 
chromatography (TLC). The initial pure fractions of NPC-PEG2K-DOPE were freeze 
dried.  
 
 Synthesis of G(4)-D-PEG2K-DOPE (Modified Dendrimer, MD) 
 
In a pre-weighed 50ml flask methanol was evaporated from 0.62ml of G(4)-D solution on 
a rotary evaporator for 20mins to get 69mg of G(4)-D. 10µl of TEA was added to 69mg 
G(4)-D re-suspended in 25ml DMF, and NPC-PEG2K-DOPE solution in DMF (12.6mg in 
2.5ml DMF] was added in a 1:1 molar ratio. The MW of NPC-PEG2K-DOPE 2663.51g/mol 
and that of G(4)-D is 14214.17 /mol. The reaction mixture was stirred overnight at RT to 




was removed by rotary evaporator. The crude mixture was dissolved in 1ml water and 
dialyzed against water as described above. The collected G(4)-D-PEG2K-DOPE 
(modified dendrimer, MD) product was freeze dried in pre-weighed vials using Virtis-
Freeze Dryer for 24hrs and characterized by nuclear magnetic resonance (NMR) 
spectroscopy using Varian 400 MHz spectroscope. In preparation for NMR analysis, 
product MD, starting materials G(4)-D (which is referred to as D) and NPC-PEG2K-DOPE 
were dissolved in d-methanol (10mg/ml).    
 
5.2 Nanocomplex formation  
 
5.2.1 D-siRNA dendriplex formation and Nitrogen:Phosphate (N/P) ratio 
determination 
 
Following nanocomplexing protocol by Biswas et al. [140], 200ng siRNA in a 10μl volume 
of Hepes and glucose buffer (BHG) buffer pH 7.4 (Appendix 14) was added to 
appropriate dendrimer concentration determined by the N/P ratio (0 – 20 range), also in 
a 10μl volume of BHG buffer. N refers to the number of moles of nitrogen (N) on the 
dendrimer, while P refers to the number of moles of phosphates (P) on the backbone of 
siRNA. N/P ratios of 0:1, 0.5:1, 1:1, 2:1, 4:1, 8:1,10:1 and 20:1; were considered in this 
study.  The amount of N (dendrimer) required, as P (siRNA) remained constant at 200ng, 
was determined by the formula in Equation 1. The mixture was incubated for 20mins at 
RT to allow dendriplexes/nanocomplexes to form. Fig.8 shows the schematic 
representation of how MD was synthesised and how dendriplexes possibly occur. 
 
 






5.2.2 Lipofectamine® RNAiMAX nanocomplex formation and optimisation for 
transfection  
 
Lipofectamine® RNAiMAX was used as a positive control for GFP knockdown in vitro as 







with Lipofectamine® RNAiMAX were made following Lipofectamine® RNAiMAX 
manufacturers guide specifications with a few modifications as follows. 5000 cells were 
seeded per well in a 96 well plate a day prior to transfection. A range of 0.6μl - 5ul 
Lipofectamine was used to complex 200ng siNegative in serum free MCDB media pH 
7.4 instead of recommended Opti-MEM® Medium. Cells were transfected with the 
nanocomplexes and monitored over 72hrs microscopically. 0.6µl Lipofectamine® 
RNAiMAX had the least cytotoxic effect on the HT1080 cells and was considered optimal 
volume to use in all the in vitro transfection experiments instead of the recommended 
0.3µl per ≈13.3ng siRNA (4.5µl per 200ng). 0.6µl Lipofectamine® RNAiMAX was used 
to complex 200ng or 500ng siRNA depending on experimental needs.   
 
5.2.3 Invivofectamine® 3.0 nanocomplex formation  
 
Invivofectamine® 3.0 was used as the second lipid based nanoparticle of interest in our 
study. The Invivofectamine® 3.0 nanocomplexes were made following Invivofectamine® 
3.0 manufacturers guide specifications with the following modifications: 10μl of 
Invivofectamine was added to an equal volume of siRNA and complex solution to give a 
final concentration of 0.6mg/ml siRNA in 20μl. The 20μl mixture was incubated for 
30mins at 50oC and no further dilution (6X dilution) of the nanocomplexes as 
recommended by the manufacturer was implemented to keep the concentration of 
nanocomplexes as high as possible for later scaffold delivery studies. The change in 
protocol of using nondiluted nanocomplexes was tested in vitro in GFP knockdown 
experiments (section 5.8.2). 6X, 3X, 2X and 0X dilution of nanocomplexes all containing 
(1000ng siGFP/Mstn-Cy3) were used in the transfection of HT1080-GFP cells to ensure 
efficacy of the nanocomplexes was maintained when used in their concentrated form 
(Appendix 12). This would allow smaller volumes with more siRNA-nanocomplexes to 
be loaded in the 30µl volume hydrogels without compromising nanocomplex efficacy. 
Once nanocomplexes were made they were immediately used in knockdown 
transfection experiments or stored at 4oC up to 1 week until use as recommended by the 
manufacturer. It was established that using diluted or non-diluted stock nanocomplexes 
had no effect on transfection, all experiments involving Invivofectamine® 3.0 









5.3 Nanocomplex formation and dissociation ability tests by: 
 
5.3.1 Gel shift assay   
 
D and MD Dendriplexes N/P ratios of 0 – 20 as well as Lipofectamine® RNAiMAX and 
Invivofectamine® 3.0 nanocomplexes were prepared in as described in section 5.2 using 
siNegative. After incubation of the nanocomplex mixtures for the recommended times, 
nanocomplex formation was tested by gel shift assay. After nanocomplex incubation, for 
dendriplexes, 20μl aliquots for each ratio were mixed with GelRedTM nucleic acid dye 
(final concentration 1X) to label siRNA and loaded into wells of a 2% (w/v) agarose gel 
for electrophoresis using a Biorad nucleic acid electrophoresis system (55V for 30mins). 
When nanoparticles condense the siRNA it renders it unable to migrate through the 
agarose gel pores, only free unbound siRNA migrates towards the anode. The siRNA 
bands were visualized under UV light using Syngene InGenius3 Gel Documentation 
system and micrograph images were taken by the system’s GeneSys image capture. 
Quantification of the siRNA bands was done by Syngene GeneTools image analysis 
software. 
 
5.3.2 Fluorescent siRNA quenching and dissociation assay 
 
Dendriplex formation and dissociation ability was tested by RiboGreen™ RNA label 
exclusion quenching assay and heparin sulphate RNA dissociation method following 
Biswas et al. [140] with modifications as follows: Dendriplexes N/P ratios of 0 – 20:1 were 
prepared using siFITC. RiboGreen™ (with an excitation/emission wavelength of 500 / 
525nm) was included in the dendriplex mixture to label and amplify the fluorescent signal 
of free siRNA. FITC has an excitation/emission wavelength of 485/520 nm similar to 
RiboGreen™. Firstly the 200ng siFITC in 9µl BHG buffer was incubated with 1µl 
RiboGreen™ stock solution for 10mins at RT to label siRNA before nanocomplexes are 
made. The labelled siRNA was incubated with 10µl D/MD for 20mins at RT to form 
dendriplexes in BHG buffer. The 20µl dendriplex solution with label was added to 40µl 
Tris-EDTA pH 8 (TE, Appendix 14) buffer to make a 60µl volume that would cover the 
well of a 96 well white opaque pate.   BHG and TE buffer only with RiboGreen™ was 
included as background control. The fluorescence intensity of any free siRNA was 




Eclipse), at 500/525 excitation and emission wavelengths. 10 and 50U of heparin 
sulphate per 1µg siRNA was added to the dendriplex mixture with mild shaking to 
dissociate siRNA from the dendrimers and fluorescence was measured again.   
 
5.4 D, MD, Lipofectamine® RNAiMAX and Invivofectamine® 3.0 
nanocomplexes siRNA serum protection ability. 
 
1000ng scramble siNegative was complexed to D and MD at an N/P ratio of 0-20:1 (as 
above in section 5.2.1) in BHG buffer pH 7.4, a total volume of 100μl master mix for each 
N/P ratio 0-20. 100µl FBS was added to each reaction tube (50% final serum 
concentration). Lipofectamine® RNAiMAX (0.6µl) and Invivofectamine® 3.0  master mix 
was also made following manufacturers guide and the protocol above in sections 5.2.2 
and 5.2.3; nanocomplexes with 1000ng siRNA were made and diluted to a total volume 
of 100μl with Iso-osmotic PBS (IsoPBS) pH 7.4.  100μl fetal bovine serum (FBS) was 
added to the reaction tubes containing the 100μl nanocomplex solutions (50% final 
serum concentration). Each reaction tube contained 200μl solution of nanocomplex and 
serum. Over a period of 10 days, 10μl aliquots of serum + nanocomplex sample (100ng 
siRNA) from each nanocomplex (D, MD, Lipofectamine® RNAiMAX and 
Invivofectamine® 3.0) were collected and snap frozen in liquid nitrogen and stored at -
200C. Samples were vortexed before each collection. After 10 days, SDS was added to 
each collected 10μl (100ng siRNA) sample to dissociate the siRNA from the 
nanoparticles (0.5% final SDS concentration). 1X Loading dye with nucleotide labelling 
dye GelRed™ was added to the samples. Fresh 100ng siRNA was included as positive 
control. Samples with SDS were incubated for 5mins after which samples were subjected 
to	electrophoresis according to protocol in section 5.3.1. 
 
5.5 Cell culture 
 
Table 3: Cell plating protocol for tissue culture 
Cell Type Plate size Cell number plated Volume of media 
HT1080 (GFP or non-GFP) 96 well 5000 100μl 
 24 well 30000 500μl 
 Transwell 15000 200μl top well 
500μl bottom well 
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HT1080 and HT1080-GFP cells were cultured in MCBD media	in an incubator at 370C 
with 5% carbon dioxide. The number of cells used in the experiments and the volumes 
of media in which they were maintained is indicated in Table 3. The media contained 
10% FBS, 1% penstrep antibiotics (100U penicillin and 100ug streptomycin). HT1080-
GFP cells were maintained in full growth media with 200ng/ml G418 (Geneticin 
antibiotic), during the growth phase only, to keep positively selecting for GFP expressing 
cells.  
 
5.5.1 Making a stable HT1080 cell line expressing GFP (HT1080-GFP) 
 
800000 cells were seeded in two 60mm cell culture plates. The following day cells in one 
plate were transfected with PolyFect transfection reagent according to supplier’s guide 
complexing 2.5ng pEGFP-C1 plasmids with a neomycin resistant gene for selection 
(Appendix 1). No DNA was added in the control plate. 24hrs post transfection media 
was removed and cells were maintained in full growth media with 600μg/ml G418. G418 
selects against non-transfected over time, and maintains selection for cells that stably 
incorporated the eGFP plasmid in their genomic DNA. After 3 weeks, 3 stable clones (9, 
10 and 16) were selected by limiting dilution following Life Technologies protocol. Cells 
seeded for experiments were maintained in normal MCDB growth media without G418. 
Flow cytometry described in section 5.6 below was carried out on the 3 clones to show 
positive GFP expression in the 3 clones, non GFP expressing cells HT1080 cells were 
included as a negative control (Appendix 2A). Clone 9 which showed the highest GFP 
expression indicated by higher geometric shift was chosen for all in vitro experiments.  
 
5.5.2 Cytotoxicity analysis for D, MD and Invivofectamine® 3.0 nanocomplexes 
	
200ng siNegative complexed to Lipofectamine® RNAiMAX, Invivofectamine® 3.0, D and 
MD (N/P ratios of 0-20:1) were added to 5000 cells in a 96 well white opaque plate that 
were seeded in triplicate 24hrs prior (150nM final siRNA concentration).	Untreated cells 
or siRNA only treated cells were included as controls. The transfection was allowed to 
occur over 4hrs without serum, and cells were incubated at 37oC for 48hrs in 100μl 
volume of growth media. Cell death was detected 48hrs post transfection using the 
CellTiter-Glo® luminescent Cell Viability Assay as per the manufacturer’s guide protocol. 
100μl of CellTiter-Glo® Reagent was added to the transfected cells and incubated for 
10mins. CellTiter-Glo was also added to 2500, 5000, 10000 and 15000 cells seeded in 
triplicates on the day of detection to generate a standard curve. The reagent lyses the 
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cells and enables the detection of ATP present in viable live cells which is proportional 
to the number of cells present ATP dependent luminescence was quantified on a 
Promega GloMax 96 microplate luminometer. The number of viable cells was 
determined from the standard curve and expressed as percentage cell survival 
normalised to untreated control cells.  The same was done for cells treated with 
Invivofectamine® 3.0 nanocomplexes. Cells were treated with nanocomplex solution 
containing 200ng siRNA (0.36µl Invivofectamine® 3.0-siRNA) for 4hrs in the absence of 
serum and further incubation and ATP detection was done as indicated above.  
 
5.6 Flow cytometry  
 
Treated and untreated HT1080 or HT1080-GFP cells with siGFP or fluorescently labelled 
siRNA (siFITC) were washed with warm PBS (pH 7.4) to remove media, trypsinised from 
the base of the plate and centrifuged at 1500rpm. The cell pellet was suspended in 500μl 
of FACS buffer and the GFP fluorescence intensity was measured and represented as 
geometric shift from the mean as measured on a Beckon Dickson FACSCalibur flow 
cytometer. 10000 cells were counted for analysis and gated using forward-scatter versus 
side-scatter to exclude debris and dead cells.  
 
 
5.7 D and MD dendriplex transfection efficiency in HT1080 cells. 
 
The FITC labelled siRNA dendriplexes were prepared as described in 5.2.1 for N/P ratios 
of 2 – 20:1. 20μl of complexes were added to 5000 HT1080 cells seeded in triplicates 
the day before in 96 well plates containing 180μl volume of serum free fresh growth 
media. Cells only and siRNA only negative controls were included in the experiment. 
After 4hrs of incubation at 37oC, cells were carefully washed 1X with PBS pH 7.4. Full 
growth media was added and cells were incubated for 24hrs.  Cells were then washed 
with PBS pH 7.4 and nuclei stained with Hoechst stain at a final concentration of 2μg/ml 
in media for 10mins. Post staining cells were washed with PBS pH 7.4 to remove excess 
staining solution. 200μl growth media was added and cells were imaged by inverted 
fluorescent microscope (Zeiss Axiovert 200M Inverted Fluorescent Microscope).  
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5.8 Nanocomplexes transfection efficacy 
 
5.8.1 Cell death assay 
 
D and MD dendriplexes were formed with 200ng siDeath/siDeath-Negative at ratios 0-
20:1. 5000 HT1080 cells seeded in triplicates a day prior in 96 well plates were 
transfected for 4hrs without serum with the dendriplexes. Untreated cells and free 
siDeath/siDeath-Negative were included as negative controls. After 4hrs full growth 
serum was added to the cells and 48hrs post transfection CellTiter-Glo® Luminescent 
cell viability assay was performed as described in section 5.5.2.  
 
 
5.8.2 Complimentary D and MD dendriplex uptake and efficacy. 
 
 siFTC uptake by D and MD dendriplexes (N/P 8) 
 
To determine transfection efficacy with siFITC, in 24 well plates, after determining the 
best transfection ratio (N/P 8) which would be applied throughout the study, 30000 
HT1080-GFP cells were seeded in triplicate. The following day the cells were transfected 
with D and MD dendriplexes containing 1000ng siFITC at (N/P of 8). Dendrimers only or 
free siFITC where included as controls. 24hrs post transfection, efficacy of the 
dendriplexes was determined by flow cytometry, which measured and quantified the 
geometric shift from control untreated cells. Flow cytometry procedure fully described in 
5.6.  
  
 GFP knockdown with D and MD dendriplexes (N/P 8) 
 
Transfection efficacy of D and MD dendriplexes was measured by flow cytometry and 
western blotting. 30000 HT1080 cells or HT1080-GFP cells were seeded in a 24 well 
plate in triplicate, the following day cells were transfected for 4hrs in serum free media 
with D and MD (N/P 8) made with 1000ng siGFP or scramble siNegative siRNAs. 48 or 
72hrs post 4hr transfection, GFP knockdown in cells was determined and analysed by 
either flow cytometry (section 5.6) or western blot analysis (section 5.10) depending on 
experimental needs. GFP knockdown analysis by flow cytometry was made 48hrs and 
72hrs post transfection. Untreated HT1080 cells, untreated HT1080-GFP cells, free 
siGFP only treated cells and D/MD nanoparticles only treated cells were included as 
negative GFP knockdown controls. Untreated HT1080 cells were used as an indication 
	 	 	 Methods	
136	
	
of GFP knockdown. GFP knockdown analysis by western blot was made 48hrs post 
transfection. Here, Lipofectamine® RNAiMAX (0.6μl/1000ng) and untreated HT1080 
cells were used as positive controls for GFP knockdown whilst untreated HT1080-GFP 
cells and free siGFP only treated cells were included as negative GFP knockdown 
controls. 48hrs post transfection whole cell lysate protein was extracted from cells 
(section 5.9) in preparation for western blot analysis. 
  
5.8.3 GFP knockdown with MD, Lipofectamine® RNAiMAX and 
Invivofectamine® 3.0 nanocomplexes. 
 
Transfection efficacy of all nanocomplexes was measured by flow cytometry. 30000 
HT1080 cells or HT1080-GFP cells were seeded in a 24 well plate in triplicate, the 
following day cells were transfected for 4hrs in serum free media with MD (N/P 8), 
Invivofectamine® 3.0 and Lipofectamine® RNAiMAX (0.6μl/1000ng) nanocomplexes 
were made with 1000ng siGFP or siNegative control siRNAs. Untreated HT1080-GFP 
only cells, free siGFP, and all three nanoparticles complexed with siNegative siRNA were 
included as negative knockdown controls. 48hrs post transfection GFP knockdown was 
and analysed in cells by flow cytometry (section 5.6).  
 
5.9 Protein extraction from HT1080-GFP cells in vitro for western blot 
analysis 
 
After cells were treated with MD nanocomplexes in the GFP knockdown experiment 
(section 5.8.2.2), cells were washed 3X with warm PBS pH 7.4, trypsinized and 
centrifuged at 1500 rpm. 50μl Ice cold radioimmunoprecipitation assay (RIPA) buffer with 
protease inhibitor (PI) cocktail (1μl /100μl RIPA) was added to the cells on ice were 
subjected to one short burst of sonication with a microprobe and incubated for 10mins 
on ice to allow complete cell disruption. After incubation, the samples were centrifuged 
at 14000rpm (40C for 5minutes) to remove debris and DNA. The supernatant was 
transferred to a fresh Eppendorf and the extracted protein quantified by Bradford’s assay 
according to Pierce™ Detergent Compatible Bradford Assay Kit manufacturer’s 
guidelines. Samples were stored at -800C prior to analysis for GFP expression (western 
blot section 5.10). 
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5.10 Western blot analysis 
 
The protein concentration to use in western blot analysis experiments for GFP 
expression and detection with the listed antibodies (Table 2) was optimised to reduce 
background. 30μg protein samples was optimal for analysis (Appendix 2B). 30μg of 
protein from either HT1080 cells or mouse tissue was electrophoresed under reducing 
conditions using 5% β-Mercapthoethanol. The sample was boiled for 10mins in the 
reducing loading dye. The proteins were then separated on a 12% SDS-page BioRad 
TGX™ FastCast™ Acrylamide gel at constant 200 volts (V) for 40mins. A Precision Plus 
Protein™ dual colour molecular weight marker was included in the protein separation to 
estimate the protein sizes. Protein transfer onto nitrocellulose membrane was done using 
semidry transblot system for 15mins at constant 10 V.  To prevent nonspecific antibody 
binding the membrane was blocked for 1hr at RT with 5% non-fat milk in Tris buffered 
saline tween (TBST). GFP (≈27 kDa), myostatin (≈50 kDa) and the loading control β-
Tubulin (≈50 kDa) protein were probed for rabbit anti-GFP, rabbit anti-myostatin and 
rabbit anti-β-Tubulin primary antibodies in 5% non-fat milk in TBST overnight at 40C. 
Membranes were washed 3 times for 10minutes with TBST.  Anti-rabbit HRP tagged 
secondary antibody in 5% non-fat milk and TBST was added to the blot and incubated 
at RT for 1hr. Membranes were washed 3X 10mins with TBST and protein band 
detection and imaging was carried out using WesternBright™ECL western blotting 
detection kit and the Syngene GeneGnome gel doc system. Since both GFP and β-
Tubulin primary antibodies were raised in rabbit and had different sizes they were where 
co-detected on the same immunoblot. For Myostatin and β-Tubulin which are the same 
size (≈50 kDa) myostatin was probed for first and the membrane was stripped for β-
Tubulin detection. The list of antibodies and concentrations used are listed in Table 4.  
 
5.10.1 Nitrocellulose membrane stripping 
 
After probing for myostatin protein, the membrane was incubated for 2hrs with shaking 
at RT in stripping buffer (Appendix 14).  The membrane was washed 3X 10mins with 
TBST buffer before blocking with 5% milk powder in TBST for 1hr. β-Tubulin primary 
antibodies in 5% non-fat milk and TBST was added and incubated overnight at 40C 
antibody. Membranes were washed 3 times for 10minutes with TBST and Anti-rabbit 
HRP tagged secondary antibody was added the protein band detection procedure 
repeated as mentioned above (5.10).
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 Table 4: Antibody concentrations used for western blotting 
Primary Antibody Primary antibody 
conditions 
(2.5% non-fat milk 





(2.5% non-fat milk 
powder in TBST) 
Rabbit anti-GFP 1:10000 Goat anti-Rabbit 1:20000 
Rabbit anti-
Myostatin 
1:5000 Goat anti-Rabbit 1:20000 
Rabbit anti-β-
Tubulin 
1:2500 Goat anti-Rabbit 1:20000 
Rabbit anti-GAPDH 1:5000 Goat anti-Rabbit 120000 
   
 
5.11 Transmission electron microscopy (TEM) analysis of D,MD and 
dendriplexes 
 
D and MD nanoparticles (5mg/ml in nanopure water) without siRNA and with scramble 
siNegative at N/P of 8 were prepared as above in section 5.2.1. Samples were primed 
for TEM and imaging by taking 3μl of each sample and loading it onto a copper grid plate, 
left for 30 seconds and excess liquid was dabbed off. Samples were left to dry for 10mins 
at RT nanoparticle and nanocomplex images were taken by FEI Tecnai G2 TEM. The 
diameter of 20 nanoparticles per group were measured. 
 
5.12 Scaffold formulation 
 
5.12.1 Fibrin hydrogel formulation, PEGylation and characterisation 
 
 Fibrin gel formulation with or without Cy5 fluorescent label  
 
A 35μl 10mg/ml Fibrin gel was prepared by mixing 8.75μl 40mg/ml stock Fibrinogen (in 
HBS pH 7.8), 4μl of 0.624 U/ml of thrombin in 40mM Ca2+ and the volume made up to 
35μl by adding HBS pH 7.4. To label fibrin gels with a Cy5 label, 2μl of 3mg/ml fibrinogen 
with Alexa Fluor™ 647 conjugate was added to the solution before thrombin and the final 
volume of HBS pH 7.4 added adjusted to make the final gel volume 35µl. For 50μl gels 
used in siRNA elution profiles, the volumes of the gel components were adjusted 
accordingly. When free siRNA, MD, Lipofectamine® RNAiMAX and Invivofectamine® 
3.0 nanocomplexes were required, they were added to the pre-gel mixture adjusting the 




 5:1 or 10:1 PEGylated Fibrin gel formulation with or without Cy5 fluorescent 
label  
 
A 35μl 10mg/ml Fibrin gel was prepared by first conjugating PEG-SMC2 to fibrinogen for 
1hr at 370C. 1.75μl of 10 mg/ml PEG-SMC2 or 3.5μl of 10mg/ml PEG-SMC2 was added 
to 8.75μl 40mg/ml stock Fibrinogen in HBS pH 7.8 (for a 5:1 or 10:1 PEG to fibrinogen 
ratio respectively). The volume was made up to 20µl by HBS pH 7.8. After incubation 4μl 
of 0.624U/ml of thrombin in 40mM Ca2+ was added and the volume made up to 35μl by 
with HBS pH 7.4.  
 
 Fibrinogen electrophoresis to show PEGylation 
 
Following protocols by Zhang et al. [351] with some modifications. 0, 5:1 and 10:1 
PEGylated fibrinogen was prepared as described above (5.12.1.1 & 2) in 20μl HBS pH 
7.8. After PEGylating, 5µl (125ng of fibrinogen protein) of the fibrinogen was added to 
8.3μl 3X loading dye with 15% β-mercapthoethanol and volume made up to 25μl with 
distilled water. Samples were boiled for 10mins, loaded onto a 7.5% SDS PAGE BioRad 
TGX™ FastCast™ Acrylamide gel and electrophoresed at 200 V for 45mins. After 
electrophoresis fibrinogen protein on the gel was stained by coomassie stain for 30mins 
and distained for 2hrs with mild shaking at RT. The images of the gel stains were taken 
by the gel doc system using white light. 
 
 Scanning electron microscopy (SEM) imaging of fibrin hydrogels 
 
50µl 10mg/ml of 0, 5:1 and 10:1 PEGylated fibrin were made as above in 5.12.1.1 & 2. 
Immediately after adding thrombin, the gels were absorbed into interconnecting 
microporous polyurethane foam discs (84% porosity, with pore sizes 125 - 180µm in 
diameter). The fibrin gels were polymerised within the foam to support the hydrogels 
during sample preparation for SEM. The polyurethane foams containing fibrin gels were 
fixed with 2.5% glutaraldehyde for 30mins. Foams were rinsed 3X with distilled water 
and freeze dried overnight. They were then gold sputter coated with Palaron range SC 
7640 sputter coater for SEM imaging.  SEM images of the fibrin gel structure were then 






 Stability of fibrin hydrogels in aqueous buffer 
 
50μl 10mg/ml (total 504ng of protein) 0, 5:1 and 10:1 PEGylated fibrin gels were 
prepared in triplicates as above 5.12.1.1 & 2 in 2ml eppendorfs. 150μl HBS pH 7.4 was 
incubated for 30mins, 1, 3, 5, 7, 10, 18 and 26 days with 150μl HBS pH 7.4 buffer 
replacement in between each time interval collection until the gels completely degraded. 
The collected released fibrin protein samples were snap frozen and quantified after the 
gels had degraded. Knowing the quantity of the starting material, the protein released 
was measured by Bradford’s assay following manufacturer’s guidelines. Serially diluted 
(504 – 0ng) fibrinogen was used to create a standard curve which allowed for 
quantification of the released fibrin over time. 
 
5.12.2 4% 8-arm PEG-VS gel and PEG-AC gel formulation 
 
PEG hydrogels were formed by crosslinking either 8-arm 20 KDa PEG-VS or PEG-AC 
with MMP1 recognition peptide (GCREGPQGIWGQERCG 1733Da MW). PEG-VS 
hydrogels were only enzymatically degradable whilst PEG-AC hydrogels were both 
enzymatic and hydrolytically degradable. For a 50µl final volume, 10µl 20% m/v PEG VS 
or AC in IsoPBS pH 7.4 was mixed with 0.88mg MMP1 recognition peptide in 20µ IsoPBS 
pH 7.4 (4 peptide : 1 PEG) and IsoPBS pH 7.4 added to 50µl. The hydrogels polymerised 
spontaneously over 20mins at 370C or in situ after injection in the tibialis anterior muscle 
of mice. When free siRNA, MD, Lipofectamine® RNAiMAX and Invivofectamine® 3.0 
nanocomplexes (1000ng siRNA) were needed, they were added to the pre-gel mixture 
adjusting the volume of additional isoPBS pH 7.4.  
  
5.12.3 4% 8-arm PEG-VS and PEG-AC gel Cy5 labelling and formulation 
 
A far red label was introduced into the PEG hydrogels through the addition of a thiol to a 
far-red labelled maleimide. Alexa Fluor® 660 C2-maleimide (Alexa) was reacted with 
DTT as follows: 1ul Alexa (10mg/ml) dimethyl sulfoxide was reacted with 9ul DTT (1.1mM 
in IsoPBS pH 7.4 at a 1 Alexa per DTT molecule) for 30mins and 370C. The Alexa-DTT 
was then added to PEG monomer at 1 Alexa-DTT molecule per 100 PEG molecules and 




5.13 siRNA release from PEG- AC and PEG-VS  hydrogels  
 
1000ng siNegative alone or MD (N/P 8), Lipofectamine® RNAiMAX and 
Invivofectamine® 3.0 nanocomplexes were made and encapsulated in PEG hydrogels. 
50μl 4% 8-arm PEG-VS or 4% 8-arm PEG-AC were prepared as described in 5.12.2. 
after polymerisation incubated in 150μl HBS pH 7.4 over 30mins, 1, 3, 5, 7 and 10 days 
with 100μl HBS pH 7.4 buffer replacements. At each collection time point 150μl HBS pH 
7.4 buffer with eluents was collected and snap frozen for siRNA quantification.  On day 
10, undegraded PEG hydrogels was digested Proteinase K in 150µl HBS pH 7.41 at a 
final 1mg/ml final concentration. The digest was collected and the siRNA or nanoparticles 
released were quantified by running samples on a 2% agarose gel (section 5.3.1). Fresh 
100, 50, 25, 12.5, 6.25 and 0ng siRNA was included per gel run and used as a standard 
curve to determine the amount of eluted siRNA at each time point. 4μl 5X loading dye, 
SDS (0.05% final concentration) was added to 10μl of the released samples, to 
dissociate the nanoparticles and volume made up to 20μl with DEPC treated water. 
Samples were loaded onto the agarose gel and run for 30mins at 55V. siRNA bands 
were visualised, imaged and quantified by Syngene GeneTools software.  
  
5.14 Effects of fibrin hydrogel components on siRNA degradation 
 
Fibrin hydrogel components fibrinogen and thrombin were incubated with siRNA over a 
period of 5 days to assay potential degradation of siRNA as they are animal derived 
products that could possibly contain RNases. 200ng siNegative was incubated at 370C 
10mg/ml fibrinogen or 0.624U/ml thrombin in 20µl HBS pH 7.4. Samples were taken 
master mix at 30mins, 1, 3 and 5 days. Samples were incubated under sterile conditions 
at 370C. At each time point 20µl samples were removed, snap frozen in liquid nitrogen 
and kept at -200C until further analysis after experiment completion. siRNA, fibrinogen 
and thrombin only were included as controls. After 5 days all samples including fresh 
siRNA were subjected to gel electrophoresis on 2% agarose gel (section 5.3.1).  
 
5.15 siRNA release from PEGylated and non-PEGylated fibrin gels  
 
50μl (10mg/ml) of 0, 5:1 and 10:1 PEGylated fibrin gels encapsulating siRNA and 
nanocomplexes were prepared following procedure described in 5.12.1.1&2: 12.6μl 
40mg/ml stock Fibrinogen, 13.6μl HBS pH 7.8 and 2.5μl or 5μl PEG-SMC2 10mg/ml (for 




370C. After incubation, 5.7μl of 0.624U/ml thrombin in 40mM Ca2+ (in HBS pH 7.4)  was 
added and volume made up to 50μl with HBS pH 7.4 with or without 1000ng siNegative 
alone, MD, Lipofectamine® RNAiMAX and Invivofectamine® 3.0  nanocomplexes. 3 gels 
per group were polymerised in and incubated in 150μl HBS pH 7.4 over 30mins, 1, 3, 5, 
7 and 10 days with 100μl HBS pH 7.4 buffer replacements. At each collection time point 
150μl HBS pH 7.4 buffer with eluents was collected and snap frozen for siRNA 
quantification. By day 3 and day 10, unmodified fibrin and 5:1 PEGylated fibrin had 
completely degraded respectively, hence sample collection stopped at those time points. 
The collection point for 10:1 PEGylated fibrin gel stopped at Day 10 though it had not 
completed degradation. The siRNA or nanoparticles released were quantified by running 
samples on a 2% agarose gel and quantified as described above (5.13).  
 
5.15.1 Bioactivity testing of the siRNA or nanocomplexes released from 
PEGylated fibrin gels in the presence or absence of serum.  
 
50μl (10mg/ml) 5:1 and 10:1 PEGylated fibrin gels encapsulating 1000ng siGFP-Cy3 or 
MD / Lipofectamine® RNAiMAX  /Invivofectamine® 3.0 nanocomplexes were prepared 
as above in 5.15. 3 gels per group were polymerised and washed in HBS pH 7.4 for 
30mins, with the initial wash excluded from the transfection experiment. Then samples 
incubated 150μl HBS pH 7.4 0-5 days and for 6-10 days with 150μl HBS pH 7.4 buffer 
replacements. At 5 and 10 days the eluent was immediately quantified and used in 
transfection experiments to test bioactivity of the released nanoparticles. For 
siRNA/nanocomplex release in the absence of serum: Gels without siRNA or 
nanocomplexes were included in the release profile and used as negative controls. After 
siRNA quantification (described in section 5.14), 100ng of the eluents in HBS pH 7.4 per 
treatment group (if sufficient siRNA was present) added to 30000 HT1080-GFP cells 
seeded in 24 well plates a day prior. 4hrs post transfection media was changed and 
48hrs later cells were analysed for GFP knockdown by flow cytometry (section 5.6). 
HT1080-GFP cells only, 5:1 and 10:1 PEGylated fibrin only eluents with no siRNA were 
used as negative controls. For siRNA release in the presence of serum, 50µl 5:1 
PEGylated fibrin gels were prepared in triplicate with siGFP or siNegative. The hydrogels 
were incubated at 37oC under sterile conditions in 200µl eluent (10% FBS in MCDB 
media) over a period of 7 days. Eluents were collected at day 4 and 7.  The extracted 
eluent was immediately used to transfect cells seeded a day prior in a 24 well plate (in 




controls. 48hrs after each transfection cells were analysed for GFP knockdown with flow 
cytometry as described in 5.6.  
 
5.16 3D cell culture assays pre in vivo experiments 
 
5.16.1 3D Transwell chemotaxis assay  
MD, Lipofectamine® RNAiMAX and Invivofectamine® 3.0 nanocomplexes were made 
with siGFP-Cy3 as described in section 3.1. Lipofectamine® RNAiMAX, MD and 
Invivofectamine® 3.0 was complexed to 500ng siGFP-Cy3. siGFP only, Cy3 labelled 
scramble siRNA (siNegative-Cy3) and HT1080 cells only were used as negative 
controls. 50μl (10mg/ml) non-PEGylated fibrin gels with 500ng siGFP-Cy3 and 
nanocomplexes were polymerised onto the transwell membrane (bottom gel layer, see 
Fig.32). 50μl (10mg/ml) non-PEGylated fibrin gels with 15000 HT1080-GFP cells 
suspended in serum free MCDB media was polymerised on top of the gel-siGFP-Cy3 
(top gel layer). The Transwell set up was then incubated for 24hrs the lower chamber 
containing MCDB media with 10% FBS (as chemoattractant), and the insert of the 
Transwell was filled with serum free MCDB media. 24hrs post seeding media was 
changed to remove excess released nanocomplexes. HT1080-GFP cells only (no siRNA 
or nanocomplexes), fibrin hydrogels with HT1080-GFP cells and free siNegative-Cy3 or 
siGFP-Cy3 (no nanocomplexes) were used as negative controls. The same experimental 
set up was used to assay invasion through 5:1 and 10:1 PEGylated fibrin hydrogel. Cells 
were monitored from 24hrs to 10 days (with media change every 48hrs. 
48hrs post treatment, cells that migrated to the surface of the	Transwell membrane and 
bottom chamber were quantified by fluorescent microscopy and flow cytometry (section 
5.6) respectively. For fluorescent microscopy, cells and excess fibrin gel on the top side 
of the transwell membrane were scraped off and the cells at the bottom of the membrane 
were washed 2X with isoPBS pH 7.4 and fixed with 10% formalin. Post fixing and 
washing 3X with isoPBS pH 7.4 the membrane was cut off the well, placed on a glass 
slide and stained with Fluoroshield™ with DAPI. A coverslip was placed on top of the 
membrane and cells were imaged by Nikon Eclipse 90i fluorescent microscope at 20x 




3D embedded cell cluster assay  
 
96 well plates were siliconized with Sigmacote® prior to cell seeding. HT1080-GF cells 
were mixed with 5μl 5:1 PEGylated fibrin gel at 1000 cells/µl prior to polymerisation. A 
5µl droplet was pipetted in the center of each transwell for 15mins at 370C. Then a 50μl 
5:1 PEGylated fibrin gel encapsulating MD / Lipofectamine® RNAiMAX / 
Invivofectamine® 3.0 nanocomplexes made with 500ng siDeath was polymerised onto 
the 5ul droplet. siDeath-Negative control siRNA was included as control. After the top 
gel-layer polymerised full growth media was added to the well (see Fig.34). Cell droplets 
were, immediately imaged by Zeiss Axiovert fluorescent microscope at 10X 
magnification. The experimental set up was then incubated for 3 and 7 days with media 
change every 48hrs. At day 3 or 7 cell death was assayed by addition of EthD-1 from the 
Live/Dead™ cell viability assay. Green HT1080-GFP cells were used as indicator of live 
cells in this experiment.  At day 3 and 7 wells with cells were washed 3X with isoPBS pH 
7.4, 2mM EthD-1 was added to the cells and incubated for 20minutes to stain dead cells 
red. Maximum intensity projection images of the cell droplets was then imaged by Zeiss 
LSM510 confocal microscope at 10X magnification. 4 fields of view across the cell 
droplet were taken per well and quantified by Image J cell counter. 
 
5.17 In vivo studies gel degradation and gene knockdown analysis 
5.17.1 Animals 
 
Animals were bred and housed at the Animal Unit, Faculty of Health Sciences, University 
of Cape Town (UCT), under standard research facility conditions. The handling of all 
mice and experiments complied with the Principles of Laboratory Animal Sciences as 
well as the UFAW Handbook on the care and management of laboratory Animals and 
followed the protocol for this study approved by UCT Faculty of Health Sciences, Animal 
Ethics Committee protocol number 014/022. 
 
6-8 week old, GFP transgenic or non-GFP mice (male and female) were used. The non-
GFP (UCT4) – BALB/c wildtype mice were obtained from the UCT Animal Unit and 
BALB/c GFP transgenic mice heterozygote (Cby.B6-Tg (UBC-GFP) 30Scha/J from 
Jackson laboratory) were provided by Frank Brombacher’s laboratory at UCT. The GFP 
transgenic mice express eGFP under the transcriptional control of a 
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human ubiqutin C promoter. Homozygote eGFP expressing transgenic parental mice 
were bred to provide the mice used in the study. Homozygote eGFP expressing mice 
were reported to be normal by Jackson laboratory and this was considered more 
convenient. Confirmation of the GFP mouse genotype during the breeding process was 
done by flow cytometry on cells isolated from the mice blood. 2ml of red blood cell lysis 
(RBCL) buffer (Appendix 14) was added to 100μl of mouse blood and incubated for 
2mins at 37oC. After incubation cells were centrifuged at 1500rpm for 3mins, and 
supernatant discarded. If the red blood cell lysis was not complete an additional cell lysis 
step was added until a clear pellet of white blood cells was visible. The cell pellet was 
resuspended in FACS buffer and GFP levels within the cells determined by flow 
cytometry (section 5.6). As seen in (Appendix 13) homozygotes GFP mice had 
approximately double the GFP fluorescence of heterozygote mice. Once parental 
homozygote GFP mice for breeding were established, their offspring were used in the in 
vivo studies.  
 
All injections on live mice with nanocomplexes and hydrogels with or without 
nanocomplexes were done using a 0.3mm 30G needle following the approved animal 
ethics protocol as follows. Animals were first anaesthetised by placing them one at a 
time in a box containing an atmosphere of 5% isoflurane in 100% oxygen for 2mins. 
Animals were placed on a nose cone with 1.5% isoflurane in 100% oxygen at 0.3l/minute. 
The injection site was swabbed with ethanol swabs and 30μl of samples 
(nanocomplexes, hydrogels or both) was injected into the tibialis anterior (TA) muscle of 
the mouse’s lower hind limb 2-5mins post mixing the gel components. Both limbs of each 
mouse were utilised to reduce the number of mice used. At appropriate time points 
(30min, 2, 4 and 7 days) mice were euthanized with 5% isoflurane for 5mins and cervical 
dislocation to confirm death. Their TA muscle were excised and analysed by histology, 
western bot and RT-PCR.  
 
5.17.2 Hydrogel injection and distribution optimisation in vivo 
 
For hydrogel injection optimisation to get optimal tissue coverage with the hydrogel, 
Injections were done on dead BALB/c mice donated by the Animal Unit that had been 
euthanised for animal breeding maintenance. Coomassie Brilliant Blue R-250 stained 
PBS pH 7.4 was used as a dye for this exercise. Various injection volumes, needle 
injection depth and angle, as well as number of injections and injection site, were tried 
to get optimal spread in the TA muscle without injection leakage.
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5.17.3 Hydrogel degradation in vivo 
 
For this experiment, 35µl PEG-VS/AC gels, non-PEGylated and PEGylated fibrin gels 
with Alexa Fluor® 660 C2-maleimide and Alexa Fluor™ 647 were prepared as 
prescribed in section 5.12 without siRNA or nanocomplexes. 30μl of the gel components 
were injected into BALB/c mice TA muscle 5-10mins post mixing, 2 legs per group of 
hydrogel. The mice were sacrificed 30mins post injection or at day 2, 4 and 7. Histology 
and image analysis for hydrogel degradation rate in vivo over 7 days was performed on 
whole TA tissue samples. Whole TA muscle samples were immediately fixed in 10% 
formalin for at least 24hrs. Post formalin fixing tissue samples were wax embedded, 
sectioned into 2 micron slices, mounted and DAPI stained by fluoroshield DAPI stain. 
Stitched fluorescent images of the whole muscle sections were taken by Nikon Eclipse 
90i fluorescent microscope at 10x magnification, with the same exposure settings, to 
image the distribution of nanocomplexes.  
 
 
5.18 In vivo analysis of RNAi     
 
Invivofectamine® 3.0 nanocomplexes were made with 5µg of siGFP-Cy3 or siMstn-Cy3 
following protocol 5.2.3. Before the Invivofectamine® 3.0 nanocomplexes were used in 
experiments, they were first dialysed under sterile conditions in isoPBS pH 7.4 for 2hrs 
using Slide – A - Lyzer® Mini dialysis device kit. This was done (as per recommendation 
in communication with the manufacturer) to remove any uncomplexed nanoparticle 
reagents that may cause cytotoxicity as high concentrations of the nanocomplexes were 
going to be used in vivo. After dialysis, the toxicity and transfection efficiency of the 
nanocomplexes was tested using cell viability Cell Titre Glow assay and GFP geometric 
shift by flow cytometry (Appendix 7). 16 mice were injected in both their TA muscles 
with the dialysed nanocomplexes encapsulated in 30µl 5:1 PEGylated fibrin. The various 
groups were randomly distributed (n=8). Post injection, mice were monitored and 
sacrificed 7 days post treatment. Their TA muscle tissue was extracted, weighed and the 
samples were immediately immersed in RNAlater® solution to protect all RNA from 
RNases. Tissue samples were later processed for histology, RNA and protein analysis. 
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5.18.1 Nanocomplex retention  
  
For nanocomplex distribution analysis in the muscle tissue, a small piece ≈1mm thick 
was cut from the middle cross section of the extracted TA muscle tissue (illustrated in 
Fig.41 below) and fixed in 10% formalin in preparation for histology as described in 
5.17.3. The remaining larger pieces were placed back in RNA later in preparation for 
protein and total RNA extraction at a later stage. The distribution of nanocomplexes in 
the presence or absence of PEGylated fibrin hydrogel relative to tissue size was further 





5.18.2 Protein and siRNA extraction from mouse AT muscle. 
 
Prior to analysis of tissue samples from the in vivo experiment GFP expression in TA of 
the GFP transgenic mice needed to be analysed. TA muscle samples of GFP expressing 
mice were excised from the mice and preserved in the RNAlater® in preparation for 
protein. Protein was extracted using mirVana™ miRNA Isolation Kit as per 
manufacturer’s instructions. The tissue samples were minced with a scalpel blade into 
the smallest possible pieces. Samples were kept on ice and subjected to two short bursts 
of sonication by Virsonic Sonicator. Protease inhibitor (PI) cocktail (1μl/100μl) was added 
Figure 41: Illustration of how the tibialis anterior muscle	 cross sectioned for nanocomplex 
distribution analysis.  
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to the isolated protein to prevent protein degradation. Protein concentration was 
quantified using Bradford’s assay. GFP protein in the tissue samples was analysed by 
western blot as described in 5.10. Non-GFP expressing TA tissue samples and HT1080-
GFP cell lysate were included as negative and positive controls. The expression of eGFP 
protein in the transgenic mice was confirmed in Appendix 11.B&C 
 
For the in vivo study described in in 5.18, after excision and RNAlater®, preservation of 
the tissue samples to be used in siRNA and protein analysis, the siRNA and protein in 
the samples was extracted using mirVana™ miRNA Isolation Kit as per manufacturer’s 
instructions and again as described above with additions as follows: The tissue samples 
were weighed and minced with a scalpel blade into smallest possible pieces. Samples 
were kept on ice and subjected to two short bursts of sonication by Virtis Virsonic 
Sonicator at speed level 2. Samples were split in half for separate protein and siRNA 
isolation following extraction kit protocol. Protease inhibitor (PI) cocktail (1μl/100μl) was 
added to the isolated protein to prevent protein degradation. Protein and siRNA were 
quantified using Bradford’s assay and Nanodrop respectively. Samples were stored at -
800C until analysis for Mstn mRNA (by RT-PCR, section 5.18.3) and GFP expression by 
western blot as described (in section 5.10).   
 
5.18.3 Quantitative RT-PCR analysis 
 
After extraction and quantification of total RNA from tissue samples in all groups, Mstn 
mRNA levels was quantified using the Roche RT-PCR system. The primer 
concentrations to use in the study for RT-PCR was initially optimised, these primer 
sequences and concentrations are listed in Table 5. The housekeeping gene to be used 
in the experiments was optimised before sample analysis as well (amplification and 
melting curves in Appendix 8A.). Mstn primers were obtained from literature [301, 302, 
308, 312] and purchased from Qiagen. The ACTN, HPRT and GAPDH primers were 
self-designed using NCBI gene sequence database and primer sequence blast and 
purchased from Qiagen. Firstly cDNA synthesis was made from the extracted total RNA 
using Roche Transcriptor first strand cDNA synthesis kit following manufacturers guide. 
mRNA levels were detected using LightCycler® 480 SYBR Green I master mix again 
following manufacturers guide. 20µl PCR reaction tubes were subjected to the following 
PCR cycle conditions were as follows: Hold at 95oC for 5mins; 45 cycles of denaturing 
at 95oC for 10secs, annealing at 60oC for 15 secs, elongation at 72oC for 15secs, 
detecting at 78oC; and a final melting step ramping from 60oC to 95oC. Water controls 
were always included in the RT-PCR runs to monitor for or primer dimer formation. 
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GAPDH was chosen as the optimal housekeeping gene to use in sample analysis. 
GAPDH (237bp) and Mstn (167bp) primer/RT-PCR products were confirmed by 
electrophoresing 5µl of the 20µl products from the reaction tube on a 2% agarose gel 
with GelRed™ loading dye (final concentration 1X) (Appendix 8B). For sample analysis 
of Mstn gene expression, the PCR efficiency values for each primer set (that is Mstn and 
GAPDH) was determined per sample run in each PCR repeat using the LinRegPCR 
software program [407]. Per every sample run the PCR efficiency is obtained by fitting a 
line of regression to a subset of data points (Ct values) in the log-linear phase using 
linear regression. The mean PCR efficiency for each primer is then calculated for the 
PCR reaction. The Mstn expression was calculated from the Roche CT value output 
taking into account the mean PCR efficiency for each primer obtained from the 
LinRegPCR program and presented normalised to the housekeeping gene GAPDH.    
 
 
Table 5: Primer sequences used in RT-PCR analysis 
Primer gene 
target name 















GAPDH 5’ -TTCACCACCATGGAGAAGGC-3’ 5’ -GGCATGGACTGTGGTCATGA-3’ 500 
 
 
5.19 Statistical analysis 
 
Data was tested for normality. One-way ANOVA with post-hoc Tukey testing for 
significance was performed on normally distributed data. For non-parametric data 
Kruskal Wallis followed by Steel-Dwass post hoc testing significance was performed. P 
values less than 0.05 were considered statistically significant. Statistical analysis was 
performed using JMP statistical analysis, a SAS software (Cary, North Carolina, USA). 
Data are presented as the mean ± standard error mean. 
 
    
 

















Appendix 1: pEGFP-C1 plasmid used in the production of an HT1080 cell line stably expressing 
GFP (HT1080-GFP). The Image was obtained from: http://www.bioss.uni-
freiburg.de/toolbox/products.php?PL-558 and the plasmid was purchesed from Clontech. 


























Appendix 2: GFP expression levels in 3 established HT1080-GFP clones and western blot 
optimisation. (A) HT1080-GFP Clone 9 with the most intensity was used through throughout the study. Data 
is a representation of an experiment done with 3 technical repeats. HT108 cells were included as negative 
control. (B) Shows protein loading optimisation using HT1080-GFP clone-9 cell lysate. 0-150ng protein was 
loaded on the 12% SDS page gel. HT1080 cell lysate was used as negative control and β-Tubulin was used 
as loading control in all GFP expression or knockdown experiments. 40ug was used in all follow up 














Appendix 3: The transfection efficiency and efficacy of D and MD nanocomplexes at N/P of 8:1, 72hrs 
post transfection. HT1080-GFP cells were transfected with D and MD dendriplexes made with 200ng siGFP 
siNegative (neg siRNA groups) for 4hrs. 72hrs post transfection flow cytometry was used to measure the 
GFP geometric mean.  Non-GFP cells, GFP cells only and siGFP only treated cells were included as negative 
controls. Data is a representation of an experiment with 3 technical repeats.  ** p<0.005 vs respective D/MD 
negative siRNA controls. 




























Appendix 4: The binding abilities of Lipofectamine® RNAiMAX at different amounts to siRNA. A 
constant amount of 200ng siNegative was used in nanocomplex formation with 0.6-5ul Lipofectamine® 
RNAiMAX. Free siRNA and Invivofectamine® 3.0 nanocomplexes were included as a controls (complexes 
made according manufactures guide with no 6X final dilution). Samples were electrophoresed on 2% 
agarose gel to show siRNA complexation.   





























Appendix 5:  A representation of optimised injection and distribution of Alexa labelled PEG-VS and 
fibrin hydrogel in the targeted hind limb tibialis anterior muscle of BALB/c mice. PEG-VS was labelled 
with Alexa Fluor® 660 C2-maleimide and Fibrin was labelled with	Alexa Fluor™ 647. The micrograph images 
of the whole TA muscle tissue extracted from BALB/c mice sacrificed 30mins post injecting the muscle with 
30µl hydrogel of Alexa (pink) labelled 8-arm 4% PEG-VS (A) hydrogel and fibrin hydrogel (B). The images 
show successful gel labelling and gel distribution and optimal coverage in the TA muscle. Blue is nuclei DAPI 
stain of tissue.  Scale bar =500µm.  
A. B. 







Appendix 6: Fluorescent images of in vitro 3D cell transfection of HT1080-GFP cells at day 0. 
Fluorescent images of Day 1 cell seeding set up of the 3D assay. These are maximal projection Z-stack 
images of cells encapsulated in 5ul 5:1 PEGylated fibrin gel droplet covered with a layer of  50µl 5:1 
PEGylated fibrin gel containing: MD/Lipofectamine® RNAiMAX/ Invivofectamine® 3.0 nanocomplexes made 
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Appendix 7: Cytotoxic effects of Invivofectamine® 3.0 nanocomplexes and the GFP knockdown 
effects of dialysing and non-dialysed nanocomplexes.  Invivofectamine® 3.0 nanocomplexes made 
with siMstn-Cy3 (neg Invivofectamine group) or siGFP-Cy3 (pos Invivofectamine group) were dialysed or 
not in preparation for the in vivo assay. Their cytoxicity (A) and efficacy (B) on HT1080-GFP cells was 
assessed by CellTiter-Glo® luminescent Cell Viability Assay and flow cytometry respectively. Cells were 
transfected with nanocomplexes, Invivofectamine® 3.0-siMstn 200ng in (A) or Invivofectamine® 3.0-
siMstn/siGFP 500ng  in (B) from the dialysed or non-dialysed groups for 4hrs. 48hrs post transfection, cell 
death and geometric mean was determined. Untreated HT1080-GFP cells (GFP cells only) were used as 
negative controls in both experiments. siMstn was used as negative control GFP knockdown in (B). *** 
p<0.0005 vs respective nondialysed/dialysed neg Invivofectamine groups. 






























Appendix 8: RT-PCR of housekeeping genes and Mstn primer optimisation. The amplification (A) and 
melting (B) curves of HPRT (500nM), GPDH (500nM), β-Actin (500nM) and Mstn (150nM) primers in 16 TA 
muscle tissue samples extracted from 8 untreated BALB/c GFP transgenic mice. The melting temperatures 
of GAPDH, β Actin, Mstn and HPRT RT-PCR products. (C) Image shows the RT-PCR single product size 
from GAPDH (237 bp) and Mstn (167 bp) RT-PCR amplification after 2% agarose gel electrophoresis. M= 



























Appendix 9: Myostatin protein expression in tibialis anterior muscle tissue samples of BALB/c GFP 
transgenic mice. Mstn expression in the tissue samples from two TA muscle, mice, lane 1 and 2, was 
analysed by western blot analysis. The image is a representations of 3 immunoblot repeats carried out after 
Mstn antibody optimisation by dot blot. β-Tubulin was included as loading control. The blot shows multiple 
unspecific bands and no clear identification of myostatin specific bands, that is: myostatin precursor 50 kDa, 
myostatin propeptide 39 kDa and myostatin mature inactive N terminal 27 kDa for quantification. Mstn = 






























Appendix 10: GFP protein expression from TA muscle tissue of BALB/c GFP transgenic mice. Total 
protein was extracted from mouse tissue and 30ug subjected to western blot analysis. Immunoblot image 
in (A) shows the expression of eGFP protein in the mouse tissue and quantified in (B). Lane 1 is non GFP 
BALB/c mouse sample negative control, lane 2 is BALB/c GFP mouse TA tissue lysate and lane 3 is 
















Appendix 11: RT-PCR of Mstn in BALB/c transgenic mice treated with Invivofectamine® 3.0 
nanocomplexes with or without 5:1 PEGylated fibrin hydrogel. 7 days post treatment post treatement 
of mice with Invivofectamine ® 3.0 nanocomplexes made with 5µg siMstn-Cy3 or  siGFP-Cy3 with   or 
without. 5:1 PEGylated fibrin hydrogel encapsulation (8 legs per group). Mstn expression was quantified by 
RT-PCR normalised to GAPDH. (A.i) The amplification and melting curves (A.ii) of Mstn and GPDH from 
samples treated with Invivofectamine® 3.0-siGFP/siMstn free nanocomplexes. (B.i) The amplification and 
melting curves (B.ii) of Mstn and GAPDH from samples treated with Invivofectamine® 3.0-siGFP/siMstn 



























Appendix 12: GFP knockdown in GFP-HT1080 cells with Invivofectamine® 3.0 nanocomplexes in 
different dilution forms. HT1080-GFP cells were transfected by Invivofectamine® 3.0 nanocomplexes 
made with 1000ng siGFP-Cy3 (pos GFP siRNA groups) or siMstn-Cy3 as a control (mstn siRNA group) for 
4hrs. The nanocomplexes to use in the transfections were made according to manufacturer’s protocol which 
suggests 6X dilution of the final nanocomplex solution. 3X, 2X and 0X dilution were included ensure efficacy 
of the nanocomplexes maintained when used in their concentrated form. This would allow smaller volumes 
with more siRNA to be loaded in the 30µl volume hydrogels without compromising nanocomplex efficacy. 













Appendix 13: Geometric means for BALB/c GFP or non-GFP mice to determine genotype. This was 
assayed by few cytometry of white cells obtained from mice blood. The GFP deficiency (A), heterozygote (B) 
homozygote (C) genotype of each mouse was determined by the level GFP fluorescence. M1=GFP geometric 




Appendix 14  
Reagents recipes 
 
1. BHG Buffer pH 7.4 
5% glucose 
HEPES 20mM 
Make up volume with dH2O to 50ml 
pH and sterilise 
 
2. 0.1% DEPC treated water 
500µl DEPC 
Make up volume to 500ml with dH2O 
Leave overnight and pH 
 
3. DTT solution 
1.7mg DTT 
10ml PBS pH 7.4 
 
4. Alexa dye solution 
1mg Alexa Fluor® 660 C2-maleimide 
100µl DMSO 
 





Make up volume to 1L with dH2O and pH 
 
6. 1X TE buffer pH 8 
1M Tris pH 8 
0.5M EDTA pH 8 
Make up volume to 500ml with dH2O 
 




890mM Tris Base 
890mM Boric acid 
20mM EDTA 
Make up volume to 500ml with RNase free treated H2O 
 
8. 1X Iso-osmotic PBS pH 7.4 (iso-PBS) 
Solution A: 0.15M NaH2PO4.H2O in 1L dH2O 
Solution B: 0.15M Na2HPO4.12H2O in 1L dH2O 
0.15M NaCl in 500ml dH2O 
Combine 13ml of (A) + 87ml (B) + 100ml 0.15M NaCl  
Adjust pH with solution A or B to maintain osmolality 
 
9. Fibrin Gel reagents: 
a. HEPES buffered saline 50ml (HBS) pH 7.4 or 7.8 




Make up volume to 50ml and filter sterilize 
 
b. HEPES buffered saline with Ca2+ 50ml (HBS/Ca2+) 
NaCl  410mg 
HEPES 297.5mg 
Na2HPO4 5mg 
Add 1ml 2mM CaCl2 
pH to 7.8 and make up volume to 50ml and filter sterilize 
 
c. Fibrinogen stock 40mg/ml 
40mg fibrinogen  
1ml HBS buffer 
Make 100µl aliquots to store at -200C 
 
d. Thrombin stock 1000U/5ml 
33.3mg thrombin 
5ml HBS 
Filter sterilize and store 50µl (10U thrombin) aliquots at -200C 
 
e. Thrombin working solution (1.4U/ml) 
50µl (10U) thrombin 
7172µl HBS/Ca2+  
Filter sterilize and store 50µl aliquots at -200C 
 






Make up to 1L with distilled water 
 
a. 10% APS (10ml) 
10% (w/v) Ammonium persulfate 
10ml distilled water 
 
b.  2X reducing Loading dye pH (6.8) (10ml) 
125mM Tris-HCl 
4% (m/v) SDS 
20% (v/v) glycerol 
10% (v/v) 2-mercaptoethanol 
Make up the volume to 10ml with distilled water. 
 
c. 10% SDS (100ml) 
10% (w/v) SDS 
Dissolve in 100ml distilled water 
 
d. 1X Transfer buffer 
6.05g Tris 
14.4g Glycine 
Dissolve in 800ml distilled water 
1ml 10% SDS 
Add 200ml methanol fresh 
 
e. Ponceau Stain (100ml)  
0.1% (w/v) Ponceau S 
15% (v/v) Acetic acid 
Make up volume to100ml with distilled water 
 




Make up volume to 1L with distilled water 
11. Red Blood Cell lysis buffer 
 8.29g NH4Cl (0.15M) 
1g KHCO3 (10.0mM) 
37.2mg Na2EDTA (0.1mM) 
Make up volume to 1L with distilled water 
pH. 7.2 - 7.4 
 
12. FACS Buffer 
 2% fetal culf serum 
1mM EDTA 





List of materials 
1, 2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), Avanti Polar Lipids (AL, 
USA). 
 8-arm 20PEG-VS, Nektar therapeutics, AL. 
8-arm 20PEG-AC, Nektar therapeutics, AL. 
7.5% SDS-PAGE gel reagents TGX™ FastCast™ Acrylamide Solutions, Bio-Rad (CA, 
USA).  
12% SDS-PAGE gel reagents TGX™ FastCast™ Acrylamide Solutions, Bio-Rad (CA, 
USA). 
 100 bp DNA Ladder, ThermoFisher scientific.  
Agarose powder, Sigma-Aldrich® (St Louis, MO). 
Alexa Fluor® 660 C2-maleimide, Invitrogen Life technologies. 
Anti-GFP - ChIP Grade rabbit polyclonal (ab290), Abcam. 
anti-Mstn - GDF-8(N-19)-R rabbit polyclonal IgG (SC-688J-R), Santa cruz. 
Anti-Rabbit Goat IgG H&L (HRP) (ab97051) antibodies, Abcam.  
Anti-β Tubulin antibody (ab6046), Abcam. 
CellTiter-Glo® luminescent Cell Viability Assay, Promega (WI, USA).  
Cellulose ester dialysis membrane (12-14000 kDa MWCO), Sigma-Aldrich® (St Louis, 
MO). 
Chemiluminescent detection kit WesternBright™ ECL, Advasta (CA, USA).  
Chloroform, Sigma-Aldrich® (St Louis, MO) 




Dithiothreitol (DTT), Sigma-Aldrich® (St Louis, MO). 
Eth D-1 stain for from Live/Dead™ cell viability assay kit from Molecular Probes Inc. 
(Eugene, OR).  
Fetal bovine serum (FBS), Biochrom GmbH (Berlin, Germany). 
Fibrinogen from human plasma, Alexa Fluor™ 647 conjugate, ThermoFisher scientific. 
Fibrinogen from human serum (T-3879), Sigma-Aldrich® (St Louis, MO). 
Forward and reverse GAPDH primers, Qiagen (MD, USA). 
Forward and reverse HPRT primers, Qiagen (MD, USA). 
Forward and reverse Mstn primers, Qiagen (MD, USA). 
Forward and reverse β Actin primers, Qiagen (MD, USA). 
G418 neomycin selection antibiotic, Sigma-Aldrich® (St Louis, MO).   
GelRed™ Nucleic Acid gel stain (41003), Biotium (CA, USA) respectively.  
Heparin sodium salt, Sigma-Aldrich® (St Louis, MO).  
HEPES, Sigma-Aldrich® (St Louis, MO) 
Hoechst stain, Molecular Probes Inc. (Eugene, OR).  
Human fibrosarcoma HT-1080 cell line, The American Type Culture Collection 
(ATCC).  
Hydrochloric acid, Sigma-Aldrich® (St Louis, MO) 
Invivofectamine® 3.0 reagents, Life Technologies (CA, USA). 
LightCycler® 480 SYBR Green I master mix, Qiagen (MD, USA). 
Lipofectamine® RNAiMAX, Life Technologies (CA, USA). 
MCDB media, Sigma-Aldrich® (St Louis, MO). 




MMP1 peptide: GCREGPQGIWGQERCG (1733 Da MW), GenScript (USA Inc, NJ)  
N, N-Dimethylformamide, Sigma-Aldrich® (St Louis, MO) 
Nitrophenyl Carbonate-Poly (Ethylene-glycol)-Nitrophenyl Carbonate with average 
MW 2000 (PEG2K-NPC2), Laysan Bio (AL, USA), 
Nuclei stains Fluoroshield™ with DAPI, Molecular Probes Inc. (Eugene, OR). 
PAMAM Dendrimer, ethylenediamine core, generation 4 [G(4)-D], 10 weight % 
solution in Methanol, Sigma-Aldrich® (St Louis, MO) 
PEG – (Succinimidyl Carboxymethyl Ester)2 MW3500 (PEG-SMC2),  JenKem 
Technology (Beijing, China). 
pEGFP-C1 plasmid, Clontech.  
Penicillin streptomycin solution (10X), Sigma-Aldrich® (St Louis, MO). 
Pierce™ Detergent Compatible Bradford Assay Kit, Sigma-Aldrich® (St Louis, MO).  
PolyFect transfection reagent, Qiagen (MD, USA). 
Precision Plus Protein™ Dual Colour standard molecular weight marker (161-0374), 
Bio-Rad (CA, USA).  
Protease inhibitor (PI) cocktail, Sigma-Aldrich® (St Louis, MO). 
Proteinase K (Sigma Aldrich).  
Quant-iT™ RiboGreen™ RNA Reagent, Life Technologies (CA, USA) 
RIPA buffer, Sigma-Aldrich® (St Louis, MO). 
Roche Transcriptor first strand cDNA synthesis kit, Qiagen (MD, USA). 
siDeath - AllStars Hs Cell Death positive control siRNA (1027299),  Qiagen (MD, 
USA). 
siDeath-Negative - AllStars Hs Cell Death scramble negative control siRNA, Qiagen 




siFITC - Fluorescein isothiocyanate  labelled scramble siNegative, Bioneer Corp 
(Daedeok District, South Korea). 
siGFP - Green fluorescence proteins: GCAUCAAGGUGAACUUCAAdTdT (sense), 
Bioneer Corp (Daedeok District, South Korea). 
siGFP-Cy3 - Cy3 labelled siGFP: GCAUCAAGGUGAACUUCAAdTdT Cy3 (sense), 
GE Healthcare Dharmacon. 
Sigmacote®, Sigma-Aldrich® (St Louis, MO). 
siMstn-Cy3 - Cy3 labelled siMstn: AAGAUGACGAUUAUCACGCUA-dTdT-Cy3 
(sense), GE Healthcare Dharmacon.  
siNegative - Negative scramble control siRNA, Bioneer Corp (Daedeok District, South 
Korea).  
siNegative-Cy3 - AllStars negative Scramble Cy3 labelled siRNA (AF555), Qiagen 
(MD, USA).  
Slide – A - Lyzer®mini dialysis device (10000 MWCO), Sigma-Aldrich® (St Louis, MO). 
Thrombin from bovine plasma (T-4648), Sigma-Aldrich® (St Louis, MO). 
Triethylamine (TEA), Sigma-Aldrich® (St Louis, MO). 



























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































     
